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ABSTRACT
MTMR2 is an active member of the MTM family of inositol lipid phosphatases
and the physiological substrates for MTMR2 play key roles in endosomal trafficking.
Additionally, loss of function mutations in MTMR2, have been associated with the
peripheral neuromuscular disorder CMT4B1.
In these studies we used mass spectrometry (MS) based methods to identify a
novel high stoichiometry phosphorylation site at Ser58 on MTMR2. Further analysis has
illustrated that a phosphorylation deficient MTMR2 (S58A) displayed constitutive
localization to early endocytic structures. Moreover, we determined that the subcellular
targeting of S58A was accompanied by depletion of PI(3)P and an increase in the
phosphorylation of ERK1/2. Recently we have used in vitro kinase assays to determine
that ERK1/2 phosphorylates Ser58.

Furthermore, we have recently confirmed a C-

terminal phosphorylation site at Ser631 and generated combinatorial mutants which have
shown to display characteristic localization to a distinct subset of endocytic
compartments as well as sustained ERK1/2 activation.
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CHAPTER 1- LITERATURE REVIEW
1.1 Cellular Protein Phosphorylation
Protein phosphorylation is a critical protein post-translational modification (PTM)
employed by numerous living systems and has long be viewed as a critical component
underlying most physiologic processes [1]. Reversible phosphorylation is an integral part
of all living systems and regulates nearly all aspects of cellular life [2]. Identification of
protein phosphorylation sites has been extensively studied utilizing complex and unique
biochemical approaches including in vivo [32P] radiolabeling, phosphoamino acid
analysis, phosphopeptide mapping and MS [3]. Recent technological advances have
made feasible the detection and quantitation of protein phosphorylation on a widespread
global scale combining stable isotope labeling by amino acids in cell culture (SILAC),
strong-cation exchange (SCX) and titanium dioxide chromatography (TiO 2) all coupled
with multistage MS [5].
Phosphorylation can be a reversible process and primarily occurs on the hydroxyl
group of threonine, serine and/or tyrosine residues and has been shown to be critical for
regulating protein function (figure 1) [4]. The reaction is catalyzed by a highly conserved
family of enzymes called protein kinases which are classified into three major categories
based on the residue they modify (Ser/Thr, Tyr and dual specific). The reverse process is
catalyzed by protein phosphatases in antagonistic actions [3]. It is estimated that there
are more than 1000 kinases and 500 phosphatases in the human genome, with the Protein
tyrosine phosphatase (PTP) domain being present in over 100 different proteins [5,6]. It
is estimated that 3-4% of genes in eukaryotes encode for members of the protein kinase
family, and that one-third of all proteins contain a covalently attached phosphate group
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[7,8]. Nearly 30% of all existent proteins are phosphorylated at any given time and
overall, the readily available amount of ATP in eukaryotic systems has deemed reversible
phosphorylation as the most general regulatory mechanism in living systems [2].
Modifications of target protein substrates can increase or decrease enzymatic activities,
control movement between different subcellular compartments, alter protein-protein
interactions or affect protein stability [2].
The addition of a phosphate group to a side chain of a protein is adding two negative
charges, which can change the characteristics of the protein. Most commonly, these
changes are conformational resulting from attractive or repulsive forces [4]. Electrostatic
interactions can be stabilizing through interaction with positively charged amino acid side
chain groups, or destabilizing if with negatively charged amino acid groups. These types
of interactions are of way of regulating the enzyme in such a way that the enzyme may be
active in one conformation and inactive in another. Aberrant and abnormal protein
phosphorylation has been linked to a number of cancers and human disease implicating
this as a critical control mechanism that is tightly regulated.

2

Figure 1. Cellular Protein Phosphorylation
Protein kinases facilitate the addition of the gamma phosphate moiety from ATP onto the
hydroxyl group of Ser/Thr or Tyr residues of the target substrates releasing ADP and
generating a phosphorylated protein. The reverse process is catalyzed by protein
phosphatases that remove the phosphate group releasing inorganic phosphate and
regenerating the original protein. [figure from reference 4]
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1.2 Protein Tyrosine Phosphatases
The Protein Tyrosine Phosphatases (PTPs) are a large group of enzymes whose
active-site catalytic consensus sequence D...HCX5RS/T is conserved throughout
evolution from unicellular to multicellular species ranging from yeast-/mouse to human
[9]. Stringent preservation of this characteristic phosphate binding loop (P-loop) suggests
that all PTP family members dephosphorylate their targets by a similar catalytic
mechanism (figure 2). The nearby Arg (R) residue stabilizes the net negative charge of
the phosphate group on the target protein shielding it in order for entrance into the active
site pocket of the enzyme. The invariant Cys (C) residue is critical for PTPase activity
and performs the nucleophilic attack on the phosphate group of the substrate, resulting in
the formation of a phospho-enzyme intermediate. Studies with site-directed mutagenesis
reveals mutation to a Ser results in complete loss of catalytic activity of the enzyme
[10,11]. The catalytic acid/base (usually an invariant Asp residue) is located within an
outer loop of the enzyme that donates a proton to hydrolyze the phosphoprotein substrate
and release the dephosphorylated target protein, and mutations of this residue results in
dramatic decrease in enzymatic activity [10]. The same Asp residue now functions also
as the catalytic base removing a proton from an incoming water molecule thereby
allowing for nucleophilic attack onto the phospho-enzyme intermediate. This action
triggers regeneration of the original enzyme and release of inorganic phosphate for
utilization and re-incorporation for subsequent ATP generation.
Protein kinases and protein phosphatases regulate the equal balance between
protein phosphorylation and dephosphorylation through antagonistic action in order to
mediate the appropriate duration of signaling throughout living systems.

Protein

phosphatases remove a phosphate group most commonly from a serine, threonine or
4

tyrosine residue and are classified based on recognition sequences, substrate specificity
and mechanism of action. The PTP family is composed of three main classes which are
further subdivided into smaller families according specifically to their target substrates
(figure 3): Class I; the classical transmembrane-receptor like tyrosine-specific
phosphatases (RPTPs), the intracellular-non-receptor tyrosine-specific phosphatase
(NRPTPs) and the VH1-like DSPs (the Tyr-Ser/Thr dual specificity phosphatases (DSPPTP), Class II; the low Mr PTPs (LMPTP) and Class III; the cell division cycle 25
phosphatases (CDC25) [12].
The Class I PTPs are the largest family of cysteine-dependent phosphatases based
on domain architecture and sequence homology between their catalytic domains. They
are further divided into several subfamilies constituting the most divergent group with
respect to substrate preference and are represented in the human genome by 38 different
genes [12].

The VH1-like DSPs were named and sub classed according to their

sequence homology and structural similarity to the yeast vaccinia virus gene VH1
encoding the classical DSP [12,13].

Unlike the classical PTPs which solely

dephosphorylate phosphotyrosine residue from their substrates, the DSPs can act to both
dephosphorylate phosphoserine and/or phosphotyrosine residues [12]. The extensive
variations for broad target substrates amongst this group is proposed to be a result of
additional targeting domains and motifs acquired throughout evolution in order to
increase rigidity to this regulation as well as they may harbour differences in the depth of
their active clefts.
The Class II PTPs is the LMPTPs and is represented in the human genome by a
single gene, ACP1 [12]. This protein in humans functions as an acid phosphatase and can
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dephosphorylate several autophosphorylated tyrosine kinases and their substrates in
addition to protein tyrosine to orthophosphate [12]. The particular regulatory function of
these PTPs remains unclear, however conservation throughout evolution from bacterial to
human indicates a critical regulatory function. Markedly, many LMPTP variants have
been shown to be common in human diseases including rheumatoid arthritis and
Alzheimer‟s disease implicating their fundamental role in a number of biological
mechanisms [12]. The Class III PTP is comprised of three cell cycle regulators that
function to dephosphorylate cyclin-dependent kinases (CDKs) at their Thr-Tyr dually
phosphorylated motifs thereby resulting in activation and further progression through the
cell cycle [12].

Presumably, the CDC25 group evolved in conjunction with the

regulation of CDKs by tyrosine phosphorylation [12]. The Asp-based PTPs are encoded
by the Eyes absent (Eya) phosphatases that have only recently been explored in upper
eukaryotic systems in which the phosphatase activity towards phospho-Tyr/Ser residues
has been shown to be required for regulating genes that encode growth control and
signaling molecules [12,14]. However the human compliment to these Asp-based PTPs
has not yet been identified, therefore an accurately based definition and functionality to
this unique subgroup of PTPs remains to be elucidated.
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Figure 2. The Mechanism of Dephosphorylation by Protein Tyrosine Phosphatases
The mechanism of dephosphorylation by PTPs is a two step process that first requires a
nucleophilic attack by the active-site cysteine onto the electron-deficient center of the
phosphoprotein substrate generating a thiol-phosphate intermediate. Donation of a proton
from the catalytic aspartic acid neutralizes the negatively charged oxygen and results in
release of the dephosphorylated substrate. The same aspartic residue then acts as a base
catalyst to remove a proton from an incoming water molecule resulting in nucleophilic
attack onto the phosphoenzyme intermediate. This causes release of inorganic phosphate
and regeneration of the original enzyme and its phosphatase active site. Throughout this
mechanism, a nearby arginine residue stabilizes and shields the negative charges of the
phosphate allowing the substrate to enter into the active site of the enzyme. The serine
residue stabilizes the nucleophilic thiolate ion of the catalytic cysteine to lower its pKa
for increased attack onto the phosphate group of the target substrate. Additionally, there
is a nearby Glutamate residue that aids in proper positioning of the incoming water
molecule. [figure from reference 47]
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Figure 3. The Classification of Protein Tyrosine Phosphatases
The protein tyrosine phosphatases can be classified into three major categories: the Class
I PTPs comprising the classical tyrosine specific PTPs and the VH1-like DSPs which
make up the largest PTP subfamily, the Class II PTPs harbouring the LMPTP, and the
Class III PTPs containing the CDC25s. Within the DPSs is a relatively large family of
phosphoinositide lipid phosphatases the MTMs, who unlike characteristic PTPs utilize
lipid substrate rather than phosphoproteins. Amongst this category is MTMR2 that
utilizes mainly PI(3)P as its physiological substrate, and is highly important as mutations
result in CMT-4B1. [figure from reference 42]

8

1.3 The Myotubularin Family of Inositol Lipid Phosphatases
The Myotubularin (MTM) family of inositol lipid phosphatases is the largest
superfamily of PTPs that is comprised of 14 members, eight of which are active and
contain the putative catalytic consensus sequence CSDGWDR and six which are inactive
and classified as the pseudophosphatases containing mutations within this highly
conserved catalytic sequence (figure 4) [15]. Myotubularins are ubiquitously expressed
containing highly conserved protein domains amongst all active/inactive members and
most have been conserved throughout evolution. All eukaryotes organisms contain MTM
and related members, with only 2 active MTMs to date found in the flower plant
Arabidopsis thaliana, 4 related members in Caenorhabditis elegans (3 active/1 inactive)
and 1 sole active MTM in Saccharomyces cerevisiae, however no homologues are
present in prokaryotes and the inactive members are absent in plants [16,17,18]. To date
it has been proposed that the evolution of the MTMRs occurred at some point and time in
vertebrates because orthologues are present in distant vertebrate species such as the
zebrafish in addition to some members of the fungus kingdom [16]. However, there is no
evolutionary history or answers at present, to explain how the inactive members evolved
and whether they originated from a single inactive ancestor or as a result of archaic
intermittent mutational events in higher organisms as a means for implementing striker
biological regulation of their active counterparts [16].
Mutations in two active MTMs (MTM1 and MTMR2) and 1 inactive member
(MTMR13) have been linked to distinct human disease including x-linked myotubular
Myopathy (MTM1), CMT4B1 (MTMR2) and CMT4B2 (MTMR13) (figure 5). X-linked
Myotubular Myopathy (XLMTM) is caused by large deletions and point mutations in the
MTM1 gene most resulting in severe decrease/loss of catalytic activity and a non9

functional protein (figure 6). Characteristic clinical features and genetic screenings are
the primary means by which this disease is diagnosed. Charcot-Marie Tooth disease
(CMT) type 4B1 and 4B2 (CMT4B1-CMT4B2) are caused by mutations in the MTMR2
and MTMR13 genes respectively (figure 6). Similar to XLMTM, point mutations in
MTMR2 yield a non-functional protein and diagnosis is done by utilizing NCV tests and
genetic screenings in addition to clinical features. CMT4B2 is unique in that the disease
causing protein is already inactive therefore, considering the similarity in clinical features
to CM4B1; diagnosis is confirmed by NCV tests and genetic screenings. It is proposed
that mutations result in the inability of MTMR13 to effectively regulate MTMR2 as
mutations result in a truncated protein lacking important interaction motifs [19].
Moreover, this is the first human disease that has been shown to be caused by mutations
in an inactive phosphatase thereby implicating the importance of the inactive MTM
members [19].

Considering that MTMR13 loss of function mutations cannot be

complimented or rescued by MTMR5 and that early onset glaucoma is a highlighted
distinctive feature from CMT4B2 suggests a potential role in the visual system [19].
Collectively, the linkage of MTM mutations to human disorders will only fully be
understood once the specific roles of these proteins are elucidated.
All MTMs members contain four of the following highly conserved domains: an
RID (Rac-induced recruitment domain), an N-terminal PH-GRAM (Pleckstrin
Homology-Glucosyl transferases, Rab-like GTPase activators and Myotubularins)
domain, a central phosphatase domain (PTP/DSP), an SID (SET-interacting domain)
[15,16]. Some members additionally contain predicted C-terminal coiled-coil (CC)
regions [15,16]. The RID domain has previously been reported to be important for the
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recruitment of MTM members to the plasma membrane and potentially represents the
region that mediates protein-protein interactions among specified homologue members
(i.e. MTMR2 with NF-L) [16]. The PH-GRAM domain is proposed to be the site of
allosteric activation by PI(5)P in a positive feedback loop, in addition to playing a role in
mediating correct protein-protein and protein-lipid interactions [15].

A number of

disease-causing mutations are located within the PH-GRAM domains and it has been
proposed to be a result of reduced responsiveness to activation and disruption of
subcellular translocation to the site where the substrates reside. The phosphatase domain
contains the active catalytic sequence CSDGWDR (CX5R) which forms a P-loop at the
base of the substrate binding pocket and is much larger than classical PTPs in order to
accommodate the large hydrophilic lipid substrates. Classical PTPs contain an additional
WPD loop near their active site, which is absent in MTMs [15]. In 2003, Bergley et.al
[20] proposed that the additional Asp acid within the P-loop, likely contributes to the
general acid-base catalytic step in substrate dephosphorylation in order to accommodate
for absence of the WPD loop. The SID domain has methyltransferase activity and is
composed of amphipatic helices and was initially proposed to be the region mediating
heterodimerization with inactive partners [16]. The PDZ-binding motif is present in
several active and inactive MTMs and has been suggested to be important in governing
protein-protein interactions with other PDZ containing proteins that are involved in
transmembrane anchoring and signaling [21]. Considering the evidence that most MTM
members are cytosolic proteins, there have been reports of nuclear localization in a minor
number of studies. However there has been no evidence to date indicating that MTMs
play roles in transcription or anywhere in the nucleus for that matter. In 2001, Firestein
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et.al [22] discovered that deletion of MTMR5 DENN domain resulted in nuclear
translocalization and attainment of transforming properties.

Therefore, it can be

proposed that MTMs could potentially play a role in chromatin remodelling as a result of
their particular nuclear subcellular localization under specific cellular conditions. The
CC region has been identified in effectively mediating interactions with the inactive
partners which has been shown to largely enhance enzymatic activity (Kim et.al 2003
[19]), in addition to mediating self-association to form homodimers [15].
The exact role of MTMs is very discrete and to date only proposed mechanisms of
involvement in the endocytic pathway have been developed. MTMs substrate lipids are
key secondary signaling molecules and accumulate to identify specific organelle
compartments. It has been suggested that the role of MTMs is to co-ordinately maintain
the precise concentrations of lipids at the correct subcellular compartment [15,20,23].
Most MTMs are not found on endosomal structures under native conditions and are often
cytosolic, however Laporte et.al (2002) have shown partial association of select MTMs
with plasma membrane ruffles and occasionally the golgi complex [23]. Tsujita et.al.
have reported that EGF stimulation results in translocation of MTMR2 to EGFR
containing endosomes resulting in the blockade of receptor degradation at the late
endosomes [24]. In addition, Berger et.al have shown MTMR2 to translocate to vacuolar
structures following hypoosmotic shock [25]. Therefore, there must be some mechanism
that governs the strict regulation in order to target these phosphatases to the sites where
their substrates reside.
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Figure 4. The Myotubularin family and conserved protein domains
Depicted are scaled representations of conserved domains amongst human MTM family
members. All members both active and inactive contain a PH-GRAM domain, an RID
domain, a PTP/DSP phosphatase homology domain even amongst inactive members, and
a SID domain. The C-terminal coiled-coil domain is present in nearly all members with
some additionally displaying a distant PDZ-binding motif. The catalytically active MTMs
all contain the putative catalytic consensus sequence VHCSDGWDRT with divergent
amino acids in the inactive members highlighted in red. [figure from reference 16]
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Figure 5. The Myotubularin family of phosphoinositide phosphatases and family
members with linked genetic mutation and corresponding human diseases
The Myotubularin family is a large subfamily of the PTPs and in the human genome is
composed of 14 members; 8 of which are catalytically active and 6 which bear mutations
in their catalytic domain rendering them inactive. Homologues containing the conserved
domains are found amongst all eukaryotes. Mutations in MTM1 result in X-linked
myotubular Myopathy, germline mutations in MTMR2 results in CMT4B1, and
MTMR13 in CMT4B2. [figure from reference 33]
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X-linked Myotubular
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(XLMTM)
-200 point mutations
(3 large deletions)
- 26% are within completely
conserved domains

MTMR22
Active

CMT4B1
- 5 point mutations
(1 large deletion)

Genetic Mutations

Clinical Features

E17X, R24X, R37X,
K47del, fs48, R69C,
L70F, L87P, fs100,
fs133, L154X,
N189S, fs198,
P205L, fs217,
R222X, R224X,
S229P, R241C,
S376N, G378R,
Y397C, G402A,
420insFIQ, R421Q,
D431, D433N,
H469P, R474X etc..

-Congenital myopathy
-Hypotrophic myofibres
with central nuclei
-Infancy/early childhood
-Death in infancy
common
-Not progressive
-Hypotonia and muscle
weakness
-Respiratory difficulties
-Usually require aid with
a ventilator

G103E, E276Q,
R283W, Q426X, ,
E482X, F494E531del , Y579fs

-Degeneration of the
peripheral nerves
-Reduced NCV (<40m/s)
-Myelin outfoldings
-Early onset with
progressive distal
weakness and sensory
loss in outer extremities
-Muscle atrophy, Pev
cavus
- Similar characteristic
features as CMT4B1
- Optic atrophy
- Early onset glaucoma

-autosomal recessive

MTMR133 CMT4B2
Inactive
2missense
(1 small deletion)

Q956Stop,
R1196stop, L351E432del

-autosomal recessive

del: deletion, fs: frameshift, ins: insert, NCV: nerve conduction velocities
*Mutations underlined are severe and within conserved domains
Figure 6. Mutations in myotubularins and genetic diseases
The Myotubularin family is a subgroup of the classical PTPs and is composed of lipid
phosphatases of which 14 members have been identified in humans, and three of which
when mutated results in human genetic diseases. Point mutations are predominant and
primarily result in a non-functional protein or truncations that are both due to mutations
within highly conserved domains. Distinctive characteristic features and genetic
screening aid in defining and differentiated between these diseases.
1

MTM1 mutations: Laporte et.al. Human mutation.15:393-409(2000), Laporte et.al. Human molecular
genetics.6;9:1505-1511(1997). MTM1 genecard
2
Houlden et.al. Brain.124;5:907-915(2001), Bolino.et.al.JBC.167;4:711-721(2004). MTMR2 genecard.
3
MTMR13 mutations: Robinson.et.al.JBC.280;36:31699-31717(2005),Robinson.et.al PNAS.105:12;49164921(2008). MTMR13/Sbf2 genecard.
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1.3.1 Myotubularin-Related Protein 2
Myotubularin-Related protein 2 (MTMR2) is a 73kDa catalytically active
member of the large family of MTM lipid phosphatases. It is ubiquitously expressed in
vivo in myelin forming and non-myelin forming Schwann cells with high preferential
expression at the onset of myelination [15,21]. Additionally, it is found in Schwann cell
axons and is abundantly expressed in neurons of the peripheral nervous system [15,21].
It is only slightly active on proteins in vitro and its main substrates are PI(3)P in vivo and
PI(3,5)P2 in vitro where both are dephosphorylated at the D3 position of the inositol ring
[15]. Canhong et.al. have shown that abolishment in MTMR2 phosphatase activity
results in elevation of cellular PI(3)P levels [26]. Phosphatase activity is enhanced by
association with inactive members MTMR5 and MTMR13, the later of which when
mutated results in CMT4B2, a disease highly resembling CMT4B1 [15]. The particular
role of interactions with these pseudophosphatases remains unclear, however the
excessive large nature of these inactive proteins implicates that they could serve as
molecular scaffolds or interaction modules [19,23].
Many active members have been shown to associate in a hetero-oligomerization
fashion with these inactive members, suggesting that they may be important in regulating
subcellular localization and activity [18]. Recently, MTMR2 has been found to interact
with neurofilament light (NF-L) chain in the peripheral nerves and post synaptic density
protein-95 (PSD-95) in central neurons the former of which is important in intermediate
filament (IF) assembly, and the later in membrane remodelling during myelination
[24,25,28]. Also, Bolis et.al have identified that MTMR2 specifically interacts with Disk
large 1 (Dlg1; also known as synapse-associated protein 97 (SAP97) in Schwann cells
and negatively regulates membrane formation [25]. Disruption in this interaction results
16

in altered Dlg1 localization [25]. Loss of negative control in membrane addition due to
impaired Dlg1 localization, results in the generation of myelin outfoldings at Schwann
cell paranodes suggesting relevancy of this interaction to CMT4B1 pathogenesis [25].
MTMR2 contains two important phosphorylation sites both with similar Prolinedirected protein kinase (PDPK) recognition sequences located at N-terminal Ser58 (SP)
and C-terminal Ser631 (SSP) (figure 7). These sites are highly conserved throughout
evolution yet intriguingly, neither the kinase(s) nor phosphatase(s) have been identified
(figure 8.A,B). Importantly to note that there are sequence variances amongst the Ser 58
phosphorylation site between MTMR2 and MTMR1 the later lacking the MAPK
recognition site (S/T-P), yet the C-terminal region is highly conserved even amongst
distant orthologues including the carpenter ant.

Additionally, multiple sequence

alignment of the MTMR2.Ser58 phosphorylation site shows conservation even amongst
the sole S.cerevisiae MTM homologue ymr1p, which has been shown to have activity
towards PI(3)P and function in PI(3)P-dependent signaling pathways [29]. Knock-out
models of ymr1p do not yield any definitive phenotypes, potentially due to the functional
overlap of phosphoinositide phosphatases in yeast which allows for compensation by the
synaptojanin-like phosphatase (Sjl3p) whereas only double knock-out models result in
increased cellular levels of PI(3)P [29].
The largest group of PDPKs are the mitogen-activated protein (MAP) kinases
which recognize the optimal recognition sequence PX(S/T)P and a minimal dipeptide
sequence motif S/T-P on non-phosphorylated proteins, making these two phosphorylation
sites of MTMR2 potential MAPK targets [30]. The role and regulation surrounding
phosphorylation sites for MTMR2 remain unidentified to date. It has been suggested that
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Ser58 may play a role in regulating substrate targeting considering its close proximity to
the PH-GRAM domain and Ser631 could be involved mediating oligomerization with
inactive members due to the concurrence to the conserved CC region and SID domain. In
addition, Ser631 resides near the PDZ-binding motif and could potentially function as a
protein interaction motif [31].

Multiple sequence alignment of the N-terminal

phosphorylation sites of both MTM1 and MTMR2 show low sequence homology of Ser58
in the S/T-P motif yet the Ser is highly conserved throughout multiple species, supporting
the notion of important biological relevancy and differential regulation. The common
primary sequence position for both sites are in close proximity and ~11 amino acids
upstream of the start of the PH-GRAM domain yet their actual sequences vary leading
one to propose regulation by different protein kinases (figure 8.A).
Furthermore, this could explain the puzzling findings that MTM1 and MTMR2
cause distinct diseases despite their high overall sequence homology, common substrates
and similar tissue expression pattern, which prompts the hypothesis that they utilize
unique cellular lipid pools. Both MTM1 and MTMR2 contain potential phosphorylation
sites in their C-terminal regions however; MTM1 has the preferred MAPK recognition
sequence (PSSP) whereas MTMR2 contains the minimal (SSP) (figure 8.B).

This

suggests that they may be regulated by different MAPKs resulting in distinct subcellular
targeting and specific cellular substrate pools.

18

41

SASVVSSDSISTSADNFS58PDLR62

PH

404

DKVESGKTSVVVHC417SDGWDR423

Catalytic Domain

SID

622

TSSSERASS631PAQCVTPVQTVV643

CC

PDZ

Figure 7. Schematic of MTMR2 phosphorylation sites and conserved MTM domains
The conserved domains amongst MTM members are depicted and represented in the
MTMR2 protein diagram: N-terminal PH-GRAM domain, consensus CX5R catalytic
phosphatase domain and the C-terminal CC region. MTMR2 has two in vivo identified
phosphorylation sites located N-terminal and in close proximity to the PH-GRAM at
Ser58 and within the distant C-terminal region at Ser631, with both sites containing the
minimal PDPK recognition sequence for MAPKs (S/T-P). [figure modified from
reference 27]

19

A
MTMR2_Human
MTMR2_Sumatran Orangutan
MTMR2_Bovine
MTMR2_Dog
MTMR2_Mouse
MTMR2_Rat
MTMR2_Pufferfish
MTMR2_Atlantic Salmon
MTMR1_Human
MTMR1_Mouse
MTM1_Human
MTM1_Bovine
MTM1_Dog
Ymr1p_s.cerevisiae

B
MTMR2_Human
MTMR2_Sumatran Orangutan
MTMR2_Bovine
MTMR2_Mouse
MTMR2_Rat
MTMR2_Red Junglefowl
MTMR2_Atlantic Salmon
MTMR2_Zebrafish
MTMR2_Carpenter Ant
MTMR1_Human
MTMR1_Mouse
MTM1_Human
MTM1_Bovine
MTMR6_Human
MTMR4_Human
Ymr1p_S.cerevisiae

SSDSISTSADNFSPDLRVLRES--NK
SSDSISTSADNFSPDLRVLRES--NK
SSDSISTSAENFSPDLRVLRES--NK
SSDSISTSADNFSPDLRVLRES--NK
SSDSISTSADNFSPDLRVLREA--NK
SSDSISTSADNFSPDLRVLRES--NK
SSDSVSTSTE-LSPELRVKPQAVNK
SSDNVSTSTE-FSPELRGRPKAV--K
-QISGSVTSENVSRDYKALRDGNK
-QISGSVTSENVSRDYKALRDGNK
-SKYNSHSLENESIK-RTSRDGVN--SKYNSHSLENESIK-RTSRDGVN--SKYNSHSLENESIK-RTSRDGVN-TTHHLIFESPQLSTE FWFP------

RSTSSSERASSPAQCVTPVQTVV
RSTSSSERASSPAQCVTPVQTVV
RSTSSSERAGSPAQCVTPVQTVV
RSTSSSERASSPAQCVTPVQTVV
RSTSSSERASSPAQCVTPVQTVV
RSTSSSERAGSPAQCVTPVQTVV
RSASSTERAGSPTRSITPVQTFVTASSSSERAGSPTRSITPVQTFVASRA-NRSVTSPAPPRIHSPVHTRSTSSSERASSPAQCVTPVQTVV
TISSSSERGSSPTHSATPVHTSVKLSDPPTSPSSPSQMMPHVQTHF
KLSDPSASPSSPSQMMPHVQTHF
NDALRTIEGSSPADNRYSEYAEE
SHSGRPSATSSPDGPSRSHLDDD
-----SEKEKFQQNLPNKTKSVW

Figure 8. Multiple sequence alignments of the N-terminal (Ser58) and C-terminal
(Ser631) phosphorylation sites on MTMR2
(A) Multiple sequence alignment (NCBI BLAST: Similarity and Homology) showing
conservation of the N-terminal Ser58 phosphorylation site within MAPK consensus
sequence S/T-P. This site is also conserved even amongst and including the distant
orthologue the Atlantic salmon that has lower yet significant full length sequence identity
(79%). Also shown is the sole S.cerevisiae MTM homologue ymr1p that displays
conservation of Ser58 yet with low full length sequence identity (28%) (B) Multiple
sequence alignment showing conservation of the C-terminal Ser631 phosphorylation site
also contained within MAPK recognition sequence. Conservation is present even
amongst distant orthologues including the Zebrafish and Carpenter ant that have lower
full length sequence identities (73% and 60% respectively). Also included are MTMR6,
MTMR4 and MTMR1 which display conservation of the C-terminal phosphorylation.
MTM1 contains the optimal MAPK recognition sequence (PxS/T-P) with significant full
length sequence identity to MTMR2 (70%). The yeast ymr1p lacks the conserved Cterminal phosphorylation site with amino acids underlined.
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1.3.2 Myotubularin-Related Protein 5
Myotubularin-Related protein 5 (MTMR5; sbf1) is a large 208kDa cytoplasmic
protein and is a catalytically inactive member of the MTM family [32].
Pseudophosphatases display extensive sequence similarities to their active counterparts
however lack important amino acids in their catalytic sequences, due to germline
substitutions thereby rendering them catalytically inactive.

The consensus sequence

CX5R in the catalytic domain amongst most active members is CSDGWDR, while
MTMR5 has the sequence LEDGWDI (figure 9) [33]. Features for the most part have
been conserved throughout evolution and six inactive members within the MTM family
have been identified [33].

The inactive MTMs contain an N-terminal DENN

(Differentially expressed in neoplastic versus normal cells) domain, a central
myotubularin domain, a PH/PH-GRAM domain in addition to a C-terminal coil-coiled
(CC) region, PDZ-binding motif and SID (SET interacting)-domain (figure 4) [19]. The
functions of DENN domains are not fully understood yet several proteins containing this
domain have been shown to associate with Rab GTPases and are thought to play a
functional role in membrane trafficking [33].
The active-site phosphatase sequence is conserved amongst both inactive and
active MTM members with the pocket sufficiently preserved to bind phosphorylated
substrates, even amongst the inactive members [35]. Several researchers propose that
they might function as naturally occurring substrate trapping mutants, whose purpose is
to oppose the action of active members thereby by contributing to regulation of cellular
lipid pools [35,36]. Firestein et.al have shown MTMR5 to be linked to cellular growth
and oncogenic transformation in vitro and that deletion of the PH domain or mutations
which restore catalytic activity abrogates its ability to modulate cellular growth in NIH
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3T3 fibroblast cells [36]. Robinson et.al have identified that the pseudophosphatase
domain alone was sufficient for membrane targeting of inactive members [33]. MTMR5
interacts directly with MTMR2 but not MTM1 through their CC domains and mutations
in either MTMR2 or MTMR5 can abolish this interaction (figure 10.A) [2]. The exact
role of this interaction is still unclear, but it is proposed that MTMR5 may regulate the
enzymatic activity and subcellular localization of MTMR2 [19]. Firestein et.al have
suggested that MTMR5 may be important in spermatogenesis and germ cell
differentiation based on his finding that MTMR5 mutations in mice resulted in infertility
and decreased spermatogenesis [35].
PDZ-binding motifs have been shown to play important roles in protein anchoring
to the cytoskeleton and holding together signaling complexes through interactions with
other proteins containing PDZ domains [36,38]. Deletion of this motif in MTMR5 has no
effect on interaction with MTMR2 implicating that this region may play a larger role
potentially with associations with key trafficking proteins [33,36,38]. The CC region of
both MTMR13 and MTMR5 mediates direct association with MTMR2 and deletion of
this region results in abolished interaction (figure 10.B) [19,33]. Ciu et.al (1998) have
implied that the SID domain in the inactive MTM members may link the epigenetic
regulatory machinery with signaling pathways that are involved in growth and
differentiation [35]. This may partially explain the consequences of deletions and
resultant in vivo oncogenic transformations observed with MTMR5 and NIH 3T3
fibroblast [35]. Nevertheless, the specific role of inactive members in regulating their
active partners is not fully understood and may function through a yet to be identified
unrelated mechanisms to which these issues warrant further investigations.
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Figure 9. Schematic of MTMR5 conserved domains
The conserved domains amongst inactive MTM members are depicted and represented in
the MTMR5 protein diagram: N-terminal DENN domain (former uDENN and latter
dDENN domains enclosed in black boxes), PH-GRAM domain, the central catalytically
inactive phosphatase domain with the putative cysteine and argenine residues mutated
(bold faced and consensus active site amongst active members underlined), the Cterminal CC region, SID and PH domains. Interaction with the active MTM partner
MTMR2 is mediated through the coiled-coil domain and shown here is the relative
proximity to the distant PH domain which has been proposed that abolishment results in
increased cellular proliferation, which may be a result of inability to regulate MTMR2
function. MTMR5 has a number potential Proline directed phosphorylation sites located
throughout the protein however they have yet to be identified in vivo or in vitro.
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Figure 10. Pairwise alignments of the regions of MTMR2 interaction with the
inactive MTM family members MTMR5 and MTMR13
Multiple sequence alignments (ClustalW2) showing partial sequence conservation of
amino acids within the proposed regions of MTMR2 interactions. (A) The region of
MTMR2 CC domain is highlighted and underlined in addition to the predicted CC
region of MTM1, displaying only partial sequence similarity (*) to MTMR2 with
significant full length sequence identity (66.8%) implicating a probable method of
selection for MTMR5/MTMR13 as opposed to MTMR12 (inactive MTM1 partner).
Additionally shown in red is the proximity to the C-terminal phosphorylation site(s) on
both MTM1 and MTMR2 displaying sequence similarity with reported MTM1
phosphorylation site underlined. (B) The high sequence similarity between MTMR5 and
MTMR13 (74.5%) yet low full length sequence identity (59.1%) implicates possible
mechanism of selection of MTMR2 for either of its inactive partner. The reported
regions of MTMR13 interaction underlined and proposed region of interaction of the CC
region of MTMR5 underlined. Coiled-coil domain boundaries of MTM1 and MTMR5
were obtained from COILS [2,5].
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1.4 Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth disease (CMT) is a genetically heterogeneous disease
consisting of motor and sensory deficits which represent the larger portion of hereditary
peripheral neuropathies [39]. Genetically, more than 35 genes have been identified and
associated with the demyelinating forms CMT-types 1,3,4 (CMT1, CMT3, CMT4) and
the axonal form CMT-types 2 (CMT2). These groups are further divided into many
subtypes based on chromosome linkage analysis, genetic screenings, and NCV tests. The
most prevalent form of demyelinating CMT is CMT1A which is caused by a 1.5Mbp
duplication on chromosome 17p12 harbouring the causative gene PMP22 [40]. In 2010
Huang et.al [40] identified that copy number variants (CNV) are the underlying cause
and importance for CMT1A manifestations. Genetic testing for CMT is generally based
on direct sequencing, and to date, no other disease-causing CNVs have been identified to
result in other forms of CMT, and all others are nearly exclusively caused by point
mutations. There have been implications that CNVs affecting several coding exons or
larger introns may be excluded by conventional methods, and therefore potentially could
be present amongst the genomic regions of the heterogeneous populations of CMT
harbouring genes.
CMT4B1 is a hereditary autosomal recessive demyelinating motor and sensory
neuropathy (HMSN) characterized by focally folded myelin sheaths in the peripheral
nerves, slow NCV tests (<40m/s) and decreased Schwann cell proliferation [41].
Currently incurable, it is the most commonly inherited neurological disorder in the
United States affecting approximately 1:2500 individuals [42].

Clinical features of

CMT4B1 include progressive muscle atrophy, distal sensory loss and weakness in the
outer extremities with typical age of onset in childhood years. Characteristic phenotypes
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in all affected individuals displayed prominent weakness beginning in the lower limbs
and spreading proximally to the upper limbs in later years [16,17,41,44,46]. However,
additional features have been described including weakness in upper facial muscles with
this data being suggestive that varying phenotypes are dependent on the severity of
mutations [34]. Bolino et.al. (1996/2000) localized the gene responsible for CMT4B1 to
chromosome 11q22 and mapped the critical interval to a 2Mb region by haplotype
sharing using two unrelated CMT4B1 pedigrees [41,43]. This disease is distinguished
from CMT4B2 which was localized to chromosome 11p15 coding for the gene SETbinding factor 2 (SBF2/MTMR13) only by direct sequencing considering it resembles
CMT4B1 both clinically and pathologically [44]. In addition, they demonstrated that 21
different transcripts along with 3 identified genes reside in this critical region.

In

particular, they identified two expressed sequence tags (EST) belonging to the same
transcript were contained within the sequence-tagged site (STS) markers for the critical
CMT4B interval, those coding for the MTMR2 gene. Most known CMT causing genes
encode myelin structural proteins in Schwann cells (MPZ: Myelin Protein Zero), regulate
expression of other myelin proteins, or have some involvement in Schwann cell
metabolism (PMP-22: Peripheral myelin protein 22). Because the exact functional role of
MTMR2 remains unclear, this implicates a critical importance of this protein to have
involvement in some form of Schwann cell-related mechanism; whether be those listed
above or cell signalling/ trafficking. It has been suggested that the lack of protein may
result in uncontrolled phosphorylation events leading to Schwann cell proliferation and
myelin overgrowth, which is observed in the peripheral nerves of CMT4B1 patients [41].

26

Researchers have identified at least 10 different base pair mutations in the MTMR2 gene
associated with causing CMT4B1 resulting in frameshift readings to yield a truncated
protein or point mutations, both rendering the protein inactive. Alterations in protein
structure most likely affect the ability of MTMR2 to modify its substrate which in turn,
could disrupt key trafficking and signaling events sensitive to correct lipid levels.
In addition, Schwann cells rely on efficient Ras/Raf/ERK signaling at different
thresholds with respect to the particular stage of myelination. Transient activation of
ERK is associated with proliferation whereas high levels of activation have been
associated with promoting differentiation in a number of cells [45]. Harrisingh et.al.
(2004) recently discovered that the ERK pathway is responsible for driving
dedifferentiation [45]. Inhibition had no effect on the differentiation processes which are
mediated by upstream Ras/Raf in Schwann cells [45]. Axon-derived signals are the
driving force in Schwann cell myelination and rely on signal transduction through the
Ras/Raf/ERK pathway to initiate differentiation. They also determined that Raf/ERK
activation in Dorsal-Root ganglion (DRG)-Schwann cell co-cultures, induced
demyelination and breakdown of the myelin sheath [45].
Schwann cells divide irregularly particularly following precise cellular demands
and are also regenerative, meaning that they myelinate axons in response to specific
axon-derived signals, dedifferentiate in response to nerve damage, and can redifferentiate
during the axonal repair process [45]. Axon/nerve damage results in strong activation of
the ERK pathway leading to sustained signal transmission which triggers myelin
breakdown. Ultimately, through efficient and tightly regulated ERK activation, Schwann
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cells dedifferentiate and proliferate, then are triggered to re-enter the cell cycle resulting
in remyelination of the damaged axon as part of the efficient nerve repair process [45,46].
Signal transduction and membrane trafficking of the axonal signal and key
secondary signaling molecules such as phosphoinositides, must be coordinately
maintained at precise cellular levels for efficient signal transport. Therefore, proteins that
are involved in regulation of cellular lipid levels in primary/early signaling stages such as
MTMR2, may ultimately be involved in regulating a subset of Schwann cell processes.
Inability of MTMR2 to maintain the correct lipid levels may result in impaired ERK
activation, therefore, disrupting the efficient nerve repair processes and myelin
development. In 2007, Chojnowski et.al. [46] determined that loss of functional MTMR2
resulted in decreased Schwann cell proliferation, implicating a role in the primary stages
of Schwann cell myelination.

Myelin outfoldings and decreased Schwann cell

proliferation are characteristic features of CMT4B1, thereby implicating that correct
MTMR2 regulation is required for proficient Schwann cell processes.
1.5 The Dynamic Role of Phosphoinositide Phosphatases
Phosphoinositide (PI) synthesis, degradation and inactivation are important
biological processes that are co-ordinately regulated by lipid kinases and lipid
phosphatases respectively [26,48].

The influence of numerous phosphoinositide

phosphatases in membrane trafficking, cell survival, cell growth and signal transduction
has largely been underrepresented as most research primarily has focused on kinases as
being the key players in various physiological systems. Only within the last decade has
there been more aim focused on studying the critical aspects of phosphoinositide
phosphatase regulation as it has become more apparent that dysregulation triggers
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aberrant phosphoinositide signaling which often results in a number of human cancers
and disease in addition to type-2 diabetes mellitus [3].
The phosphatase and tensin homologue deleted from chromosome 10 (PTEN) is a
tumour suppressor gene that has been found to be deleted in a number of human cancers
and characteristically results in invasive phenotypes [50,51].

Somatic and germline

mutations in PTEN are found to be predominantly the cause of carcinomas, gliomas and
relatable to other genetic disorders including Cowden disease and Lhermitte-Duclos
syndrome in addition disruption in expression has also been implicated in cardiovascular
disease [51]. Unlike MTMR2 and MTM1, PTEN utilizes PI(3,4,5)P3 rather than PI(3)P
or PI(3,5)P2 as its physiological substrate, implicating its activity to be dependent and
antagonistic towards PI3K signaling in addition to PI(3)P effector proteins such as Akt
[51]. Akt is responsible for governing key signaling pathways that control growth, cellcycle and apoptosis, and it has been proposed that the tumour development as a result of
loss in PTEN activity, triggers metastatic tumour growth through defects in an Aktmediated fashion [51]. Loss of phosphatase activity results in the inability of PTEN to
act as a tumour suppressor thereby resulting in increased levels of PI(3,4,5)P 3 and
overactive Akt signaling which stimulates tumour cell proliferation [26,50,51]. Studies
by Birle et.al. [52] and Xu et.al. [53] demonstrated that phosphorylation of PTEN
triggers conformational changes that elicit a closed conformation resulting in greater
protein stability yet catalytically inactive. As a result, these changes impact PTENs
ability to interact with membrane targeting binding factors thereby culminating in
inaccessibility to its phosphoinositide substrates [52,53].
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Conversely, dephosphorylation of PTEN results in an open conformation, allowing for
targeting to the plasma membrane and access to its substrate [53].
1.6 Endocytosis and Constitutive Membrane Trafficking
The process of endocytosis involves a complex organization of membrane-bound
receptors and intracellular vesicles that mediate the efficient internalization of molecules
and correct endocytic sorting. Endocytosis is crucial for an array of cellular functions
and can occur through several distinct morphologically and biochemically diverse
mechanisms with the capacity to internalize both small molecules to entire cells [54].
Adequate regulation ensures the precise maintenance of important cellular functions and
organelle targeting, whereas aberrant disruption in these processes in addition to incorrect
post-endocytic sorting, often results in diseases [55,56].
The most common and well characterized mechanism for the intracellular entry of
molecules is via complementary cell-surface receptors, initially resulting in formation of
clathrin-coated pits and subsequently commencing in receptor-mediated endocytosis
(RME) (figure 11) [56]. Internalized receptors contain specific signals composed of short
tyrosine-based sequence motifs (-YXXZ-/-NXXZ-) in their cytoplasmic domains (in
which X is variable and Z is a large bulky hydrophobic group i.e Phe, Trp) permitting
recognition by adaptor proteins (AP) [54,56,7]. The functional activation of the APs and
receptor membrane targeting is closely coupled to direct clathrin membrane recruitment
and coated pit assembly [55,57]. Clathrin binding to the region of ligand-bound receptor
on the inner surface of the plasma membrane, triggers pit invagination and bud formation
[58,59]. The newly formed clathrin-coated vesicles must then effectively be “pinchedoff” from the plasma membrane to complete the initial stages of endocytosis and
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commence in vesicular trafficking. The clathrin coat must then be rapidly removed in
order to enable the vesicle to fuse with its target membrane, ultimately recycling the coat
components back to the cell membrane surface for further use and targeting of the newly
formed vesicle to the initial molecular sorting stations at the early endosomes [60].
Collectively, this leads to long held classical view of endocytosis that following
extracellular ligand-receptor binding, the complexes are internalized via fission and
consumed within the newly formed clathrin-coated vesicles (figure 11) [55]. Progression
through the endocytic pathway is subsequently characterized by the shedding of clathrin
wherein the cargo-containing vesicles proceed inwards and fuse with the early endosomes
[55]. These organelles are responsible for directing the internalized vesicles to their
proceeding pathway, consequently; the Endocytic Recycling Compartment (ERC) for
redirection towards the plasma membrane, towards the trans-Golgi Network (TGN) for
packaging prior to trafficking to its destined subcellular compartment, or they may be
targeted to the late endosomes/lysosomes (Multivesicular bodies; MVB) for degradation
[61,62].

Regulation of the endosomal sorting system that ultimately directs active

receptor tyrosine kinases (RTK) to the lysosomes can be prolonged and affect the
duration of the stimulus and hence, perpetuate the length of signaling events [63]. The
complex functionality of these subcellular compartments can be defined and enhanced by
particular marker proteins in addition to specific subdomains within these organelles [55].
The Rab family of small GTP binding proteins is known to regulate vesicular trafficking
processes and they are markedly established proteins for distinct endocytic compartments
[64].

Highly modulated exchanges of GDP/GTP aid in the correct regulation of

constitutive endocytosis, which in turn can ultimately be modified by extracellular stimuli
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[65]. The small GTPases Rab5 in particular, is a key regulator of trafficking events such
as vesicle formation, docking, and fusion from the cell membrane into and between the
early endosomes [65,66]. Rab5 associates with endosomes in its active GTP bound form
which is co-ordinately mediated by the endosomal Guanine exchange factor (GEF)
RABX-5. Notably, RABX-5 maintains Rab5 activation on endosomes and is spatially
modulated by the endosomal protein SAND-1/Mon1 (Monensin sensitivity protein 1) in a
PI(3)P dependent fashion [67]. It is therefore highly conceivable that the adequate
regulation of Rab5-dependent trafficking events that are sensitive to PI(3)P, could be
modulated by proteins and/or events that alter specific cellular pools of PI(3)P.
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Figure 11. Subcellular localization of phosphoinositides in the endocytic pathway
and cellular translocation of binding components of the endocytic machinery
The processes along the endocytic pathway are regulated in such a manner that particular
steps can be identified by specific organelle subdomains and marker proteins. Various
phosphorylated forms of PIs are located along different regions of the pathway and
represent key components of early-late endosomal compartments. Correspondingly, the
small Rab GTP-binding proteins are proficient in their ability to recruit further
components required for homotryptic fusion (EEA-1), retrograde transport (SNX-1/4) and
ESCRT machinery binding (Hrs) [61]. [figure from reference 61]
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1.6.1 The Early Endosomes and Late Endosomes
The canonical early endosomes are characterized by the presence of Rab5, in
addition to its effectors Rabenosyn-5, Early Endosomal Antigen 1 (EEA1) and the lipid
PI(3)P [55,64]. The efficient recruitment of Rab5 effector complexes regulate endosomal
vesicle tethering and is coupled to membrane fusion events which are mediated by
SNARE (soluble N-ethylmaleimide–sensitive factor (NSF) attachment protein receptor)
proteins [66,68].

Highly coordinated events of SNARE functions coupled with

membrane tethering, effectively organizes membrane subdomains on early endosomes
[65,66,68]. Morphological studies have shown that Rab5 occupies a distinct domain on
endosomes thereby recruiting the PI3-kinase isoform hVPS34, and generating localized
production of PI(3)P [68].

The complementary presence of Rab5 and PI(3)P is a

necessary element for the proficient recruitment of the Rab5 effector complex EEA1
[55,64,68].
In mammalian systems, the levels of PI(3)P are typically low and only ~0.2% are
phosphorylated at the D3 position however, the direct localization to early endosomes
implies a highly specialized role of this phosphoinositide in membrane trafficking [69].
EEA1 binds PI(3)P though a specialized zinc finger FYVE (Fab1p, YOTB, Vac1p and
EEA1) domain thereby effectively allowing for docking of this membrane tethering
molecule [68,69]. Interactions of basic side chains in highly conserved FYVE finger
domain motifs (R(R/K)HHCR and RVC) form a coordination shell with the 3-phosphate
[68]. Additional side chains with a third conserved motif (WxxD) interact with the 4-/5/6- hydroxyl groups of the inositol head group thereby preventing interactions with
alternative phosphoinositides and implicating the ligand specificity of FYVE fingers for
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PI(3)P [68].

In addition, proteins containing FYVE domains which are located on

endosomes have been shown to function in endocytosis and growth factor signaling, and
those located on the plasma membrane assist in the regulation of the actin cytoskeleton
[61,70]. Moreover, researchers have adequately devised a method for locating specific
PIPs within the cell, in which fusion of the lipid binding modules definitive for a PI
species such as the FYVE domain to green fluorescent protein (GFP) as a means of
specifically identifying regions rich in the desired PI [61,72]. Collectively, strict
regulation in the turnover of PIPs managed by the complex enzymology governing
phosphoinositide synthesis, degradation and homeostatic control can be directly
associated with phosphoinositide phosphatase deficiencies linked to a number of human
diseases [61].
The presence of Rab5 on early endosomes allows for the efficient recruitment of
effector complexes that are essential for correct maturation of endosomal organelles [55].
Zoncu et.al. (2009) have recently identified that the membrane adaptor protein APPL1
(Adaptor protein, Phosphotyrosine interaction, PH domain and Leucine zipper containing
1) directly binds Rab5 and is considerably distinct from classical early endosome marked
by EEA1 [55,64,73]. At the very early stages of endocytosis, APPL1 vesicles are formed
immediately following fission of endocytic vesicles [74]. The loss of APPL1 as vesicles
moved centrally from the plasma membrane coincides with the recruitment of EEA1 and
subsequently maturation into the canonical PI(3)P positive endosomes, and in turn further
recruitment of Rab5 [74]. APPL1 directly binds Rab5 and portions of the lipid bilayer
via a Bin–Amphiphysin–Rvs (BAR) and a PH domain, in addition to the cytoplasmic
portion of a subset of membrane receptors (i.e. EGFR) [74]. This subpopulation of
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endosomes positive for APPL1, is presumed to precede the canonical Rab5 and EEA1,
with a known functional role in assembly of signaling complexes for MAPK and Akt
pathways [55,73]. Therefore, the presence of APPL1 profoundly impacts Akt and MAPK
signaling and recent advances have indicated a lack of APPL1 endosomes is linked to
increased apoptosis during development as a result of decrease in key growth factor
related signaling pathways [74]. Recent work has shown that increased levels of PI(3)P
acts as a molecular switch to turn off growth factor signaling [74].
Furthermore, select specialized phosphoinositide molecules such as PI(3)P,
PI(3,4)P2, and PI(3,5)P2 also play fundamental roles as molecular tags along the
endocytic pathway [55]. The transition between early and late endosomes could be
mediated by the simultaneous loss of Rab5 from an endosome which occurs
concomitantly with the acquisition of Rab7 [67].

The physiological importance of

signalling from endosomes post-internalization requires further understanding and more
detailed delineation, in order to fully comprehend the complexities associated with
examination of endosome signal in intact mammalian systems.
1.6.2 Linking Receptor Internalization to Signaling Pathways
The corresponding signaling cascades following receptor internalization are
activated promptly after receptor ligation provoking signal transduction and initiation of
endocytic trafficking.

The most sought about and characterized forms of cellular

response to stimuli coupled with internalization and intracellular trafficking is the RME
and Epidermal Growth Factor Receptor (EGFR) signaling pathway [56,75]. Haugh et.al.
(1999) discovered that receptor tyrosine kinases (RTKs) are capable of signaling
following activation by EGF and internalization as a result of autophosphorylation and
activation of the intracellular kinase domains of the receptors [76]. In particular, they
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along with others have determined a crucial downstream event following receptor
complex formation directly linked to the EGFR pathway that is the activation of the
ERK/MAP kinase cascade [76,77]. It is proposed to be a result of recruitment of the APs2 and RTK substrate Eps15 that mediates the growth factor responses in eukaryotic
systems [75,77]. Notably, Barbieri et.al (2000) showed that EGF stimulation under
serum conditions triggered Rab5 GTP loading (activation) and as a result, enhanced the
effects of ligand induced endocytosis and ultimately signal transduction [75].
Furthermore, they showed that total cellular PI(3)P depletion resulted in the blockade of
the EGF effects on endocytosis and hence, prevention of EGF induced endocytosis [75].
Profound evidence has now shown that aberrant EGFR trafficking is associated with
uncontrolled signaling events and may be ultimately a result of abnormal initial
trafficking events that may be dependent on the activity of phosphoinositide
phosphatases.
The functional regulation of rapid endocytosis of activated receptors is one of the
most highly conserved processes in multicellular systems, and is a means of correctly
mediating receptor signaling from the plasma membrane [80]. Eukaryotic organisms have
adequately devised a mechanism for turning off signals generated as a result of ligandinduced activation of receptors, as a means of mediating precise signal transduction
levels. The long held concept underlying endocytosis is that the molecular mechanisms
are presumably for receptor down-regulation and reducing the number of available
ligands, mediated through recruitment of ubiquitin ligases following receptor activation
to ubiquitin-binding platforms that direct receptor sorting [61,78,79]. Accordingly, the
number of active cell surface receptors is controlled via constitutive internalization and

37

prompted to recycling back to the plasma membrane surface as a means of controlling the
number of available cell surface receptor comparative to appended ligands. The spatial
and temporal regulation of receptor endocytosis is required in order to maintain and
control signalling and to elicit the appropriate biological responses.
The small GTPases protein Ras is an additional factor that can contribute to
cellular signal transduction cascades which is located at the plasma membrane and has
also been shown to be present on intracellular membranes of endosomes [82]. RasGTPases have crucial roles in RTK signaling and activation, in which the GTP-bound
state is presumed to be crucial for the activation of an array of signaling pathways [79].
Ras localization to endosomal vesicles is presumed to in part be mediated by association
with the Rab5 GEF RABX-5, which promotes the ubiquitination of Ras concomitantly
with GTP Rab5 activation thereby promoting endosome maturation ultimately leading to
the suppression of ERK activation [79,82,83]. Defects in the mechanisms of receptor
internalization and degradation results in RTKs acquiring oncogenic properties ultimately
associated with defective endocytosis and prolonged amplitude/duration of biochemical
growth factor signals (i.e. enhanced proliferation). As a result, the functional aspects of
the endocytic pathway have long been viewed as a means of receptor down regulation
and attenuation of growth factor signals. Irrespective of evidence indicating signaling
following endocytosis, the ultimate fate of activated RTKs is targeting for degradation in
the lysosomes [63].
1.7 The Essential Roles of Phosphoinositides in the Endocytic Pathway
Phosphorylated

forms

of

phosphatidylinositols

are

referred

to

as

phosphoinositides (PIs) which are ubiquitous components of eukaryotic cell membranes
and key secondary signaling molecules in vesicular trafficking (figure 11) [84]. The
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spatially segregated generation of PIs within the cell reflects the significance of
maintaining a precise balance between the activities of kinases and phosphatases at
distinctive cellular locations in response to extracellular cues, in addition to intracellular
cargo transport between various compartments. Of the seven known species of phosphoPIs in the cell which are generated as a result of versatile and differential phosphorylation
of the inositol headgroup, there are four well established and characterized PIs that play
key roles in the endocytic pathway. The recruitment of endocytic proteins to the plasma
membrane is governed by PI(4,5)P2 which predominates on the plasma membrane,
resulting in sequential endocytic protein invagination and subsequent vesicule formation
[85]. Activation of the PI(5) kinase-1 which in turn phosphorylates the D5 position of
PI(4)P to generate PI(4,5)P2 following growth-factor receptor binding, and can
additionally lead to increased localized production to the site of subsequent coated-pit
formation and receptor internalization [79]. The question arises as to what factors
regulate the local synthesis of PI(4,5)P2 and restriction to the plasma membrane. PIbinding effectors are likely to play a major contribution in sequestration of the preformed PI pools at the plasma membrane, which in part is tightly correlated with the
myrisotoylated alanine-rich C-kinase substrate (MARCKS) association [86]. Association
is mediated through basic amino acid stretches thereby keeping PI(4,5)P2 restricted to the
plasma membrane and requires release initiation by reversible phosphorylation by protein
kinase C (PKC) and calmodulin (CAM) binding following triggering of action by specific
extracellular stimuli (i.e. EGF, NGF) [86]. Cellular growth factor stimulation leads to
activation of two distinct PI3Ks, PI3K and Vps34, which transiently phosphorylates the
D3 position of the inositol ring of PI(4,5)P2 resulting in generation of PI(3,4,5)P3, with the
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latter phosphorylating only at the early endosomes. This PI is responsible for binding to
the PH-GRAM domain of the AGC (named from: cAMP-dependent protein kinase A,
cGMP-dependent protein kinase G, and phospholipids-dependent protein kinase C)
family protein kinases thereby recruiting them to the plasma membrane commencing in
allosteric activation and consecutive regulation of growth, proliferation and survival [84].
The small GTPase Rab5 can cycle between endosomal membrane bound and
cytoplasmic, based on its association with the guanine nucleotide dissociation inhibitor,
(GDI) [87]. The direct complex formation of Rab5-GDI is responsible for govering Rab5
localization and ultimately the direct interaction with Vsp34 and PI3K

leading to

controlled generation of PI(3)P [87]. Sequentially, PI(3,4,5)P3 is dephosphorylated by
inositol polyphosphate 5-phosphatases (PIPP,SKIP,ORCL) and the 4-phosphatases (Type
I,II) to generate PI(3)P which is the major phosphoinositide on early endosomes.
Additionally, it has been shown that Rab5 directly interacts and stimulates the activity of
PI3K , 4- and 5-phosphatases. Therefore, Rab5 can be implicated in being involved in
the enzymatic turnover of PIs from the plasma membrane to the early endosomes.
Concomitantly it presumably functions with PI3K

and the 4-, 5-phosphatases which

function as Rab5 effectors, leading to PI(3)P synthesis, efficient endocytosis and signal
transduction [87].
Recently, Clague et.al (2009) made a critical observation indicating a major role
of 3-phosphoinositides in homotryptic early endosomal fusion in which inhibition of the
PI3K by wortmanin, subsequently could inhibit the trafficking of a number of growth
factor receptors [88]. Additionally, PI(3)P is a precursor for the generation of PI(3,5)P2
in which the FYVE domain containing PI5-kinase, PIKfyve, is recruited to the early
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endosomes leading to the phosphorylation at the D5 position of the inositol head group
allowing for further maturation into late endocytic organelles marked by PI(3,5)P2
[70,86]. Association of Rab5 with early or Rab7 with late endosomes is not affected by
PI3K inhibition with wortmanin and therefore, localization of these distinct
compartmental membrane proteins is not dependent on the endosomal levels of PI(3)P
[67]. However, a positive feedback loop involving the GEF RABX-5 in turn, is disrupted
by the regulator SAND-1/Mon1 that is dependent on recruitment to the early endosomes
based on the age and accumulation of PI(3)P within early endosomes [67]. In turn, this
results in the subsequent displacement RABX-5 for recruitment of Rab7 and is proposed
to be a result of interactions through the Rab7 GEF Class C Vps/HOPS complex [67].
Loss or disruption in the ability of SAND-1/Mon1 to consummate conversion to Rab7
endosomes, results in a large accumulation of Rab5 protein and enlarged Rab5 positive
endosomes, unable to undergo homotryptic fusion [67]. Therefore, the likelihood that
proteins whose function is to regulate early endosomal PI(3)P levels, could potentially
contribute to the mechanistic control of Rab5 dependent trafficking and maturation into
late endosomes.
1.7 The Mitogen-Activated Protein Kinase Signaling Pathway
The Mitogen Activated Protein Kinase (MAPK) signaling cascade controls a vast
array of complex biological functions and plays key roles in mediating signal
transduction of extracellular signals to elicit the appropriate cellular response.

The

function and regulation is tightly controlled mechanism which has been conserved
throughout evolution from unicellular to multicellular organisms [89,91,94].

In

mammalian systems, there have been three well characterized MAPK families: the
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classical Extracellular regulated kinases (ERK), c-Jun N-terminal kinase/Stress activated
protein kinases (JNK/SAPK) and p38 kinases (figure 12) [89]. Only recently, has there
been identified a fourth MAPK, ERK5 which responds to oxidative stress and growth
factors in addition to stimuli similar to ERK1/2 however unlike ERK1/2, ERK5 has key
roles in cardiovascular development and neural differentiation [90].
All MAPK cascades operate on a three-tiered system of enzymes that are activated in
series (MAPKKK-MAPKK-MAPK) ultimately leading to the amplification and
activation of downstream targets in response to cellular signals [89]. Activation of
MAPKKK by upstream signals triggers the dual phosphorylation of downstream
MAPKKs at two Ser/Thr residues in which selectivity is conferred by distinct motifs in
their sequence and with respect to different stimuli responses [91,94]. The
phosphorylated MAPKKs are dual specificity kinases that then act to phosphorylate the
downstream MAPKs at Thr/Tyr residues, such as ERK1/2 Thr-Glu-Tyr (TEY) motif
[92]. MAPKs are a subgroup of the proline-directed Ser/Thr kinases because they share
the partial sequence recognition of PDPKs (P-X-S/T-P-X-Z), whereby Z is a basic amino
acid (H, K or R) and X is any amino acid [93]. The activated MAPKs then act to
phosphorylate target substrates based on their specificity. MAPKs have the recognition
X-S/T-P, with the similarity to PDPKs being the Proline preceding the phosphorylated
Ser/Thr residue [92]. The reverse is catalyzed by MAPK phosphatases that
dephosphorylate MAPKs to return them to their original inactivated state and it is the
rapid and reciprocal actions that allows for cells to quickly respond to changes in their
external environment [94].
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One of the best and well characterized MAPK cascade is the Ras-Raf-MEK-ERK
pathway which plays a critical role in the regulation of cell proliferation in response to
cytokines and growth factors, in addition to the regulation of G1/S cell cycle progression
[89]. Sequentially, binding of extracellular stimuli such as EGF to the corresponding
RTK, leads to receptor autophosphorylation/activation which provokes further
downstream activation of the MAPKs in a multistep process [89].

Ultimately,

phosphorylation of ERK1/2 by MEK1/2 triggers activation and increased enzymatic
activity leading to phosphorylation of target substrates and partial ERK1/2 nuclear
translocation, resulting in transactivation of specific transcription factors thereby
producing effects on growth, gene expression and differentiation [89]. Loss of control in
MAPK cascades ultimately leads to impaired cellular signaling and transduction resulting
in defective growth and development [89]. In addition, MAPK pathways have been
shown to be involved in many pathological human disease and cancer [89]. In particular,
the proto-oncogene Ras is found upstream of Raf and leads to its activation [90].
However Ras mutations that result in Ras acquiring oncogenic properties results in
persistent activation of ERK1/2 pathways contributing to the overactive growth rate of
tumour cells, implicating that pathways surrounding and governing ERK1/2 activation
need to be tightly controlled [90].

43

EGF

Injury/Ischemia/ROS

TNFα

Figure 12. The Mitogen Activated Protein Kinase signaling cascade4
The MAPK pathway is a signaling cascade that is activated in response to inflammatory
cytokines, stress and growth factors. The MAPKKK are activated in response to effector
molecules that bind to either RTKs or G-protein coupled receptors. The downstream
MAPKs are activated by phosphorylation of Thr and Tyr residues in the activation loop
by the upstream dual specific kinases, the MAPKKs. The activated MAPKs are Ser/Thr
kinases that phosphorylate specific targets including transcription factors, regulators and
cytoplasmic proteins.

4

Image modified from; http://www.cellsignal.com/reference/pathway/MAPK_Cascades.html
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1.8 Utilization of Mass Spectrometry to Identify Protein Phosphorylation
Mass spectrometry (MS) is used as a site mapping tool for the quantification of
protein post-translational modifications. Protein phosphorylation is a central mechanism
used by all eukaryotic systems as a means for precise regulation and controlling cellular
signaling. Protein kinases and phosphatases govern reversible phosphorylation events
and it is estimated that one-third of all proteins are phosphorylated at any given time,
implicating the importance of correct regulation [81].

The detection of covalent

modifications and monitoring changes is a key feature of MS. More specifically, MS
utilizes mass-to-charge (m/z) ratio to detect a mass increase of +80 m/z for singly
phosphorylated peptides (HPO3) in addition to changes as a result of the neutral loss of a
phosphate group from an amino acid residues of -98 m/z (H3PO4) following gas-phase
fragmentation (MS/MS) of phosphopeptides [81]. This neutral species (H3PO4) is lost as
a result of cleavage of the phosphodiester bond from phosphorylated serine or threonine
residues. Generally, phosphopeptides are rarely detected in total trypic digest pools,
primarily owing to their low stoichiometry and inefficient ionization in MS therefore,
usually will require further purification and/or enrichment steps. Covalent coupling to
chemical tags and affinity purification steps such as immobilized metal affinity
chromatography (IMAC), TiO2, and zirconium dioxide (ZrO2) are widely used as a
means for enrichment of phosphoanalytes [81].
Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) - MS is
a common technique utilized for the detection of modifications on larger molecules such
as proteins [71]. The purpose of MALDI is to decrease the amount of direct energy
transfer to the analyte molecules in order is avoid excess decomposition and
fragmentation [71]. The digested samples are pre-mix with an absorbing matrix such as
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α-cyano-4-hydroxycinnamic acid (CHCA) in combination with highly purified water
(milliQ), acetonitrile (ACN) and a low percentage of trifluoroacetic acid (TFA) then
spotted onto a MALDI plate [71,81]. The solution vaporizes and results in the formation
of co-crystals containing the absorbing matrix and the analyte. Once the sample is
allowed to dry, it is placed into the mass spectrometer under high vacuum and the laser is
fired which ionizes the matrix allowing for efficient energy transfer to the analyte
molecules thereby avoiding the harsh direct energy transfer. The TOF analyzer measures
ions in the gas phase which travel through an energy free region known as the “flighttube” or “drift region” based on their m/z, meaning that larger molecules will travel
slower than smaller ones [71]. MALDI generally produces singly charged protonated
ions [MH+], which in MALDI-linear mode, represents the parent ion of the fragmented
peptide as a peptide mass fingerprint [71,78]. Dominant peptide peaks are then chosen
for further fragmentation in MS/MS mode or post-source-decay (PSD) in order to obtain
the primary peptide sequence which allows for greater accuracy in the identification of
post-translational modifications [37,71]. The MALDI-PSD spectra are then utilized to
search large protein data bases in order to match the corresponding peptide
fragmentations and identify the amino acid sequence, ultimately assisting in the
identification of phosphorylated residues [37].
1.9 Research Objectives
The focus of this research is to gain further understanding and insight into the
critical biological aspects of MTMR2 regulation by reversible phosphorylation.
Although several studies have implicated MTMRs to be involved in vesicular trafficking,
lack of profound evidence yields misunderstanding into the particular role that these PIP
phosphatases play.

In addition, the definitive biological consequences related to
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alterations in MTMR2 phosphorylation have yet to be identified. Particular emphasis of
this research will be placed on determining the cellular responses associated with
MTMR2 phosphorylation as well as the biological relevancy particularly with respect to
the endocytic pathway.
The specific aims are as follows:
(i) To evaluate the effects of Ser58 phospho-mutants on the stability of interaction with
MTMR5 in vivo in addition to its lipid phosphatase activity in vitro and will be carried
out as follows:
a. Investigate the extent of interaction upon co-expression of MTMR2 and
phospho-variants

with

MTMR5

in

cell

culture

followed

by

co-

immunoprecipitation
b. Purify recombinant MTMR2 proteins and examine the lipid phosphatase
activity in vitro using water soluble phosphorylated-phosphoinositol lipid
substrates. The phosphorylated form of MTMR2 (S58E) will be represented and
function as a phosphorylation-mimic and investigate if activity is enhanced by
phosphorylation.
(ii) Identification of kinase(s) involved in regulation of Ser58 phosphorylation
a. Purify recombinant wild-type MTMR2 protein and examine phosphorylation by
several MAPKs using pSer58 antibody.
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b. If MTMR2 is determined to be phosphorylated by a specific kinase, inhibitor
treatments will be applied in cell culture to monitor the effects on subcellular
localization and Ser58 phosphorylation in vivo using pSer58 antibody.
(iii) Characterization of MTMR2 subcellular targeting and signal transduction through
regulation by phosphorylation
a. Generated single and combinatorial phosphorylation mutants for the Ser58 and
Ser631 phosphorylation sites and monitor potential alterations in their subcellular
localization using endogenous endosomal marker proteins.
b. Investigate the relationship to the endocytic pathway by monitoring lipid
substrate localization and relatable signaling pathways.

48

REFERENCES
[1] Mary Katherine Tarrant and Philip A. Cole. The Chemical Biology of Protein
Phosphorylation. Annu Rev Biochem. 78; 797–825 (2009)
[2] Philip Cohen. The origins of protein phosphorylation. Nature Cell Biology. 4; E127130 (2002)
[3] Jimmy Lin, Zhi Xie, Heng Zhu and Jiang Qian. Understanding protein
phosphorylation on a systems level. Briefing in functional genomics. 9:1; 32-42 (2010)
[4] David Secko. Protein Phosphorylation: A global regulator of cellular activity. The
Science Creative Quarterly. 3; (2003)
[5] Anirban Bhaduri and R. Sowdhamini. A genome-wide survey of human tyrosine
phosphatases. Protein Engineering. 16:12; 881-888 (2003)
[6] Rob Hooft van Huijsduijnen. Protein tyrosine phosphatases: counting the trees in the
forest. Gene. 225:1-2, 28; 1-8 (2003)
[7] G Manning, GD Plowman, T Hunter, S Sudarsanam. Evolution of protein kinase
signaling from yeast to man. Trends in Biochemical Sciences. 27:10; 514-520 (2002)
[8] Tomas Mustelin. A Brief Introduction to the Protein Phosphatase Families. Chp 2; 922. Methods in Molecular Biology, 365: Protein Phosphatase Protocols (2007) 211
[9] Andres Alonso, Joanna Sasin, Nunzio Bottini, Ilan Friedberg, Iddo Friedberg, Andrei
Osterman, Adam Godzik, Tony Hunter, Jack Dixon and Tomas Mustelin. Protein
Tyrosine Phosphatases in the human genome. Cell. 117; 699–711 (2004)
[10] Zhong-Yin Zhang, Yuan Wang, and Jack E. Dixon. Dissecting the catalytic
mechanism of protein-tyrosine phosphatases. Proc. Natl. Acad. Sci. 91;1624-1627
(1994)
[11] John M. Denu and Jack E. Dixon. A catalytic mechanism for the dual-specific
phosphatases. Proc. Natl. Acad. Sci. 92;5910-5914 (1995)
[12] Andrew W. Stoker. Protein tyrosine phosphatases and signalling. Journal of
Endocrinology. 185; 19-33 (2005)
[13] Martell KJ, Angelotti T, Ullrich A. The "VH1-like" dual-specificity protein tyrosine
phosphatases. Mol Cells. 8:1;2-11 (1998)
[14] Xue Li, Kenneth A. Ohgi, Jie Zhang, Anna Krones, Kevin T. Bush, Christopher K.
Glass, Sanjay K. Nigam, Aneel K. Aggarwal, Richard Maas, David W. Rose & Michael
G. Rosenfeld. Eya protein phosphatase activity regulates Six1–Dach–Eya transcriptional
effects in mammalian organogenesis. Nature.426;247-254 (2003)
49

[15] Michael J. Clague and Oscar Lorenzo. The Myotubularin Family of Lipid
Phosphatases. Traffic. 6: 1063-1069 (2005)
[16] Laporte J, Bedez F, Bolino A, Mandel JL. Myotubularins, a large disease-associated
family of cooperating catalytically active and inactive phosphoinositides phosphatases.
Hum. Mol. Genet. 12 (Spec No.2): R285-R292 (2003)
[17] Alessandra Bolino, Annalisa Bolis, Stefano Carlo Previtali, Giorgia Dina, Simona
Bussini, Gabriele Dati, Stefano Amadio, Ubaldo Del Carro, Dolores D. Mruk, Maria
Laura Feltri, C. Yan Cheng, Angelo Quattrini and Lawrence Wrabetz. Disruption of
Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired
spermatogenesis. JBC. 167:4;711–721 (2004)
[18] Fred L. Robinson, and Jack E. Dixon. The Phosphoinositide-3-phosphatase MTMR2
Associates with MTMR13, a Membrane-associated Pseudophosphatase Also Mutated in
Type 4B Charcot-Marie-Tooth Disease. J. Biological Chem. 280;36: 31699–31707
(2005)
[19] Kim, Soo-A; Vacratsis Panayiotis O, Firestein Ron, Cleary Michael L and Dixon
Jack E. Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase
by MTMR5, a catalytically inactive phosphatase. PNAS. 100:8; 4492–7 (2003)
[20] Begley MJ, and Dixon JE. The structure and regulation of myotubularin
phosphatases. Curr Opin Struct Biol.15;6:614-20 (2005)
[21] Ponting CP, Phillips C, Davies KE, Blake DJ. PDZ domains: targeting signaling
molecules to sub-membranous sites. Bioessays 19:6;469–479 (1997)
[22] Jocelyn Laporte, Valérie Biancalana, Stephan M. Tanner, Wolfram Kress, Vreni
Schneider, Carina Wallgren-Pettersson, Franziska Herger, Anna Buj-Bello, François
Blondeau, Sabina Liechti-Gallati, and Jean-Louis Mandel. MTM1 Mutations in X-Linked
Myotubular Myopathy. Human Mutation. 15:393.409 (2000)
[23] Laporte J, Liaubet L, Blondeau F, Tronchère H, Mandel JL, Payrastre B. Functional
redundancy in the myotubularin family. Biochem Biophys Res Commun. 291:2; 305-12
(2002)
[24] Tsujita K, Itoh T, Ijuin T, Yamamoto A, Shisheva A, Laporte J, Takenawa T.
Myotubularin regulates the function of the late endosome through the gram domainphosphatidylinositol 3,5-bisphosphate interaction. J.Biol Chem. 279:14;13817-24 (2004)
[25] Philipp Berger, Christiane Schaffitzel, Imre Berger, Nenad Ban, and Ueli Suter.
Membrane association of myotubularin-related protein 2 is mediated by a pleckstrin
homology- GRAM domain and a coiled-coil dimerization module. PNAS. 100:21; 1217782 (2003)

50

[26] Canhong Cao, Jonathan M. Backer, Jocelyn Laporte, Edward J. Bedrick, and Angela
Wandinger-Ness. Sequential Actions of Myotubularin Lipid Phosphatases Regulate
Endosomal PI(3)P and Growth Factor Receptor Trafficking. Mol Biol Cell.; 19(8): 3334–
3346 (2008)
[27] Norah E. Franklin, Gregory S. Taylor, Panayiotis O. Vacratsis. Endosomal Targeting
of the Phosphoinositide 3-Phosphatase MTMR2 Is Regulated by an N-terminal
Phosphorylation Site. JBC.286(18):15841-53 (2011)
[28] Raul Perez-Olle, Sidonie T. Jones and Ronald K.H. Liem. Phenotypic analysis of
neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture
models. Hum. Mol. Genet. 13:19; 2207-2220 (2004)
[29] William R. Parrish, Christopher J. Stefan, and Scott D. Emr. Essential Role for the
Myotubularin-related Phosphatase Ymr1p and the Synaptojanin-like Phosphatases Sjl2p
and Sjl3p in Regulation of Phosphatidylinositol 3-Phosphate in Yeast. Mol Biol Cell.
15:8;3567–3579 (2004)
[30] L. Bardwell. Mechanisms of MAPK signalling specificity. Information Processing
and Molecular Signalling, Biochemical society. 837-841 (2006)
[31] Kim E, Sheng M. PDZ domain proteins of synapses. Nat Rev Neurosci. 5:10;77181(2004)
[32] Ron Firestein, Peter L. Nagy, Megan Daly, Phil Huie, Marco Conti, and Michael L.
Cleary. Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for
the pseudophosphatase Sbf1. J Clin Invest. 109:9; 1165–1172 (2002)
[33] Philipp Berger, Andrijana Kriz, and Katharina Schmid. Myotubularins. BMR:
Molecular
Cell
biology;
Villigen,
Switzerland.
(2007)
[http://mcb.web.psi.ch/research/Myotubularins.htm]
[34] B A Ishpekova, L G Christova, A S Alexandrov, P K Thomas. The
electrophysiological profile of hereditary motor and sensory neuropathy–Lom. J Neurol
Neurosurg Psychiatry. 76, 875–878 (2005)
[35] Cui X., De Vivo I., Slany R., Miyamoto A., Firestein R. and Cleary M.L.
Association of SET domain and myotubularin-related proteins modulates growth control.
Nat. Genet. 18; 331-337 (1998)
[36] Flint, A. J., Tiganis, T., Barford, D. and Tonks, N. K. Development of “substratetrapping” mutants to identify physiological substrates of protein tyrosine phosphatases.
Proc. Natl. Acad. Sci. 94;1680 -1685 (1997)

51

[37] Talbo GH, Suckau D, Malkoski M, Reynolds EC. MALDI-PSD-MS analysis of the
phosphorylation sites of caseinomacropeptide. Peptides. 22:7;1093-8 (2001)
[38] Ranganathan R, and Ross E. PDZ domain proteins: scaffolds for signaling
complexes. Curr Biol 7:12; R770–3 (1997)
[39] Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Eun HW, Suh JS, Hwang JH,
Kim WK, Seo BC, Kim SH, Son IH, Kim SM, Sunwoo IN, Choi BO. Early onset severe
and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations.
Brain. 129;Pt.8:2103-18 (2006)
[40] Huang J, Wu X, Montenegro G, Price J, Wang G, Vance JM, Shy ME, Züchner S.
Copy number variations are a rare cause of non-CMT1A Charcot-Marie-Tooth disease. J
Neurol. 257;5:735-4 (2010)
[41] Bolino A, Levy ER, Muglia M, Conforti FL, LeGuern E, Salih MA, Georgiou DM,
Christodoulou RK, Hausmanowa-Petrusewicz I, Mandich P, Gambardella A, Quattrone
A, Devoto M, Monaco AP. Genetic refinement and physical mapping of the CMT4B
gene on chromosome 11q22. Genomics. 63:2;271-8 (2000)
[42] Joanna Sasin, Nunzio Bottini, Ilan Friedberg, Iddo Friedberg, Andrei Osterman,
Adam Godzik, Tony Hunter, Jack Dixon, and Tomas Mustelin. Protein Tyrosine
Phosphatases in the human genome. Cell. 117; 699–711 (2004)
[43] Bolino A, Brancolini V, Bono F, Bruni A, Gambardella A, Romeo G, et al.
Localization of a gene responsible for autosomal recessive demyelinating neuropathy
with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and
aplotype sharing. Hum Mol Genet 5: 1051–4 (1996)
[44] Jung-Hwa Lee, M.D., Byung-Ok Choi, M.D. Charcot-Marie-Tooth Disease:
Seventeen Causative Genes. Journal of Clinical Neurology. 2; 92-106 (2006)
[45] Marie C Harrisingh, Elena Perez-Nadales, David B Parkinson, Denise S Malcolm,
Anne W Mudge and Alison C Lloyd. The Ras/Raf/ERK signalling pathway drives
Schwann cell dedifferentiation. The EMBO Journal. 23:3061–3071(2004)
[46] Chojnowski A, Ravisé N, Bachelin C, Depienne C, Ruberg M, Brugg B, Laporte J,
Baron-Van Evercooren A, LeGuern E. Silencing of the Charcot-Marie-Tooth associated
MTMR2 gene decreases proliferation and enhances cell death in primary cultures of
Schwann cells. Neurobiol Dis. 26:2;323-31 (2007)
[47] Kolmodin K. and Aqvist J. The catalytic mechanism of protein tyrosine
phosphatases revisited. FEBS Lett. 498; 208-213 (2001)

52

[48] Yury J. Sigal, Mark I. MCDermott and Andrew J. Morris. Integral membrane lipid
phosphatases/phosphotransferases: common structure and diverse functions. Biochem. J.
387; 281–293 (2005)
[49] Dan F. Lazar and Alan R. Saltiel. Lipid phosphatases as drug discovery targets for
type 2 diabetes. Nature Reviews: Drug Discovery. 5;333-342 (2006)
[50] Larissa Kotelevets, Jolanda van Hengel, Erik Bruyneel, Marc Mareel, Frans van
Roy, and Eric Chastre. The lipid phosphatase activity of PTEN is critical for stabilizing
intercellular junctions and reverting invasiveness. The Journal of Cell Biology.
155:7;1129–1135 (2001)
[51] Matthew J. Wishart and Jack E. Dixon. PTEN and myotubularin phosphatases: from
3-phosphoinositide dephosphorylation to disease.TRENDS in Cell Biology. 12:12; 579585 (2002)
[52] Birle D, Bottini N, Williams S, Huynh H, deBelle I, Adamson E, Mustelin T.
Negative feedback regulation of the tumor suppressor PTEN by phosphoinositideinduced serine phosphorylation. J Immunol.169:1;286-91(2002)
[53] Xu D, Yao Y, Jiang X, Lu L, and Dai W. Regulation of PTEN stability and activity
by Plk3. JBC.285.L51;39935-42 (2010)
[54] M. Marsh and H. T. McMahon. The Structural Era of Endocytosis. Science. 285; 9
(1999)
[55] Francesca Santini, Michael S. Marks, and James H. Keen. Endocytic Clathrin-coated
Pit Formation Is Independent of Receptor Internalization Signal Levels. Mol Biol Cell.
9;5: 1177–1194. (1998)
[56] Michael J. Clague. Molecular aspects of the endocytic pathway. Biochem. J. 336:
271-282 (1998)
[57] J. L. Salisbury, J. S. Condeelis, N. J. Maihle, and P. Satir. Receptor-mediated
Endocytosis by Clathrin-coated Vesicles: Evidence for a Dynamic Pathway. Cold Spring
Harb Symp Quant Biol. 46: 733-741(1982)
[58] Kirchhausen T. Clathrin. Annu Rev Biochem. 69:699-727 (2000)
[59] Benjamin Lewin, Lynne Cassimeris, Vishwanath R. Lingappa and George Plopper.
Cells. Chp 4: Protein Trafficking between membranes. pp153-192. Jones and Bartlette
publishers, USA (2007)
[60] Sandra K Lemmon. Clathrin uncoating: Auxilin comes to life. Current Biology.
11;2: R49-R52 (2001)

53

[61] Michael J. Clague, Sylvie Urbé, Jand ane de Lartigue. Phosphoinositides and the
endocytic pathway. Experimental Cell Research; 315: 1627–1631 (2009)
[62] Frédéric Bard and Vivek Malhotra. The Formation of TGN to-Plasma-Membrane
Transport Carriers. Annu. Rev. Cell Dev. Biol.;22:439–55 (2006)
[63] Pier Paolo Di Fiore and Pietro De Camilli: Endocytosis and Signaling: An
Inseparable Partnership. Cell. 106: 1-4 (2001)
[64] Pereira-Leal JB, Seabra MC. Evolution of the Rab family of small GTP-binding
proteins. J Mol Biol.;313(4):889-901 (2001)
[65] Marta Miaczynska, Savvas Christoforidis, Angelika Giner, Anna Shevchenko,
Sandrine Uttenweiler-Joseph, Bianca Habermann, Matthias Wilm, Robert G. Parton and
Marino Zerial. APPL Proteins Link Rab5 to Nuclear Signal Transduction via an
Endosomal Compartment. Cell. 116: 445–456 (2004)
[66] Erik Nielsen, Savvas Christoforidis, Sandrine Uttenweiler-Joseph, Marta
Miaczynska, Frederique Dewitte, Matthias Wilm, Bernard Hoflack, and Marino Zerial.
Rabenosyn-5, a Novel Rab5 Effector, Is Complexed with hVPS45 and Recruited to
Endosomes through a FYVE Finger Domain. JBC. 151;3: 601–612 (2000)
[67] Poteryaev, D., Datta, S., Ackema, K., Zerial, M., and Spang, A. Identification of the
switch in early-to-late endosome transition. Cell 141: 497-508 (2010)
[68] Christoforidis, S., H.M. McBride, R.D. Burgoyne, and M. Zerial. The Rab5 effector
EEA1 is a core component of endosome docking. Nature. 397: 621–625 (1999)
[69] Harald Stenmark, Rein Aasland, Paul C. Driscoll. The phosphatidylinositol 3phosphate-binding FYVE finger. FEBS Letters. 513: 77-84 (2002)
[70] Michael G. Roth. Phosphoinositides in Constitutive Membrane Traffic. Physiol Rev,
84: 699–730, (2004)
[71] Michael Karas, Franz Hillenkamp. Laser desorption ionization of proteins with
molecular masses exceeding 10,000 daltons. Anal. Chem. 60:20;2299–2301 (1988)
[72] David J. Gillooly, Anne Simonsen and Harald Stenmark. Cellular functions of
phosphatidylinositol 3-phosphate and FYVE domain proteins. Biochem. J. 355: 249-258
(2001)
[73] Heidi J. Chial, Ruping Wu, Carolyn V. Ustach, Linda C. McPhail, William C.
Mobley and Yong Q. Chen. Membrane Targeting by APPL1 and APPL2: Dynamic
Scaffolds that Oligomerize and Bind Phosphoinositides. Traffic; 9: 215–229(2008)

54

[74] Roberto Zoncu, Rushika M. Perera, Daniel M. Balkin, Michelle Pirruccello, Derek
Toomre, and Pietro De Camilli. A Phosphoinositide Switch Controls the Maturation and
Signaling Properties of APPL Endosomes. Cell; 136: 1110–1121 (2009)
[75] M. Alejandro Barbieri, Richard L. Roberts, Aysel Gumusboga, Hilary Highfield,
Carmen Alvarez-Dominguez, Alan Wells, and Philip D. Stahl. Epidermal Growth Factor
and Membrane Trafficking: EGF Receptor Activation of Endocytosis Requires Rab5a.
The Journal of Cell Biology. 151; 3: 539-550 (2000)
[76] Jason M. Haugh, Kevin Schooler, Alan Wellsi, H. Steven Wiley, and Douglas A.
Lauffenburger. Effect of Epidermal Growth Factor Receptor Internalization on
Regulation of the Phospholipase C-γ1 Signaling Pathway. JBC. 274:13;8958–8965(1999)
[77] Confalonieri S, Di Fiore PP. The Eps15 homology (EH) domain. FEBS Lett.
513:1;24-9 (2002)
[78] J. C. Lorquet. Basic questions in mass spectrometry. Organic Mass Spectrometry.
16:11;469–482 (1981)
[79] Sorkin A and Von Zastrow M. Signal transduction and endocytosis: close encounters
of many kinds. Nature Review in Molecular Cell Biology. 3;8:600-14 (2002)
[80] Mark von Zastrow and Alexander Sorkin. Signaling on the endocytic pathway. Curr
Opin Cell Biol. 4: 436–445 (2007)
[81] Eric S Witze, William M Old, Katheryn A Resing and Natalie G Ahn. Mapping
protein post-translational modifications with mass spectrometry. Nature Methods.
4:10;798-806 (2007)
[82] Gregory G. Tall, M.Alejandro Barbieri, Philip D. Stahl and Bruce F. Horazdovsky.
Ras-Activated Endocytosis Is Mediated by the Rab5 Guanine Nucleotide Exchange
Activity of RIN1. Developmental Cell. 1;1: 73-82 (2001)
[83] Xu L, Lubkov V, Taylor LJ, Bar-Sagi D. Feedback regulation of Ras signaling by
Rabex-5-mediated ubiquitination. Curr Biol. 20;15:1372-1377 Epub (2010)
[84] Megan V. Astle, Gillian Seaton, Elizabeth M. Davies, Clare G. Fedele, Parvin
Rahman, Laima Arsala and Christina A. Mitchell. Regulation of Phosphoinositide
Signaling by the Inositol Polyphosphate 5-Phosphatases. Life. 58;8: 451-456 (2006)
[85] Itoh T, Takenawa T. Regulation of endocytosis by phosphatidylinositol 4,5bisphosphate and ENTH proteins. Curr Top Microbiol Immunol. 282: 31-47 (2004)
[86] Michael Krauß and Volker Hau9cke. Phosphoinositide-metabolizing enzymes at the
interface between membrane traffic and cell signalling. EMBO reports.8;3: 241-246
(2007)

55

[87] Shin HW, Hayashi M, Christoforidis S, Lacas-Gervais S, Hoepfner S, Wenk MR,
Modregger J, Uttenweiler-Joseph S, Wilm M, Nystuen A, Frankel WN, Solimena M, De
Camilli P and Zerial M. An enzymatic cascade of Rab5 effectors regulates
phosphoinositide turnover in the endocytic pathway. J Cell Biol. 170;4: 607-18 (2005)
[88] Michael J. Clague, Sylvie Urbé, Jand ane de Lartigue. Phosphoinositides and the
endocytic pathway. Experimental Cell Research; 315: 1627–1631 (2009)
[89] WEI Zhang and HUI TU Liu. MAPK signal pathways in the regulation of cell
proliferation in mammalian cells. Cell Research. 12:1; 9-18 (2002)
[90] Satoko Nishimoto and Eisuke Nishida. MAPK signaling: ERK5 and ERK1/2.
EMBO Reports. 7:8; 782-786 (2006)
[91] Hans J. Schaeffer and Michael J. Weber. Mitogen-activated protein kinases: specific
messages from ubiquitous messengers. Mol Cell Biol.19:4;2435-44 (1999)
[92] Nils Blüthgen and Hanspeter Herzel. MAP-Kinase-Cascade: Switch, Amplifier or
Feedback Controller? Logos-Verlag; 55-62 (2001)
[93] Rong Ji Guan, Frederick L. Hall, and Jeffrey A. Cohlberg. Proline-Directed Protein
Kinase (p34cdc2/p58cyclin A) Phosphorylates Bovine Neurofilaments. J. Neurochem. 58:4;
1370 (1992)
[94] Steven Pelech. Dimerization in protein kinase signaling. J of Biology. 5;12:12.1-12.7
(2006)

56

CHAPTER 2
Endosomal Targeting of the Phosphoinositide 3-Phosphatase MTMR2 Is Regulated
by an N-terminal Phosphorylation Site

This Chapter incorporates the outcome of joint research undertaken in
collaboration with Dr. Gregory S. Taylor, Department of Biochemistry and Molecular
Biology, University of Nebraska. In all cases, the key ideas, primary contributions,
experimental designs, data analysis and interpretation, were performed by the authors and
the contribution of co-authors was through the provision of experimental assistance,
analysis and data interpretation.; Dr. Gregory S. Taylor and Dr. Panayiotis Vacratsis
performed the [32P] orthophosphate labelling and the MALDI-TOF-MS analysis for the
identification of the phosphorylation site Ser58 on FLAG-MTMR2.

Dr. Gregory S.

Taylor provided all of the original wild-type pCNF-FLAG-MTMR2 and pET-MTMR2His6 constructs. My contribution to this manuscript was preparation of the MS samples
from immunoprecipitated mammalian cells that were utilized in the studies for the
identification of Ser58 stoichiometry by MS, protein purification for in vitro phosphatase
assays,

co-immunoprecipitation

experiments,

localization

experiments

and

characterization of the phenotype, as well as cell signaling analysis.
These results were published:

Norah E. Franklin, Gregory S. Taylor, and

Panayiotis O. Vacratsis (2011). Endosomal Targeting of the Phosphoinositide-3Phosphatase MTMR2 Is Regulated by an N-terminal Phosphorylation Site. JBC 286,
15841–15853
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INTRODUCTION
The protein-tyrosine phosphatase superfamily can be divided into distinct
subfamilies, which include the receptor tyrosine phosphatases, the intracellular tyrosine
phosphatases,

and

the

dual

specificity

phosphatases,

which

dephosphorylate

phosphoserine/threonine residues, as well as phosphotyrosine residues [1-3]. All proteintyrosine phosphatase family members possess the invariant catalytic sequence C(X)5R
and use a thiol phosphate intermediate as a catalytic mechanism [4]. In recent years, other
protein-tyrosine phosphatase families have been identified that dephosphorylate
phosphatidylinositol phosphates (PIPs) as their physiologic substrates [3]. These inositol
lipid phosphatases include the phosphatase and tensin homolog deleted on chromosome
10 (PTEN) and the myotubularin-related (MTMR) subgroups [5,6]. PTEN has been
widely characterized as a tumor suppressor protein [7,8], and mutations in three MTMR
genes have been identified in distinct human neuromuscular diseases, signifying their
importance in fundamental biological processes [9–12].
Phosphatidylinositol is an abundant membrane lipid that is phosphorylated by PI
kinases on positions 3, 4, and 5, of the inositol head group in response to various
extracellular signals, yielding seven unique PIPs [13,14]. These unique PIPs function to
recruit target proteins containing the appropriate PIP binding domains [15] to discrete
membrane locations where they can properly respond to extracellular stimuli. These
highly specific lipid-protein interactions are subsequently regulated through the
phosphorylation/dephosphorylation of the PIPs.
Active MTMRs dephosphorylate the lipid second messengers PI(3)P and
PI(3,5)P2 [16-18]. These phosphoinositides play key roles in membrane targeting,
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vesicular trafficking, and regulation of signal transduction pathways [19]. In particular,
the presence of PI(3)P on early endosomes has recently been shown to facilitate
endosome maturation and attenuate growth factor receptor signaling from endocytic
structures, indicating that regulators of endosomal PI(3)P levels can directly impact the
rate of endocytosis and duration of growth factor signaling [20].
Although the PIP substrates for MTMRs are constituents of membrane bilayers in
structures such as endosomes, numerous groups have observed that MTMRs, including
MTMR2, do not extensively localize to suborganellar structures containing its lipid
substrates [21-23]. In this study, we have used MS to identify a high stoichiometry
phosphorylation site on MTMR2 that regulates targeting to endocytic structures. An
MTMR2 phosphorylation-deficient mutant (S58A) exhibited strong localization to early
endocytic structures, where it efficiently depleted PI(3)P. In contrast, wild-type MTMR2
was highly phosphorylated at this site and did not localize to these structures.
Furthermore, a phosphomimetic MTMR2 mutant (S58E) exhibited localization identical
to that of wild-type MTMR2. Our findings suggest that MTMR2 phosphorylation at Ser58
regulates its targeting to endosomal membranes and access to phosphoinositide
substrates. The significance of this effect was underscored by the fact that signaling
through pathways known to be sensitive to endosomal PI(3)P levels were dramatically
altered in cells expressing the MTMR2 S58A mutant.
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MATERIALS AND METHODS
2.1 Cloning Expression and Plasmid Constructs
The mammalian expression vector for N-terminally FLAG-tagged MTMR2
protein was created by inserting cDNA fragments containing the complete MTMR2 open
reading frame into the 5_-NheI/3_-KpnI of pCDNA3.1-NF as previously described [24].
Vectors for the expression of bacterial recombinant His6-tagged MTMR2 were created
using the pET21a vector (Stratagene, La Jolla, CA). The pET-MTMR2 construct was
created by inserting a DNA fragment containing the MTMR2 open reading frame without
a stop codon into the 5_-NheI and 3_-NotI sites of pET21a in-frame with the six-histidine
tag as previously described [24].
The synthesis of pCDNA3.1-NF and pET21a vectors containing wild type
MTMR2 have been previously described [24]. Plasmids were harvested from a 5 mL
overnight Luria Broth (LB)-Ampicilin (100 µg/ml) culture as described by the
manufacturer using GenElute Plasmid Miniprep Kit (Sigma-Aldrich, Inc.). Site-directed
mutagenesis reaction mixtures were as follows: 5 µl of 10x reaction buffer, 100 ng
template DNA, 1.5 µl dNTPs, 125ng each of forward and reverse primers, 1 µl MgSO4
and 1 µl of Cloned Pfu DNA Polymerase (600154; Stratagene). To generate pCDNA3.1NF and pET21a with point mutations of S58A and S58E to mimic the nonphosphorylated
and phosphorylated version of the protein respectively, PCR-based site directed
mutagenesis was performed on purified pCDNA3.1-NF or pET21a plasmids containing
the wild type MTMR2 insert. Oligonucleotide primers (synthesized by Invitrogen Corp.)
were designed to carry out the N-terminal phosphorylation site mutations of
Ser58Ala(S58A), Ser58Glu(S58E) and to generate the catalytically inactive mutant
Cys417Ser(C417S). The forward primer for the generation of S58A used was 5‟60

CTGCCGACAACTTTGCTCCTGATTTGAGGGTC-3‟ while the reverse primer was 5‟GACCCTCAAATCAGGAGCAAAGTTGTCGGCAG-3‟. The forward primer for the
generation

of

S58E

used

was

5‟-

CTTCTGCCGACAACTTTGAGCCTGATTTGAGGGTCC-3‟ while the reverse primer
was 5‟-GGACCCTCAAATCAGGCTCAAAGTTGTCGGCAGAAG-3‟.

The forward

primer

was

for

the

generation

of

C417S

used

5‟-

CTGTGGTAGTGCATAGCAGTCATGGTTGGG-3‟ while the reverse primer was 5‟CCCAACCATCACTGCTATGCACTACCACAG-3‟.
designed

to

carry

out

the

C-terminal

Oligonucleotide primers were

phosphorylation

site

mutations

of

Ser631Ala(S631A) and Ser631Glu(S631E). The forward primer for the generation of
S631A used was 5‟-GAGAGAGCCAGCGCTCCTGCACAGTG-3‟ while the reverse
primer was 5‟-CACTGTGCAGGAGCGCTGGCTCTCTC-3‟. The forward primer for
the

generation

of

S631E

used

5‟-

was

CAGAGAGAGCCAGCGAGCCTGCACAGTGTGTC-3‟ while the reverse primer was
5‟-GACACACTGTGCAGGCTCGCTGGCTCTCTCTG-3‟.

Following

PCR,

the

products were subjected to DpnI (Invitrogen Corp.) digestion for 1 h at 37°C to degrade
template DNA. Highly competent DH5α cells were then transformed with PCR products
(proceeding DpnI digestion) as described below. Plasmids were harvested using
GeneElute Plasmid Miniprep kit (Sigma-Aldrich) and plasmids verified by agarose gel
electrophoresis and automated DNA sequencing (ACGT Corp. and Bio Basic Inc.).
Transformation of plasmid constructs was carried out using 90 μl of highly
competent DH5α cells that were thawed on ice, and ~500 ng of DNA was added. The
E.coli/DNA mixtures were then incubated for 30 min on ice, followed by a 42°C water
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bath heat shock for 45 seconds, then cold shocked for 2 min on ice. 500 μl of autoclaved
LB was then added to the tubes and incubated at 37°C with constant shaking (225 rpm)
for 1 h. The cells were pelleted at 12,000 rpm at room temperature for 1 min. All but
100 μl of liquid was removed, and the pellet was resuspended in the remaining LB liquid.
The resuspended pellet was then plated onto a LB-ampicillin (AMP) or LB-Kanamycin
(pEGFP-2xFYVE) agar plates and incubated inverted at 37°C overnight. An individual
transformed colony (per plate) was then selected and resuspended in 150 ml of
autoclaved LB and incubated at 37°C with constant shaking (225 rpm) overnight. DNA
from the cells was then purified using QIAGEN HiSpeed plasmid maxi-prep kit
according to manufacturer‟s instructions. Agarose gel electrophoresis was then used in
order to confirm the correct DNA purification, based on migration in relation to the
number of base pairs. DNA concentrations were then determined by measuring A260 in
μg/μl and verifying the purity of DNA by the 260/230 and 260/280 ratios (range of 2.02.2 and ~1.8 respectively).
2.2 Cell Culture, Transfection and Cell Lysis
HeLa cells and HEK293 cells were obtained from the American Type Tissue
Culture Collection (ATCC; Manassas, VA). HeLa cells and HEK293 cells were grown
as a monolayer and maintained at 37°C with 5% CO2 in Dulbecco‟s Modified Eagles
Medium/Nutrient (DMEM: Sigma-Aldrich; D6421) Ham F-12 containing 10% fetal
bovine serum, 2 mM L-glutamine, and supplemented with antibiotics (100 units/mL
Penicillin, 100 μg/mL streptomycin). Cells were seeded 24 h prior to transfection and
were approximately 60-70% confluent at the time of transfection. Cells grown on 100
mm culture dishes were transiently transfected with 10 µg plasmid DNA using either the
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Polyethylenimine (PEI) reagent (100 mm dishes: Sigma-Aldrich - St Louis,
MO;Cat.No.408727) or 5 µg using FuGENE® HD (100 mm dishes for signalling studies:
Roche Diagnostics; Cat.No.04 709 705 001) according to the manufacturer‟s instructions.
PEI transfections were carried out as follows: 50 µl of a 150 mM sterile NaCl solution
was mixed and incubated with 10 µg plasmid DNA while simultaneously 50 µl of 150
mM NaCl was mixed with 15 µl of a 1 mg/ml solution of PEI reagent (pH 7.4) for 10 min
at room temperature. The solutions were then mixed and incubated for an additional 10
min, then added drop wise to the culture plates, gently mixed, then incubated at 37ºC.
Fresh media was replaced 4 h following transfection, and then the culture plates were
returned to 37ºC for 24-42 h incubation. HeLa cells cultured on treated slides were
transfected with 0.5 µg pCNF: FLAG-wild-type, S58A and S58E MTMR2 constructs in
addition to 0.25 µg of pEGFP-2xFYVE ( a generous gift from Harald Stenmark, Oslo
University and Norwegian Radium Hospital, Norway) [26,50] where indicated, at a 3:1
ratio of FuGENE® HD:DNA respectively. At 42 h post-transfection, cells were washed
with ice-cold phosphate-buffered saline (PBS) and lysed in 0.5 ml (100 mm dish) of icecold lysis buffer (50 mM Tris-HCl, pH.7.4, 1% Triton-X 100, 150 mM NaCl, 0.1% SDS)
containing protease inhibitors (17.4 mg/ml Phenylmethylsulfonyl fluoride: 1 mg/ml
Aprotinin). Lysates were vortexed and cleared by centrifugation (15,000 g for 20 min at
4°C). The supernatant was then subjected to Bradford analysis or immunoprecipitation
(as indicated) and stored at -20°C until analyzed by SDS-PAGE.
2.3 Immunofluorescence Analysis
HeLa cells were seeded on four-chamber Polystyrene vessel tissue culture treated glass
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slides (BD Falcon – BD biosciences) in DMEM and cultured as described above. After
attachment (~24 h following seeding), cells were then transiently transfected by using
FuGENE® HD transfection reagent (Roche Diagnostics; Cat.No.04 709 705 001) as
previously described and according to manufacturer‟s instructions. 42 h post-transfection,
coverslips/cells used for pEGFP-2xFYVE intracellular translocation assays for
comparative control with S58A, were treated with the class III specific PI3K inhibitor
wortmanin (LC Laboratories; W-2990) for 1 h at a final concentration of 1 µM (pEGFP2xFYVE alone as control). All coverslips/cells (treated and untreated) were washed
twice with PBS (pH 7.4) and fixed with 3.7% PFA in PBS (pH 7.3) for 10 min at room
temperature. Where indicated, cells were initially treated with 0.01% saponin (Sigma;
100902805) in PBS for 2 min room temperature prior to fixation. The cells were then
washed with Tris-buffered saline (TBS) and permeabilized with 0.15% Triton X100/TBS for 2 min. For immunostaining, cells were pre-treated for 60 min with 5%
BSA/PBS as a blocking agent. Then, cells were incubated with 1.0% BSA/PBS
containing affinity purified monoclonal mouse-anti-FLAG® M2 antibody at a 1:500
dilution (Sigma-Aldrich; F1804), in conjunction with a rabbit polyclonal antibody raised
against the amino acids 614-709 of the endogenous human APPL1 (Santa Cruz
Biotechnology; H-96:sc-67402) at a 1:80 dilution, a rabbit polyclonal antibody raised
against the amino acids 1-215 of the full length Rab5A of human origin (Santa Cruz
Biotechnology; FL-215:sc-28570) at a 1:80 dilution, a rabbit affinity isolated antibody
raised against the amino acids 163-177 of human Rab7 (Sigma-Aldrich; R4779) at a 1:80
dilution, a rabbit polyclonal raised within 350 residues of the C-terminus of human
LAMP1 (Abcam; ab24170) and rabbit polyclonal antibody raised against a peptide
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mapping at the C-terminus of human EGFR (Santa Cruz Biotechnology; 1005:sc-03) at a
1:50 dilution. Cells were then washed with PBS three times 5 min and incubated with
Alexa Fluor® 568 goat anti-mouse secondary antibody (Invitrogen – Molecular Probes;
A11004) at a 1:500 dilution for anti-Flag visualization and affinity purified Fluoresceinconjugated goat-anti-rabbit IgG (Vector Laboratories; FI1000) or Alexa Fluor® 568 goat
anti-rabbit secondary antibody (Invitrogen – Molecular Probes; A11011) where indicated,
in 1.0% BSA/PBS for 60 min. The cells were then washed as previously and incubated
with Hoechst 33342 stain (0.5 mg/ml in PBS; Invitrogen – molecular probes) for 2 min at
room temperature for DNA visualization (Fluorescence excitation 350 nm and emission
461nm). Coverslips were then washed with PBS, and incubated in equilibration buffer
(Invitrogen – molecular probes) for 5 min then mounted with S2828 Slow-fade antifade
in glycerol/PBS (Invitrogen – molecular probes) with 22 mm microscope glass covers
(Fisher Scientific).

Fluorescence analyses were performed using a Leica DM IRB

inverted fluorescent microscope equipped with FITC/TRITC/DAPI filter cubes and HCX
PL S-APO 40x/0.75 objective with a 1300i FAST Cooled mono 12-bit camera (Qimaging
Retiga). Additionally, a Zeiss Axiovert 200M inverted fluorescent microscope with
FITC/TRITC/DAPI filter cubes and LD Plan-APO-Neofluar 63x/0.75 or EC PlanNeofluar 40x/1.3oil objectives equipped with 1030x1300 monochrome CCD camera
(Axiovision MRM) was also used.

Captured pictures from both microscopes were

processed with Northern Eclipse software 6.0 (Empix, Mississauga, ON) with
contrast/brightness and exposure image corrections performed using program processing
application software in addition to Adobe Photoshop 7.0. The criteria for cells that were
included in the size quantification analysis had to be individual in order for discrepancies
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and isolation amongst clustered cells and approximately circular in geometry.

All

vesicles meeting these criteria were included for analysis and the vesicle areas for
quantification were measured from 8-10 cells in three independent experiments for each
with APPL1: wt_+U+SP, S58A_+SP, S58A/S631A, S58A/C417S/S631A. The area of
each vesicle was measured using Image-J software (National Institutes of Health,
Bethesda, MD) as described previous (Colliver et al.2000) with an analyze set scale of 15
µm according to image magnification.
2.4 Immunoblotting
Following cellular lysis, protein concentrations were determined using the BioRad
Protein Assay reagent (Cat No.500-0006) and standard BSA at 2.0 μg/μl diluted to
desired concentrations. A standard curve was generated by reading absorbance values at
λ595nm on the Ultrospec 31 2100 pro UV/Visible spectrophotometer, followed by
absorbance readings of samples. These absorbance values were used to determine the
volume (μl) of samples required in order to obtain the same protein concentrations (μg).
Equal amounts of total protein were loaded onto polyacrylamide gels (gel percentages as
indicated) and separated by SDS-PAGE. Proteins were transferred to a Polyvinylidene
fluoride (PVDF) membrane (Millipore), and blocked with 5% skim milk solution in 1X
TBST (TBS with tween 20) or 5%BSA/TBST (pSer58.MTMR2, Pathscan®, pJNK1 and
pEGFR.Tyr1173). For co-immunoprecipitaion experiments, both lysates and IP samples
were then incubated with mouse monoclonal anti-FLAG® clone M2 antibody (Sigma;
F3165) in 1% skim milk at a 1:3000 dilution for 1 h at room temperature or overnight at
4°C with constant shaking. The membrane was washed three times in 1X TBST and
incubated with anti-mouse IgG HRP conjugate (W4021; Promega) in 1% skim milk at a
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1:5000 dilution for 45 min room temperature with gentle agitation. The secondary
antibody was removed, washing steps performed as previously described, and then
imaging was performed using the Alpha Innotech Imager and the chemilmager v5.5
software with chemiluminescence filter. Bound antibodies were visualized using Super
Signal® West Femto maximum sensitivity substrate (34095; Thermo scientific).
2.5 Protein Expression and Purification
Highly competent Escherichia coli BL21 (DE3) Codon Plus cells (Stratagene)
were transformed (80 µl cells) with 500 ng of a bacterial recombinant pETvector
containing C-terminally His6-tagged fusion proteins of either wild-type MTMR2 or
phospho-mutants (S58A,S58E), plated onto LB-ampicillin+chloramphenicol (100
µg/mL,30 µg/mL) agar plates and incubated inverted overnight at 37ºC. A 5 mL solution
of 2xYT containing 100 µg/mL:30 µg/mL ampicillin:chloramphenicol was inoculated
with a single bacterial colony and incubated at 37oC overnight with shaking at 225 rpm.
This entire 5 mL culture was then used to inoculate 500 mL of 2xYT media
supplemented with 100 µg/mL:30 µg/mL ampicillin:chloramphenicol. The large scale
culture was incubated at 37oC with 225 rpm shaking for approximately 2.5 h, until
reaching an optical density of 0.6 at a wavelength of 600 nm.

Expression of the

recombinant His6-tagged fusion proteins was induced by the addition of isopropyl-β-Dthiogalactopyranoside (IPTG) to a final concentration of 0.8 mM and shaken at 240 rpm
at room temperature for 16 h.

Following incubation, cultures were pelleted by

centrifugation at 6000 rpm for 15 min at 4oC. The supernatant was discarded and the
pellets were fully resuspended in lysis buffer (50 mM Tris, 300 mM NaCl, 20 mM
Imidazole, 0.5% Triton X-100, 1 mM PMSF, 0.05% β-mercaptoethanol, pH 8.0 with

67

phosphatase and protease inhibitors; 17.4 mg/ml PMSF: 1 mg/ml Apr). The suspended
cells were sonicated at 4ºC in ice, for 3 min followed by centrifugation at 2,000g for 15
min at 4ºC. HIS-select Ni2+-affinity resin (Sigma-Aldrich; P-6611) was equilibrated
with 10 ml of lysis buffer, centrifuged in a swinging bucket rotor at 1600 g for 2 min at
4ºC, and the buffer solution discarded prior to sample loading. The supernatant lysates
were added to 1 mL of pre-equilibrated HIS-select Ni2+-affinity resin and incubated for 2
h at 4ºC. The resultant was centrifuged at 2,000 g for 5 min at 4ºC and the supernatant
was discarded. The resin was washed three times with lysis buffer containing 0.5%
Triton X-100, then an additional three times in lysis buffer without detergent (no Triton
X-100). The HIS-tagged fusion proteins were eluted from the resin for 3 x 30 min with
0.5 ml of elution buffer (50 mM Tris, 50 mM NaCl, 300 mM imidazole, 0.1% v/v βmercaptoethanol pH 8.0) containing protease inhibitors (17.4 mg/ml PMSF: 1 mg/ml
Apr) and filtered through a 0.2 µm syringe filter. The purified proteins were stored in
10% glycerol, 1 mM DTT, 1 mM PMSF and retained at -80°C until further use. Protein
concentrations were determined by the Bradford assay using BSA as a standard as
described previously. Protein purification was determined by SDS-PAGE followed by
Coomassie staining.
2.6 EGF Treatments and Signaling Pathway Analysis
Cells were transiently transfected with pCNF-FLAG MTMR2 constructs (wildtype, S58A, S58E, and S58A/S631A) as previously described, were incubated in serum
free medium (DMEM Ham-F12 supplemented with glutamine and antibiotics as
previous) at 37°C for 30 min. Subsequently, an equal volume of serum free medium
containing EGF used at final concentration of 5 ng/ml (Sigma-Aldrich; E4127) was
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added to the dishes and incubated at 37°C. At the indicated time points, cells were
washed in cold PBS and lysed in lysis buffer prior to immunoblotting analysis as
previously described. The antibodies used for signal detection are as follows: rabbit
PathScan® Multiplex Western Cocktail I (5301; Cell signalling technology) at a 1:200
dilution in 5% BSA/TBST overnight at 4°C with secondary anti-rabbit HRP used at a
1:2000 dilution in 1% skim milk (Bio-Rad; cat.no.170-6515) with all subsequent
secondary antibody dilution at 1:5000, rabbit anti-MAPK antibody (M 56701; Sigma) at
1:10,000 dilution, rabbit anti-EGFR (1005.sc-03; Santa cruz biotechnology) at a 1:3000
dilution, rabbit-phospho-EGFR (Tyr1173) at a 1:200 dilution in 2.5%BSA/TST with
secondary anti-rabbit at 1:2000 in 2.5% BSA/TBST and affinity isolated rabbit anti-actin
(Sigma-Aldrich: A2066) at a 1:3000 dilution.
2.7 Immunoprecipitation
HEK293 cells co-transfected with pCNF-FLAG-MTMR2 constructs (as
indicated) and pCNF-FLAG-MTMR5-FRI (a generous gift from Fred Robinson,
University of San Diego, CA) [25] were immunoprecipitated using goat anti-MTMR5 (I13.sc-51135; Santa Cruz biotechnology) at 1 µg antibody/20µl Protein A-agarose
(Invitrogen; cat.no.15918-014 ) for co-immunoprecipitation studies (as indicated), or
with anti-flag-M2 affinity gel as indicated (Sigma).

Immunoprecipitations were

incubated for 3 h at 4 °C and subsequently washed with 0.5 ml of IP wash buffer (50 mM
Tris-HCl, pH 7.4, 0.1% Triton-X 100, 150 mM NaCl, 0.1% SDS) three times.
Immunoprecipitates were suspended in 2X SDS sample buffer (0.12 M Tris-HCl pH 6.8,
4% SDS, 0.3% β-mercaptoethanol, 10% glycerol, 0.004% bromophenol blue, 3% DTT)
boiled at 95°C for 5 min, vortexed, and centrifuged at 15,000 rpm for 2 min. All
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immunoprecipitates

and

lysates

were

resolved

in

8

(for

MTMR5

co-

immunoprecipitation), 10 or 12% Ployacrylamide (BioRad laboratories) gels, transferred
to polyvinylidene difluoride (PVDF) membranes (Millipore), and analyzed by
immunoblotting.

Immunoprecipitated samples preparation for gel excision for MS

analysis were isolated using anti-FLAG-M2 affinity gel (Sigma)
2.8 Sample Preparation for MALDI MS
Immunoprecipitated FLAG-tagged proteins were first separated on a 10%
polyacrylamide gel and the proteins of interest were excised and subjected to in-gel
trypsin digestion. The excise bands of interest were initially destained 3x 25 min at 37°C
225 rpm with 50% acetonitrile:50% ammonium bicarbonate.

The gel pieces were

dehydrated with 100% ACN, centrifuged at 5,000 rpm for 30 sec, with this process
repeated twice, each removing the supernatant. The gel pieces were dried in a speed
vacuum for 20 min and the resultant was re-hydrated with 13 ng/ml trypsin (in 50 mM
ammonium bicarbonate) and incubated at 37°C 225 rpm for 2 h. A 2 µl “pre-extract”
sample was aliquoted with the addition of formic acid ([ ]F = 1%), then stored at -20°C
until further analysis. The gel/trypsin sample was returned to the 37°C incubator for
overnight digestion. The “extract” sample was obtained following overnight digestion
with the addition of peptide extraction solution (60% ACN, 39% ddH2O, 1% formic acid)
and incubation at 37°C for 45 min (repeated 2x). The resultant supernatants were stored
in a siliconized micro centrifuge tube containing formic acid ([ ]F = 5%) at -20°C until
further analysis. The resulting solutions containing proteolytic fragments were spotted (1
μL) on a MALDI sample plate followed by 1 μL of a freshly prepared solution of a UV
absorbing matrix (1% α-cyano-4-hydroxycinnamic acid (Sigma), 60% ACN (HPLC
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grade, Burdick and Jackson), 0.01% formic acid. Peptide fragments were analyzed by
MALDI-TOF-MS in linear mode using Voyager DE Pro Biospectrometry Workstation
(Applied BioSystems).
2.9 In Vitro Phosphoinositide Phosphatase Assays
All phosphatidylinositol polyphosphate substrates used in this work were obtained
from Echelon Research Laboratories (Salt Lake City, UT). Phosphatase assays were
carried out using 50 ng of bacterial recombinant purified MTMR2-His6 proteins in
reaction buffer (50 mM Tris, 150 mM NaCl, 50 mM Bis-Tris and 5 mM DTT, pH 7.0)
containing 100 µM of nonfluorescent di-C8- phosphatidylinositol phosphate derivatives
(Echelon;D8-myo-Phosphatidylinositol lipid substrates [PI(3)P, PI(3,4)P2,PI(3,5)P2,
PI(3,4,5)P3, PI(5)P] reconstituted in autoclaved sterile milliQ H2O at final concentration
of 1 mg/ml. Reactions were carried out at 30 °C for 5 min and terminated using equal
volume of 20 mM Sodium Orthovanadate (pH 10.0. Sigma-Aldrich; S6508), and
phosphate release was determined using a malachite green-based assay system (Echelon;
K-1500) for detecting inorganic phosphate as described [25].

The absorbance

measurements at wavelengths 620nm/660nm were measured using a Victor3TM wallac
1420 multilabel counter (Perkin Elmer) and Workout 2.0 program applications with free
phosphate release determined using non-linear regression analysis [(specific activity
reported in terms of mol·min-1·mol-1(mol inorganic phosphate released/min·mol
enzyme)].
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RESULTS
2.1 The N-terminus of MTMR2 Posses a High Stoichiometry Phosphorylation Site
In order to examine if MTMR2 is modified by phosphorylation, wild-type FLAGMTMR2 was immunoprecipitated from HEK293 cells and protein samples resolved by
SDS-PAGE. The protein band corresponding to MTMR2 was excised and subjected to
in-gel trypsin digestion for analysis by MS (Supplemental figure 1). Phosphorylated
proteins are rarely detected in unfractionated trypsin digests primarily owing to their low
stoichiometry and poor ionization therefore will generally require some form of
purification and/or phosphopeptide enrichment step.

Interestingly, when a „pre-

extraction‟ aliquot was analyzed by MALDI-TOF, we detected a prominent peptide peak
at m/z 2322 which corresponds to a phosphorylated N-terminal peptide containing a
single phosphate moiety (figure 1). Additionally, we observed a prominent peptide peak
at m/z 2242 corresponding to the same peptide lacking the phosphate moiety (figure 1).
Reproducible scans in independent experiments yielded these two peptides are present at
relative equal intensities. Taken together, these results support the notion that the
stoichiometry of phosphorylation at Ser58 on MTMR2 is at least or greater than 50%
implicating that MTMR2 is highly phosphorylated at this site under the cellular
conditions used in this study.
2.2 Identification of Ser58 as the N-terminal Phosphorylation Site
Considering the results implicating high levels of MTMR2 phosphorylation under
normal cellular conditions, previous work performed by Dr. Otis Vacratsis and Dr.
Gregory Taylor were aimed at precisely identifying the site of phosphorylation within the
phosphorylated N-terminal peptide (m/z 2322). In order to elucidate and identify the
particular site of MTMR2 phosphorylation, FLAG-MTMR2 was immunoprecipitated
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Figure 1. MTMR2 possesses a high stoichiometry phosphorylation site within its Nterminus
FLAG-tagged MTMR2 was isolated from HEK293 cells by immunoprecipitation and
separated by SDS/PAGE. The MTMR2 band was excised from the gel and subjected to
in-gel digestion with trypsin. Displayed is the MALDI-TOF linear spectrum of the total
pool of MTMR2 tryptic peptides. The m/z values corresponding to the unphosphorylated
(m/z 2242) and phosphorylated (m/z 2322) forms of peptide Ser41-Arg62 are boxed. This
region is also shown as an expanded view.
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Figure 2. Mapping the N-terminal phosphorylation site using MALDI-CAF-MS
MTMR2 tryptic peptides were fractionated by reverse phase HPLC. (A) The HPLC
fraction containing the phosphopeptide of interest was further analyzed by MALDI-TOF
MS/MS. The neutral loss of the phosphate moiety (-98m/z) is indicated. (B) The same
HPLC fraction was subjected to CAF labeling and re-analyzed by MALDI-TOF MS/MS.
The fragment ions whose m/z value corresponds to y or b ions with the loss of a
phosphate group are indicated. The observed fragment ions are labeled on the spectrum
and peptide sequence (phosphorylated Ser58 is underlined and in bold text).
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from HEK293 cells that were radiolabeled with [32P] orthophosphate, resolved by SDSPAGE and analyzed by autoradiography. Correspondingly, results revealed that the
FLAG-MTMR2 immunoprecipitated protein was highly phosphorylated. In attempts for
further purification, the proteins were separated by SDS-PAGE and the band of interest
was excise and subjected to in-gel trypsin digestion. The total tryptic peptide pool was
then separated using reverse phase HPLC and the phosphorylated peptide of interest was
identified in HPLC fraction 68 that was further analyzed by MALDI-MS/MS. The parent
ion at m/z 2322 was readily detected in MALDI-linear mode, and further fragmentation
(MALDI-PSD) yielded an intense peak at m/z 2224 corresponding to the same Nterminal peptide with a neutral loss of the phosphate group (figure 2.A). However, this
peptide exhibited no additional fragmentation and recognizing that there were a total of
eight potential phosphorylation sites within this N-terminal peptide, additional steps were
required for precise identification. To improve the MS/MS spectrum, the tryptic peptides
were further subjected to Chemically-Assisted Fragmentation (CAF) analysis which
successfully increased fragmentation along the peptide backbone [26]. Precise analysis
of the fragmented ion series allowed for unambiguous identification of phosphorylation
to Ser58 (figure 2.B).
2.3 MTMR2 Ser58 Phosphovariants Retain Catalytic Competence and MTMR5
Binding Activity
The most prevalent form of cellular PTMs is reversible phosphorylation which
has largely been thought of as a means to induce conformational changes in enzymes that
causes alterations in their catalytic activity. The N-terminal phosphorylation site on
MTMR2 resides in close proximity to the PH-GRAM domain, which has been proposed
to be important in mediating correct lipid substrate interaction. To test whether the N-
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terminal site has an effect on catalytic activity, phosphovariants were generated by site
directed mutagenesis to produce a phosphorylation mimetic (S58E) and phosphorylationdeficient (S58A) MTMR2 mutant proteins. We purified recombinant MTMR2 proteins
from BL21 Escherichia coli lysates (Supplemental figure 2) and compared their in vitro
phosphoinositide phosphatase activity against water soluble physiological substrates diC8-PI(3)P and -PI(3,5)P2 (D8-myo-Phosphatidylinositol lipids). A darker protein band at
73kDa in the induced lanes represents successful induction with IPTG and the large thick
band in the elution lane indicates purification of the protein of interest. We determined
the pH optimum and most favourable incubation period for activity to be pH 7.0 and 10
min at 30°C, parallel to recently published data on MTMR6 [27]. Three independent
trials were performed and the average phosphatase activity represented as pmol of
phosphate released using the Malachite-Green based assay system, were then compared
by statistical analysis and relative phosphatase activities were determined (figure 3A).
MTMR2 and phosphovariants retained full catalytic activity towards their known
physiological substrates PI(3)P and PI(3,5)P2 and did not demonstrate and significant
differences in activity with comparison to wild-type MTMR2. Moreover, there was no
significant activity towards other control phosphoionositols indicating that point
mutations at Ser58 do not have any effects on the phosphatase activity of MTMR2.
Previously, it has been demonstrated that MTMR2 interacts with the catalytically
inactive MTMR proteins; MTMR5 and MTMR13 and that deletion of the critical Cterminal CC region of MTMR2 results in loss of heterocomplex formation and abolishes
this interaction [28]. In addition, it has been shown that the closely related
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Figure 3. Lipid phosphatase activity and MTMR5 association is unaffected by the
phosphorylation status of Ser58
(A) Phosphatase assays using purified recombinant MTMR2 proteins were carried out at
30 °C for 10 min with 50 ng of enzyme (■ wild-type; ■ S58A; ■ S58E) and 100µM of
the indicated phosphoinositide substrates as described under “Materials and Methods.”
Phosphate release was measured using a malachite green-based assay for inorganic
phosphate. The relative amount of phosphate released by recombinant MTMR2 proteins
in these assays is shown in picomoles and represents the mean of triplicate
determinations ±S.D. (n=3). (B) Immunoprecipitation of overexpressed FLAG-tagged
MTMR5 (lane 2) and co-expression with MTMR2 proteins (lanes 3-5) from HEK293
cells. At 42 h post-transfection, cell lysates were prepared and subjected to
immunoprecipitation (IP) using anti-MTMR5 antibody conjugated to Protein A-agarose
beads. Following SDS-PAGE, immunoprecipitated proteins were detected by
immunoblotting (IB) using anti-FLAG antibody. Whole cell lysates were probed for
MTMR5 and MTMR2 to verify protein expression.
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family member MTMR6, interacts with the catalytically inactive MTMR9 resulting in
increased 3-phosphatase activity of MTMR6 [27].

Collectively, this implicates an

important role with respect to the correct biological modulation of their corresponding
active partners. We therefore sought to examine the in vivo effect of the N-terminal Ser58
phosphorylation site mutations on the binding capability towards MTMR5 by transiently
co-expressing both FLAG-MTMR2 and phospho-variants with FLAG-MTMR5 in
HEK293 cells. Following 42 h transfection, cells were lysed and co-immunoprecipitation
was performed. Following co-immunoprecipitation, the samples were then separated by
8% SDS-PAGE and probed for both of the overexpressed FLAG proteins. The
association affinity towards MTMR5 was not affected upon point mutations at Ser58
(figure 3B) implicating the unambiguous association primarily to be through the Cterminal coiled-coil region as previously described [27]. Thus, the imposing interaction
of MTMR2 and MTMR5 is not modulated by N-terminal phosphorylation and may
collectively be influenced by alternative biological signals. Taken together, these results
demonstrate that phosphorylation of Ser58 does not affect the lipid phosphatase activity of
MTMR2 or its ability to interact with inactive MTMR proteins.
2.4 Phosphorylation of Ser58 regulates MTMR2 Subcellular Localization
The overexpression of MTM1 and MTMR2 has been previously shown to result
in decreased cellular pools of PI(3)P, and that siRNA mediated MTM depletion resulted
in a striking accumulation of both PI(3)P and PI(3,5)P2 [30]. Predominant cytosolic
staining with greater intensity in the perinuclear region for wild-type MTMR2 has been
formerly reported in COS-1 cells and HEK293 cells [28,30,31]. Additionally, there was
no detectable localization of overexpressed wild-type or endogenous MTMR2 with any
particular subcellular organelle(s) or membrane compartment in these systems [28,30].
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More recent studies have shown that the closely related family member, MTM1 localizes
to Rab5 positive endosomes and to a lesser extent with Rab7 [30].
MTMR2 contains an N-terminal PH-GRAM domain which has been proposed to
be important in MTMR2 localization and function as a PIP binding module [32]. It is
plausible that protein modifications and/or mutations that affect PH-GRAM function,
may also affect localization as previously shown with MTMR2 in COS-cells, in which
mutations within this domain, prevented its localization to vacuole membranes following
hypoosmotic shock [32].

Considering that the N-terminal phosphorylation site of

MTMR2 resides approximately 11 amino acids upstream of the PH-GRAM domain, we
therefore investigated its potential involvement in regulating MTMR2 subcellular
localization. As a primary step to understanding the functional differences between wtMTMR2 and mutations, localization patterns of phosphorylation site mutants were
compared (figure 4). In order to study the potential involvement of MTMR2 in the
endocytic pathway, HeLa cells were transfected with FLAG-wild-type, S58A or S58E
then fixed, permeabilized and incubated with mouse monoclonal M2-α-FLAG antibody
with corresponding α-mouse Alexa Fluor® 568 secondary antibody and analyzed by
immunofluorescence as previously described under “Materials and Methods”.

We

observed that wild-type MTMR2 displayed dispersed localization predominantly in the
cytoplasmic region of FLAG transfected HeLa cells, with greater fluorescence intensity
in the perinuclear region as previously reported (figure.4.A) [28,30]. Saponin prior to
fixation and immunostaining has been shown to deplete soluble cytoplasmic proteins, and
permit visualization of membrane-localized proteins [33].

When HeLa cells over

expressing wild-type MTMR2 were treated with saponin there was greatly reduced
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Figure 4. MTMR2 S58A localizes to punctate structures
HeLa cells were transfected with FLAG-MTMR2 phosphorylation mutants: wild-type (A
and B), S58A (C and D), S58E (E and F). Following fixation, the cells were
immunostained with anti-FLAG monoclonal antibody to localize FLAG-MTMR2
proteins. Saponin treatment (right panels) (0.01%) was used to enhance detection of
membrane-localized proteins via depletion of cytosolic contents. Images were collected
using 63x and 40x HD objectives. The scale bar represents 15 µm (10 µm in expanded
views).

80

fluorescence intensity observed, suggesting that wild-type staining was predominantly
cytoplasmic (figure 4.B). Intriguingly, the phosphorylation mimetic mutant S58E, also
displayed an identical characteristic localization phenotype within the cytosolic region
and complete loss of fluorescence staining following saponin treatment (figure.4.E,F).
These results imply and are coincident with the stoichiometric MS data implying that
wild-type MTMR2 is highly and differentially phosphorylated at Ser58.
Furthermore, our phosphorylation-deficient mutant S58A displayed an opposite
and unique phenotype with distinct punctate localization staining indicative of endosome
localization (figure 4.C). Accompanying treatment with saponin revealed a larger portion
S58A fluorescence remained in a punctate staining pattern, implying direct localization to
intact subcellular organelles (figure.4.D). Additionally, expression of empty-vector
FLAG alone did not reveal any punctate localization as a comparative control and was
mainly observed as nuclear staining with moderate observance in the cytoplasmic region
(figure 4.G-H). This is the first report of MTM regulation by phosphorylation and may
be the link surrounding involvement in the endosomal pathway with efficient and correct
substrate targeting. Collectively, these results strongly suggest that phosphorylation of
Ser58 thus regulates MTMR2 subcellular localization whereby phosphorylation sequester
MTMR2 in the cytoplasm and preventing its targeting to endocytic membranes. These
findings are also highly suggestive that only once MTMR2 is dephosphorylated will it
then preferentially localize to endocytic-like vesicles.
2.5 MTMR2 Phosphorylation Deficient Mutant Localizes to Early Endosomes
On the basis of distinct localization changes and known functions of MTMR2 in
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PI(3)P regulation, we next sought to examine into the particular subcellular compartment
to which S58A may be localized.

Considering that formation of the physiological

substrates of MTMR2 are differentially regulated by the small GTPases Rab5 and Rab7,
respectively, and have been previously demonstrated to play a pivotal role in PI(3)P
degradation, we initially examined these compartments for the primary target(s) [30].
Additionally, these GTPases have been well characterized to associate with early/late
endosomes where they facilitate endosome maturation and trafficking processes [34]. To
test whether FLAG-MTMR2 proteins localized to Rab5 positive vesicles, we
overexpressed MTMR2 in HeLa cells and performed immunofluorescence probing for
the endogenous early endosomal protein Rab5. Wild-type MTMR2 displayed no colocalization with Rab5, with the absence of any punctate distribution within the cytosolic
region as previously shown here and also formerly reported (Supplemental figure 3.A-C)
[28,30,31]. Additionally, S58E displayed an identical pattern to wild-type MTMR2
displaying dispersed cytosolic staining and lack of any co-localization with Rab5
(Supplemental figure 3.G-I). However, when S58A was overexpressed in HeLa cells and
probed for Rab5, there were to a significant extent a subset of vesicles displaying colocalization with Rab5 within the punctate patterns of the cytosolic region as displayed
within the enlarged sections (figure 5.A-C). Notably following saponin treatment, there
was significant Rab5 and S58A immunostaining that were found on neighboring vesicles
or opposite sides of the same vesicle (figure 5.D-F). Moreover, saponin treatment
revealed to a greater extent that these coalesced regions lie directly on subcellular
organelles and a greater percentage of co-localized regions remained. In contrast, we did
not detect significant co-localization of wild-type MTMR2, S58A or S58E with Rab7
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Figure 5. Co-localization of MTMR2 S58A with the early endosomal protein Rab5
HeLa cells were transiently transfected with FLAG-MTMR2 S58A for 42 h and analyzed
by immunofluorescence microscopy without saponin treatment (A–C), or with saponin
treatment (D–F). Cells were probed for endogenous Rab5 (green) (A and D) and FLAGMTMR2 S58A (red) (B and E). Merged images are shown to indicate partial colocalization (yellow) (C and F). Arrowheads indicate regions of interest and are presented
in expanded views. Images were collected using 63x (top panel) and 40x oil (lower
panel) objectives. The scale bar represents 15 µm (10 µm in expanded views).
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(Supplemental figure 4.A-C, D-F, G-I).
Acknowledging only partial staining of MTMR2.S58A and Rab5, we considered
that this may be attributed to the phosphatase activity of MTMR2. Progression of
endocytosed vesicles to Rab5 positive early endosomes in addition to Rab5 dependent
trafficking events, are tightly regulated by the association of PI(3)P binding proteins,
implicating these events may be sensitive to changes in PI(3)P levels. Therefore, in order
to precisely define the compartment to which S58A localized, we generated a
catalytically inactive MTMR2 phosphorylation-deficient mutant (S58A/C417S) and
performed co-immunofluorescence analysis with various endocytic markers (figure 6).
Following immunostaining for our overexpressed protein S58A/C417S and endogenous
markers, we observed a strong degree of co-localization with Rab5 in addition to the
PI(3)P marker EGFP-2xFYVE (figure 6.top two panels). However, when this inactive
mutant was overexpressed and probed for endogenous markers of late endosomes, we did
not observed any regions of co-localization with Rab7 or LAMP1 (figure 6. bottom two
panels). These results are highly suggestive that dephosphorylation of MTMR2 results in
subcellular targeting particular to early endosomes that are rich in its physiological
substrate PI(3)P.
2.6 Endocytic Localization of S58A Greatly Enhances Endocytic PI(3)P Depletion
In addition to Rab GTPases, levels of PI(3)P are indicative of actively maturing
endosomes. The MTMR2.S58A mutant contained lipid phosphatase activity that was
comparable with that of the wild-type enzyme. Considering the evidence determined in
this study, we were interested in further distinguishing and examining if S58A
localization to early endosomes resulted in targeted PI(3)P depletion. More specifically,
wild-type MTMR2 did not display any localization to endosomal structure however our
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Figure 6.Co-localization of catalytically inactive MTMR2 S58A.C417S with early
endosome markers
HeLa cells were transiently transfected with FLAG MTMR2 S58A.C417S alone or cotransfected with EGFP-2xFYVE (upper panel) for 42 h and analyzed by
immunofluorescence microscopy with saponin treatment. Cells were probed for FLAGMTMR2 S58A (red) and endogenous Rab5, Rab7, or LAMP1 (green). Merged images
are shown on the right panels with yellow indicative of co-localization. Boxes indicate
regions of interest and are presented in expanded views. Images were collected using 63x
objectives. The scale bar represents 15 µm (10 µm in expanded views).
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S58A did exhibit marked localization predominantly to early endosomes. Therefore, we
were interested in determining whether S58A affected PI(3)P levels on the surface of
these vesicles. Early endocytic vesicle fusion requires EEA1 which in turn is localized to
early endosomes via the C-terminal FYVE finger and PI(3)P [53].

The construct

comprises two FYVE domains with C-terminal EGFP fusion, supporting specific PI(3)P
binding and localization to early endosomes.

The results displayed are punctate

structures within the cytoplasm of cells with binding being dependent upon PI3K activity
in order to generate the PI(3)P product from phosphorylation of PIs.
HeLa cells were co-transfected with FLAG-MTMR2 proteins and EGFP2xFYVE, a marker used for the detection of PI(3)P rich endosomes which was also
useful for monitoring translocation effects such as through indirect immunofluorescence
[8]. The subcellular localization of EGFP and endogenous MTMR2 has been previously
reported in HEK293 cells showing global GFP fluorescence for empty vector-EGFP
constructs and cytoplasmic localization for both endogenous and overexpressed wild-type
MTMR2 respectively [28,30,31,36]. Specific proteins bind to the PI(3)P lipid head
groups through Phox homology (PX) domains or cysteine rich double zinc FYVE-fingers
[35].

Depletion of the PI(3)P through PI3K inhibition with wortmanin has been

demonstrated to result in marker re-distribution as a result of EGFP-2xFYVE dissociation
from early endosomes (figure 7.D-F) [35]. The Phosphoinositide PI(3)P is crucial for
correct endocytic membrane trafficking, and as a result, excessive endosome depletion
could disrupt the recruitment of proteins to specific membrane compartments such as
Rab5 [35]. We identified that co-transfection of EGFP-2xFYVE with wild-type MTMR2
displayed the observed cytoplasmic phenotype, and had no effect on the distribution
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pattern of the FYVE domain marker, with characteristic punctate staining (figure7.J-L).
Moreover, the phosphomimetic S58E mutant displayed a similar phenotype of
cytoplasmic localization with no overall translocation effects on the EGFP-2xFYVE
marker (figure 7.M-O). Intriguingly, HeLa cells that were positively co-transfected with
S58A resulted in cytoplasmic dispersion of the marker following endosomal targeting as
displayed by the punctate fluorescence staining pattern of S58A (figure 7.G-I). The
intracellular translocation of the marker implies that PI(3)P rich endosomes are depleted
therefore rendering absence of the FYVE finger to bind to the phospholipid ligands.
Also, the catalytically inactive dephosphorylated MTMR2 (S58A,C417S) did not
disperse the EGFP-2xFYVE PI(3)P marker (figure. 6. top panel) in contrast to the
catalytically active dephosphorylated MTMR2 (S58A) indicating that the observed
depletion of PI(3)P does require the phosphatase activity of MTMR2. Taken together,
these results indicate that phosphorylation deficient MTMR2 preferentially localizes to
early endosomal vesicles, where it effectively targets and depletes PI(3)P. These results
further suggest that the localization of MTMR2 is mediated by reversible
phosphorylation, and ultimately regulates localization to early endosome in addition to
the levels of PI(3)P at these regions.
2.7 MTMR2 Phosphorylation Site Mutant Augments EGF Signaling
The overexpression of wild-type MTMR2 has been previously elucidated to have
a total cellular effect on PI(3)P pools resulting in large reduction of lipid levels [29].
However, the particular function of MTMR2 in the endocytic pathway has yet to be
elucidated [32,37]. There have been implications regarding the importance of MTM lipid
phosphatases in regulation of PI(3)P and PI(3,5)P2, yet it has not been determined the
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Figure 7. MTMR2 S58A expression depletes PI(3)P from endosomes
HeLa cells were co-transfected with EGFP-2xFYVE and FLAG-MTMR2
phosphorylation mutants. After fixation, the cells were immunostained with anti-FLAG
and Alexa Fluor® 568 anti-mouse secondary to detect MTMR2 proteins. Localization of
the PI(3)P sensor EGFP-2xFYVE (right panels) on endosomes was detected as a punctate
pattern. The punctate pattern is seen in control cells (A–C), and cells expressing wild-type
MTMR2 (J–L) and S58E (M–O). The altered localization of the EGFP-2xFYVE marker
was observed in both wortmanin-treated cells (D–F) and in cells expressing MTMR2
S58A (G–I). Images were collected using 63x and 40x HD objectives. The scale bar
represents 15 µm.
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particular link to endosomal PI levels [29]. Recent work has shown that recruitment of
the catalytically active MTM1 to Rab5 endosomes resulted in targeted PI(3)P depletion,
which emanated in enhanced and prolonged Erk1/2 phosphorylation in addition to
increased phosphorylation of Akt substrates [28]. In order to address the potential effects
of MTMR2 endosomal targeting on subsequent signaling pathways, HeLa cells were
transiently transfected with FLAG-MTMR2 and S58A, lysed and the phosphorylation of
EGFR effectors was monitored over several times periods following low dose EGF
(5ng/ml) stimulation (figure 8). Our own work showed that MTMR2 is recruited to early
endosomes induced by dephosphorylation of the N- terminal Ser58 site resulting in
depletion of PI(3)P (figure.7). We therefore examined whether several early EGFR
effector pathways were induced, by monitoring two different mammalian cell lines. An
intense increase in the phosphorylation of Erk1/2 was observed with S58A compared to
wild-type transfected cells (figure 8A) predominantly in the earlier treatment time periods
(3-5 min).

Quantification by densitometry analysis revealed an ~2-fold increase in

Erk1/2 phosphorylation observed with S58A versus wild-type at the early time periods of
3 min and 5 min respectively (figure 8B). An obvious difference in phosphorylation of
Akt (Ser473), S6 Ribosomal Protein (Ser235/236) and 90 Ribosomal S6 Kinase (Ser380)
was also observed, however with a less discrete difference, possibly a result of early
activation and signal diminishment.
We then determined and compared the relative strength of the enhanced signaling
activity by comparing two independent mammalian cells lines concentrated at the earlier
5 min time period; HEK293 and HeLa cells (figure 9). The strength and increase in
Erk1/2 phosphorylation was distinctively observed with S58A in comparison to untransf-
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Figure 8. Phosphorylation-deficient MTMR2 increases activation of EGF signaling
(A) HeLa cells transfected with wt FLAG-MTMR2 and S58A were serum starved for 30
min and treated with 5 ng/ml of EGF for the indicated times. Lysates were
immunoblotted (IB) for proteins phosphorylated in response to EGF treatment using the
Pathscan® Multiplex antibody to detect phosphorylated proteins. Loading controls
included total ERK1/2 and actin. FLAG-MTMR2 was immunostained with anti-FLAG to
confirm equal MTMR2 expression levels in each of the samples. (B) ERK1/2
phosphorylation levels were quantified by densitometry using Image J, and normalized to
total ERK1/2 levels. The values indicate the mean ±S.D. (n =3).
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Figure 9. ERK1/2 activation enhanced by phosphorylation deficient MTMR2
(A) HeLa and HEK293 cells were transfected with FLAG-MTMR2 expression vectors
for 42 h. The cells were serum starved for 30 min and treated with 5 ng/ml of EGF for 5
min at 37 °C. ERK1/2 phosphorylation was determined by immunoblotting. Total
ERK1/2 and actin levels served as loading controls. FLAG-MTMR2 immunoblotting was
used to confirm equal transfection between samples. (B) ERK1/2 phosphorylation was
quantified by densitometry using the Image J program and normalized to total ERK1/2
levels (■HeLa;■HEK293). The values are shown as fold-change from control ±SD (n=3).
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-ected cells, wild-type MTMR2 and phospho-mutant S58E (figure 9A). Quantification
by densitometry revealed a striking difference with nearly a ~2-fold increase in ERK1/2
phosphorylation with S58A in both HEK293 and HeLa cells, with values normalized to
total ERK1/2 expression levels (figure 9B). Additionally, the observable increased
signaling of phospho-90RSK could be a result of downstream ERK1/2 activation and
appears that there may be variation within different systems considering a larger was
contrast observed with HEK293 cells in comparison to HeLa cells. Interestingly, there
was also observed a large increase in phospho-Akt which suggest that the affect of
MTMR2 N-terminal dephosphorylation (as represented by S58A) may represent
alternative effects on signaling pathways and may not only be specific to EGFR effectors.
These

findings

provide

a

biological

consequence

of

MTMR2

N-terminal

dephosphorylation and present evidence of the important role of MTMR2 in the
regulation and trafficking of not only growth factor receptors, but within the regulation of
the early endocytic pathway.
We also sought to address any potential effects on EGF-receptor activation and
localization under these same conditions. HeLa cells were transfected with MTMR2S58A and stimulated with EGF (5 ng/mL) particularly at 5 min stimulations and analyzed
by immunofluorescence. Under these conditions, we observed strong regions of colocalization with endogenous EGFR indicating that dephosphorylation of MTMR2.Ser58
results in receptor interaction in the early endocytic stages (figure 10). Additionally, we
examined direct receptor activation of EGFR at Tyr1173, which is a known site of
activation by phosphorylation that is linked to ERK1/2 signaling events. HEK293 cells
were transfected with FLAG-MTMR2 and phospho-variants for 42 h then stimulated

92

with EGF (5 ng/mL) for 5 min (figure 11). We observed a modest yet reproducible
increase in EGFR-Tyr1173 phosphorylation with S58A compared to wild-type, S58E and
untransfected cells.
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Figure 10. Co-localization of MTMR2 S58A with EGFR
HeLa cells were transiently transfected with FLAG-MTMR2 S58A for 42 h and analyzed
by immunofluorescence microscopy. Cells were probed for endogenous EGFR (red) and
FLAG-MTMR2 S58A (green). Merged images are shown to indicate partial colocalization (yellow). Boxed areas indicate regions of interest and are presented in
expanded views. Images were collected using 63x objectives. The scale bar represents 15
μm.
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Figure 11. EGFR phosphorylation at Tyr1173 is enhanced by phosphorylation
deficient MTMR2
HEK293 cells were transfected with FLAG-MTMR2 expression vectors for 42 h. The
cells were serum starved for 30 min and treated with 5 ng/ml EGF for 5 min at 37°C.
EGFR phosphorylation at position Tyr1173 was determined by immunoblotting. Total
EGFR and actin levels served as loading controls. FLAG-MTMR2 immunoblotting was
used to confirm equal transfection between samples (n=3).
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DISCUSSION
The results of this study demonstrate that reversible phosphorylation represents a
critical mechanism for regulating the subcellular localization of MTMR2. The finding
that an MTMR2 phosphorylation-deficient mutant preferentially localized to endocytic
structures where it depleted PI(3)P suggests a mechanism by which phosphorylation of
Ser58 impairs the localization of MTMR2 to compartments containing one of its
physiological substrates, PI(3)P. Because the stoichiometry of MTMR2 Ser58
phosphorylation under normal cell culture conditions was quite high, we hypothesize that
extracellular signals are required to induce Ser58 dephosphorylation (figure.12). By
analogy, attenuation of signals that activate the kinase(s) responsible for phosphorylating
MTMR2 at Ser58 would also result in an unphosphorylated MTMR2 and allow its
localization to endocytic structures, including those containing PI(3)P.

Following

depletion of PI(3)P by MTMR2, phosphorylation of Ser58 may be required to dissociate
MTMR2 from the vesicle to attenuate signal(s) generated by MTMR2-dependent PI(3)P
dephosphorylation. In light of the highly dynamic role of PI(3)P in endocytic processes,
the balance between MTMR2 Ser58 phosphorylation and dephosphorylation is likely to
contribute to the maturation and signaling capacity of a distinct set of endosomes.
One of the most striking aspects of the Ser58 phosphorylation site was the
apparent high stoichiometry determined by MS. Phosphopeptides are rarely detected in
unfractionated trypsin digests primarily due to their low stoichiometry, making them
underrepresented in a complex mixture and thus subject to suppression by other
unphosphorylated peptides present [30]. However, the phospho-Ser58 peptide was readily
detected in the complex peptide pool, along with the unphosphorylated peptide. These
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cognate peptides were reproducibly detected at approximately equal intensities. Taking
into consideration the widely held view that phosphate addition reduces peptide
ionization, we can safely conclude that the stoichiometry of phosphorylation is at least
50% and is likely to be considerably higher under the conditions used in the study. This
conclusion is further supported by subcellular localization studies and PI(3)P depletion
experiments, where localization of wild-type MTMR2 and endocytic PI(3)P depletion
were indistinguishable from the MTMR2 S58E phosphomimetic mutant. In contrast, the
unphosphorylatable MTMR2.S58A mutant displayed striking endosomal localization and
caused a marked depletion of endosomal PI(3)P. These findings further substantiate our
working model that MTMR2 exists in a constitutively phosphorylated state, where it is
sequestered away from its physiological substrate until the appropriate signal leads to its
dephosphorylation and subsequent targeting to endocytic vesicles, where PI(3)P is
localized. It must be taken into consideration that we utilized MTMR2 overexpression
throughout these studies. However, during the course of elucidating the functional
relevance of the Ser58 phosphorylation site, three independent phosphoproteomic
screening studies reported phosphorylation at Ser58 of endogenous MTMR2, thus
validating the results obtained in our overexpression studies [34-36]. Ongoing efforts of
developing a Ser58 phosphospecific antibody will help determine the relative
stoichiometry of phosphorylation at Ser58 on endogenous MTMR2 under various
conditions.
Inhibitory phosphorylation events that affect membrane binding have been shown
to be critical for other inositol lipid phosphatases, including PTEN. Several lines of
evidence suggest that phosphorylation of PTEN by casein kinase II and other kinases can
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inhibit its cleavage by caspase 3 and increase its stability [37,38]. Phosphorylated PTEN
also exhibits decreased lipid phosphatase activity and is unable to interact with binding
factors that target it to the inner surface of the plasma membrane [39-41]. Collectively,
these findings have led to a model by which phosphorylation of PTEN induces a closed
conformation that is stable, but inactive. PTEN dephosphorylation induces an open
conformation that allows PTEN to localize to membrane compartments and act on its
lipid substrate, PI(3,4,5)P3. The membrane-associated (unphosphorylated) form of PTEN
is more susceptible to proteolytic cleavage, which functions to allow down-regulation of
PTEN signaling.
The exact mechanism of MTMR2 phosphorylation remains to be elucidated.
However, the sequences surrounding the phosphorylation site can often offer clues to the
kinases involved. Ser58 resides in a so-called SP motif, suggesting that MTMR2 is
regulated by proline-directed kinases such as members of the MAPK family. Although
numerous proline-directed kinases are encoded in the human genome, which represent
potential MTMR2.Ser58 kinases, a wide array of chemical inhibitors and proteomic tools
are available that will aid in our ongoing efforts to identify the specific kinase(s) that
phosphorylate MTMR2 at Ser58.
At this time it is uncertain what extracellular stimuli may be responsible for
regulating MTMR2 reversible phosphorylation. However, Berger et al. (2003) reported
that hypo-osmotic stress in COS-1 cells caused translocation of MTMR2 to membrane
vacuoles rich in PI(3,5)P2 [21]. Furthermore, a CMT4B disease-associated point
mutation in the PH-GRAM domain greatly reduced binding to these vacuoles. We now
present compelling data that phosphorylation of a site in close proximity to the
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Figure 12. Phosphorylation Regulates Endosomal Targeting of MTMR2
Inhibition of MTMR2 Ser58 phosphorylation results in subcellular targeting to PI(3)Ppositive endosomes, which leads to PI(3)P depletion and increased growth factor receptor
signaling via endosomal pathways. Phosphorylation of Ser58 by a proline-directed kinase
sequesters MTMR2 in the cytoplasm, thus preserving the levels of PI(3)P and promoting
endosomal maturation/trafficking.
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PHGRAM domain regulates endosomal membrane targeting. Because hypo-osmotic
stress is known to regulate proline-directed kinases, including MAPK members [42,43], it
is plausible that the localization of MTMR2 to vacuolar structures in response to osmotic
stress may involve dephosphorylation of MTMR2 at Ser58. We are currently exploring
this possibility as well as systematically identifying regulatory signals that can regulate
Ser58 phosphorylation.
Several studies have demonstrated that active MTMRs are positively regulated by
inactive MTMR binding partners [22,25,44,45]. MTMR2 has been shown to interact
with two highly homologous members within the inactive MTMR subtypes, MTMR5 and
MTMR13. The mode of interaction between active and inactive MTMRs is thought to be
mediated by the coiled-coil domains found in the C termini of the active and inactive
binding partners [22,25]. These associations have been suggested to be important for
MTMR2 localization. Because we detected no significant difference in the ability of
MTMR2 phosphorylation site mutants to interact with MTMR5, and overexpression of
MTMR5 did not alter the phosphorylation levels of MTMR2 (data not shown), we
conclude that MTMR2 Ser58 phosphorylation is unlikely to regulate its interaction with
MTMR5 or MTMR13. Because MTMR13 mutations are also associated with type 4B
CMT disease, it will be important to conduct similar experiments focused on MTMR13
to determine whether MTMR2 Ser58 phosphorylation might affect its interaction with
MTMR13.
Another interesting observation was the co-localization of MTMR2.S58A and
Rab5. We observed a subset of Rab5 positive endosomes that were also positive for
catalytically active MTMR2 S58A, suggesting that unphosphorylated MTMR2 is targeted
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to endocytic like vesicles. However, a considerable amount of MTMR2 S58A positive
vesicles were Rab5 negative but often directly adjacent to Rab5 positive endosomes
(figure. 5). This perhaps signifies that targeting of MTMR2 S58A to endocytic structures
could affect Rab5 function. Moreover, this putative function would require phosphatase
activity as the catalytically inactive variant (MTMR2 S58A,C417S) displayed strong colocalization with Rab5 (figure. 6). Notably, Rab5 endosomal activities have been linked
to PI(3)P levels [33, 46]. For example, the critical endosomal effectors Rabenosyn-5 and
early endosomal antigen 1 require association with Rab5 and PI(3)P simultaneously to
localize to early endosomes [47–49]. Furthermore, Rab5 associates with endosomes in
its GTP bound form, which is maintained by endosomal guanine exchange factors such as
RABX-5. Poteryaev et al. (2010) have recently discovered that the endosomal protein
Mon1/SAND-1 removes RABX-5 (and subsequently Rab5) from endosomes in a PI(3)Pdependent manner [46]. Therefore, based on our co-localization results and the ability of
MTMR2 S58A to effectively deplete endosomal PI(3P), it is conceivable that reversible
phosphorylation of MTMR2 could regulate Rab5-dependent trafficking events that are
sensitive to PI(3)P. Moreover, the observed co-localization between MTMR2 S58A and
EGFR and the MTMR2 S58A-mediated increase in EGF signaling is consistent with a
model whereby phosphorylation deficient MTMR2 disrupts the ability of Rab5 to
modulate EGFR endocytosis resulting in prolonged receptor signaling.
In conclusion, we have identified a novel mechanism through which the
endosomal targeting of MTMR2 is regulated by reversible phosphorylation at Ser58. This
discovery provides critical insight into how MTMR2 activity toward its lipid substrates
can be spatially and temporally controlled. Furthermore, differential phosphorylation of
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other MTMR family members may represent a specific means for targeting these
enzymes to distinct pools of PI(3)P and PI(3,5)P2. Likewise, understanding the
mechanistic details of MTMR phosphorylation may help to clarify how similar gene
products (MTM1 and MTMR2) can cause distinct human disorders. Thus, it is of great
interest to further investigate whether other MTMR members are phosphorylated and
how these modifications regulate their activities.
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CHAPTER 3 – INTRODUCTION
Within the N-terminus of MTMR2 resides a high stoichiometry phosphorylation
site (Ser58) that is contained within the minimal MAPK recognition sequence.
Previously, we have shown that phosphorylation-deficient Ser58 (S58A) results in early
endosomal targeting of MTMR2 with a subsequent depletion of PI(3)P and an increase in
ERK1/2 signaling events [17].
In mammalian systems, the MAPK signaling cascades consists of three well
characterized members: ERK1/2, JNK/SAPK and p38 kinases [4,50]. MAPKs are a
subgroup of the proline-directed Ser/Thr kinases in which they recognize and
phosphorylate the consensus sequence (P-X-S/T-P-X-Z) on their substrate targets [5].
These kinase cascades mediate the transmission of extracellular signals to various
intracellular targets including transcription factors, facilitating the appropriate changes in
gene expression to respond to the extracellular stimuli [4,50].
extracellular

ligands

to

the

corresponding

RTK,

leads

The binding of
to

receptor

autophosphorylation/activation provoking further downstream activation of the MAPKs
in a multistep process [4,6]. Aberrant MAPK activation ultimately leads to impaired
cellular signaling resulting in defective growth and development [4].
Activation of each MAPK cascade results in biological responses that are most
often regulated and transmitted through RME [50]. More recently it has been shown that
endosomes rich in the adaptor protein APPL1 function as the regulatory switch mediating
the initial stages of endosome maturation coupled to the strength of MAPK signaling
[1,53]. In addition, the APPL proteins function as Rab5 effectors and are suggested to
play an important role in signaling events rather than the general housekeeping of
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endocytosis [51]. The loss of APPL1 as vesicles move centrally coincides with the
recruitment of EEA1 and subsequent maturation into the canonical PI(3)P-Rab5 positive
endosomes [1,52]. APPL1 vesicles are known to play a functional role in the assembly
of signaling complexes for MAPK and Akt pathways therefore, the presence of APPL1
profoundly impacts Akt and MAPK signaling [1-3,51,53]. Recent work has shown that
increased levels of PI(3)P acts as a molecular switch to turn off growth factor signaling
through the simultaneous loss of APPL1 on these endosomes [1]. Here, we present the
novel finding that the targeting of MTMR2 to these newly defined APPL1 endosome
subpopulations is mediated by dephosphorylation of MTMR2 at two phosphorylation
sites (Ser58/Ser631 - S58A/S631A) and may present a mechanism through which MTMR2
shuttles between endosome compartments to target different pools of PI(3)P.
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MATERIALS AND METHODS
3.1 Cell Treatment with Kinase Inhibitors
HEK293 cells (immunoblotting) or HeLa (immunofluorescence) cells were
treated with a JNK inhibitor (SP600125: LC laboratories; Woburn,MA), a highly specific
p38 inhibitor (SB203580: LC laboratories; Woburn,MA) or a potent MEK1/2 inhibitor
(U1026: LC laboratories; Woburn,MA) prior to cell lysis or immunofluorescence
analysis as indicated.

Cells were treated for 30 min with SB203580 at a final

concentration of 20 μM; for 1 hr with SP600125 at a final concentration of 40 μM; or for
1 hr with U1026 at a final concentration of 50 μM. Following cell lysis as previously
described, samples were purified by FLAG-IP, separated on 12% acrylamide gel, and
subjected to immunoblotting analysis as described (Chapter 2 – pg.66). For inhibition
controls, cells were first serum starved for 30 min followed by preincubation with U0126
as previous, then stimulated with 5 ng/ml EGF for 5 min and subsequently lysed and
analyzed by immunoblotting to determine extent the of ERK1/2 inhibition using primary
antibodies ERK1/2 and Pathscan® as previous and phosphorylation changes at
Ser58MTMR2 using chicken-anti-pSer58.MTMR2 (Christopher Bonham) at a 1:1500
dilution in 2.5% BSA/TBST at 4ºC overnight followed by incubation with donkey-antichicken HRP (DAIgY-HRP: Gallus Immnotech Inc.) at 1:3000 dilution in 2.5%
BSA/TBST for 1 h room temperature. For detection of JNK1 inhibition, cells were
serum starved for 60 min and pre-incubated with SP600125 as previous then subjected to
hypoosmostic shock by incubation in hypotonic medium (0.25x serum free medium plus
antibiotics in sterile DIUF H2O) for 30 min at 37°C or hyperosmotic shock by incubation
in hypertonic medium (150mM NaCl in serum-free medium plus antibiotics) for 30 min
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at 37°C. Cells were lysed, immunoblotted and probed for total JNK1 using rabbit-antiJNK1 (C-17: sc-474 Santa cruz Biotechnology) at a 1:1000 dilution in 2.5% BSA/TBST
overnight 4°C with secondary dilutions as previous, and mouse-phospho-JNK1 (G-7: sc6254; Santa Cruz biotechnology) at a 1:1000 dilution in 2.5% BSA/TBST overnight at
4°C, ERK1/2, pERK1/2 (Pathscan®), FLAG, and actin as previous and goat-anti-mouse
HRP, goat-anti rabbit HRP as previously described.
3.2 In Vitro Kinase Assay
Kinase assays were carried out using 5 µg of bacterial recombinant purified
MTMR-His6 proteins in reaction buffer (Assay dilution buffer (ADB) sterile filtered: 25
mM HEPES, pH 7.2, 12.5 mM β-glycerol phosphate, 25 mM MgCl2, 5 mM EGTA, 2
mM EDTA, 0.25 mM DTT) with 200 µM ATP reconstituted in ADB and 100 ng
activated kinase in ADB (total reaction vol = 50 µl). Reaction mixtures were incubated
at 30°C for 30 min with gentle shaking and the reaction was terminated by the addition of
30 µl 2x SDS, boiled for 5 min and centrifuged at 15,000 rpm for 2 min for elution (final
reaction vol = 80 µl). Samples were separated on a 10% polyacrylamide gel and the
following amounts of reaction mixtures were analyzed: 20 ng using anti-pSer58MTMR2
as previously described, 20 ng of reaction mixture to probe for ERK1 and ERK2 at
dilutions

previously

described,

p38α

using

rabbit-anti-p38

MAPK

antibody

(Thr180/Tyr182; #9211S: Cell signalling) at a 1:1000 dilution in 5% BSA/TBST
overnight 4°C with secondary antibody goat-anti-rabbit HRP at a 1:5000 dilution in 2.5%
BSA/TBST, JNK1 as previous,

total MTMR2 using mouse-anti-MTMR2 (I-15:sc-

100398; Santa Cruz Biotechnology) at a 1:1000 dilution in 1% skim milk and secondary
goat-anti-mouse IgG HRP conjugate (W4021; Promega) at a 1:5000 dilution in 1% skim
milk and 1 µg was used for Coomassie staining to detect total protein levels.
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RESULTS
PART I) Identification of the Kinase Governing MTMR2.Ser58 Phosphorylation
3.3 Phosphorylation of MTMR2 Ser58 is regulated by ERK1/2
ERK1 and ERK2 are MAPKs with over 160 known substrates including other
kinases/phosphatases, proteins involved in membrane trafficking/signaling, transcription
factors and membrane receptors [7,8]. The primary recognition sequence for MAPKs
and in particular ERK1/2 is P-X-S/T-P however, they have been shown to phosphorylate
several substrates containing the minimal dipeptide sequence X-S/T-P including Protein
Kinase C-alpha (PKCA) at Thr 638 (PVLTPP) and MAPK phosphatase-1 (MKP-1) on
Serine 359/Serine 364 (YLQSPI/ITTSPS) ultimately leading to complete protein
activation, greater protein stability and resultant effects on receptor-mediated signaling
[9,10]. Considering that Ser58 on MTMR2 resides within a similar MAPK recognition
sequence (DNFSPD) we first examined the potential for phosphorylation by several of
the well known and characterized MAPKs: ERK1, ERK2, p38α and JNK1.
Recombinant wt MTMR2 was purified from BL21 E.coli cell lysates and in vitro
kinase assays were performed. Substrate and kinase concentrations were determined
from titration trials and the optimal amounts were utilized for the kinase assays.
Following the in vitro kinase assay, the reaction mixture was then analyzed by
immunoblotting.

To ensure that the same amount of protein was utilized for each

reaction, 20 ng of purified wt MTMR2 protein from each of the reaction mixtures (tot vol=
5 µg/80 µl ~ 62.5 ng/µl → 16 µl = 1 µg: therefore samples were diluted to 0.001 µg/µl →
20 µl analyzed) was separated on a 10% SDS-PAGE gel and probed with α-MTMR2
antibody to detect total protein levels (figure 1). As an additional control 1µg of the same
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Figure 1. In vitro phosphorylation of recombinant wt MTMR2 by ERK1/2
Purified His6-tagged recombinant wt MTM2 was the substrate in the in vitro MAPK
kinase assay. (A) Each reaction contained 5 µg of recombinant wt-MTMR2, each 100 ng
of kinase and 200 µM ATP and reactions were incubated at 30°C for 30 min. The
phosphorylation of MTMR2 at position Ser58 was detected using a phospho-specific
antibody (pSer58MTMR2) and total MTMR2 levels determined by immunoblotting with
α-MTMR2 antibody and Coomassie staining.. (B) Reactions were probed for kinase
levels which served as additional controls (ERK2 68kDa, ERK1 42 kDa, p38α 67kDa,
JNK1 70 kDa).
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samples were also stained with Coomassie.

For the detection of MTMR2

phosphorylation at Ser58, Christopher Bonham from our lab generated a chicken-αpSer58.MTMR2 phospho-specific antibody to allow for the unambiguous identification of
phosphorylation definitively at this site. It was determined that both ERK1 and ERK2
phosphorylated MTMR2 at Ser58 at relatively the same intensities in vitro (figure 1 (A)
upper panels).
For the detection of all activated kinases utilized in these studies, 20 ng each were
analyzed by immunoblotting. The detection of ERK1 and ERK2 indicated ERK1 was
present at the respective 42kDa however ERK2 was detected at 68kDa due to the
recombinant GST-tag. Furthermore, the GST-p38α and GST-JNK1 were detected by
immunoblotting at their respective masses of 67kDa and 70kDa.
3.4 Inhibition of ERK1/2 alters MTMR2 subcellular localization
Selective MAPK inhibition is a widely utilized method to detect changes in
cellular systems and mechanisms as a result of targeted „shut-down‟ of kinase
phosphorylation events. The inhibitors utilized in this study are competitive and specific
MAPK inhibitors that have been widely characterized and used in a number of biological
systems [13-15].
In order to examine the effects of MAPK inhibition in vivo, HeLa cells were
transfected with FLAG-S58A or FLAG-MTMR2, then subsequently treated with
MEK1/2, p38 or JNK1 MAPK inhibitors and analyzed by immunofluorescence as
described under “Materials and Methods”. As an inhibitor control, HEK293 cells were
transfected with wt MTMR2 and subsequently simulated under various conditions that
are known to activate the JNK1 pathway (figure 2). Stimulation by hypoosmotic shock
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Figure 2. In vivo inhibition of JNK1
HEK293 cells were transiently transfected with wt FLAG-MTMR2 for 42 h. Cells were
serum starved for 1 h then subjected to hypoosmotic shock (0.25x medium) or
hyperosmotic shock [54] (150 mM NaCl) for 30 min at 37°C. Where indicated,
SP600125 was added at final concentration of 40 µM as a 1 h pretreatment. Lysates were
probed for total JNK1, actin and FLAG levels which served as loading controls and to
confirm equal transfection between samples. Activation of ERK1/2 with hypoosmotic
shock was not affected by JNK1 inhibitor treatment.
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resulted in activation of both the JNK1 and ERK1/2 pathways as detected by
immunoblotting of HEK293 lysates to detect JNK1 (figure 2 – 2nd panel lanes 3,4) and
ERK1/2 phosphorylation (figure 2 - 4th panel lane 3) . Moreover, hyperosmotic stress
was shown to only activate JNK1 thereby allowing for comparative controls for
inhibition studies (figure 2 – 2nd panel lane 4). Following pre-incubation with the JNK1
inhibitor (SP600125: +SP), it was observed that only JNK1 activation was selectively
inhibited (figure 2 – 2nd panel lanes 7,8) under both stimulation conditions whereas
ERK1/2 was still activated by phosphorylation (figure 2 – 4th panel lane 7).

The

displayed selective inhibition prompted us to examine the potential effects on the
subcellular localization of wt-MTMR2 in vivo following MAPK inhibitor treatments.
Under normal untreated conditions S58A displayed the unique punctate
localization and wild-type MTMR2 displayed the characteristic cytoplasmic staining
pattern as previously observed (figure 3.A-B,I-J). Moreover, following inhibition of
either p38 or JNK1, we did not detect any significant difference in subcellular
localization compared to that of wild-type wherein the transfected cells displayed the
dispersed cytoplasmic staining (figure 3.E-F,G-H). Interestingly, following treatment of
HeLa cells overexpressing wild-type with a MEK1/2 (ERK1/2) inhibitor resulted in loss
of MTMR2 cytoplasmic staining and a distinct punctate localization similar to that which
was observed with FLAG-S58A, and is highly indicative of unique vesicular and intact
subcellular organelle localization (figure 3.C-D). These results indicate that inhibition of
ERK1/2 in vivo elevates MTMR2 endosomal targeting potentially by preventing Ser58
phosphorylation.
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Figure 3. ERK1/2 inhibition triggers targeting of MTMR2 to punctate regions
HeLa cells were transiently transfected with FLAG-MTMR2 or FLAG-MTMR2 S58A (A
and B) for 42 h and analyzed by immunofluorescence microscopy. Cells were left
untreated (I and J) or treated with various inhibitors; U0126 (MEK1/2) at 50 µM for 1 h
(C and D), SB203580 (p38) at 20 µM for 30 min (E and F), and SP600125 (JNK) at 40
µM for 1 h (G and H). Cells were then probed for FLAG-MTMR2 or FLAG-MTMR2
S58A using Alexa Fluor® 568. Boxes indicate regions of interest and are presented in
expanded views. Images were collected using 63x objectives. The scale bar represents 15
μm.
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3.5 Ser58 Phosphorylation is greatly reduced following ERK1/2 inhibition
In response to various stimuli including heat shock, hypoosmotic stress and
growth factors, ERK1/2 becomes activated by phosphorylation which in turns leads to the
downstream activation and/or inhibition of the target substrates [1,10,13]. Interestingly,
ERK1/2 activation by growth factors such as EGF are normally transient, but in some
circumstances sustained activation of upstream kinases leads to prolonged ERK1/2
activation and differential effects on target proteins. Inhibition of ERK1/2 on the other
hand, has been shown to alter receptor signaling [10,13]. Consequently, there are effects
on proliferation, growth and differentiation leading to altered cellular mechanisms that
are important for survival. Therefore, in an effort to examine the regulation and/or
changes of MTMR2.Ser58 phosphorylation in vivo, we utilized a very well known and
characterized inhibitor U0126 which functions by inhibiting the upstream MEK1/2 kinase
that mediates ERK1/2 phosphorylation.
HEK293 cells were transiently transfected with wild-type MTMR2 and examined
for the effects on Ser58 phosphorylation following ERK1/2 inhibition (figure 4).
Untreated transfected samples functioned as the control in order to monitor Ser58
phosphorylation under normal resting state conditions.

Under untreated conditions,

MTMR2.Ser58 displayed high levels of phosphorylation which dramatically decreased
following a 30 min serum starvation (figure 4.A). Serum deprivation has been shown to
reduce the basal activity of ERK1/2 under moderate starvation conditions (~ 30 min-120
min) [16].

Most generally, ERK1/2 displays modest activity under resting state

conditions however; in some cell lines it can remain undetected potentially as a result of
culture conditions [16]. Following a 30 min serum starvation period, low dose EGF
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stimulation (5 ng/ml) was used to monitor ERK1/2 activation (pERK1/2) and the
subsequent phosphorylation of Ser58. After 5 min and 30 min stimulation with EGF,
ERK1/2 was transiently activated and we also observed activation of a downstream
ERK1/2 substrate phospho-S6 kinase (pS6K) which was monitored as a control.
Moreover, MTMR2 Ser58 phosphorylation levels also increased relative to the untreated
samples. In comparison to serum starved conditions, a nearly 60% increase in Ser58
phosphorylation following ERK1/2 activation was detected (figure 4.B).

A slight

decrease in Ser58 phosphorylation was observed following a longer stimulation period at
30 min. However, following serum starvation cells were pre-incubated for 1hr with an
ERK1/2 inhibitor (+U0126) that resulted in the lack of Ser58 phosphorylation following
the same EGF stimulation conditions. The MEK1/2 inhibitor, U0126 inhibited EGFstimulated ERK1/2 activity and MTMR2.Ser58 phosphorylation in parallel wherein
pERK1/2 levels were undetected and Ser58 phosphorylation levels were ~80% lower
compared to untreated conditions (figure 4.B).

Also, pS6K phosphorylation was

diminished indicating that inhibition of ERK1/2 activation prevented the phosphorylation
of downstream substrates (figure 4.A). Collectively, these results indicate that inhibition
of ERK1/2 prevents Ser58 phosphorylation and the aforementioned changes in MTMR2
subcellular localization is a result of lack in Ser58 phosphorylation.
3.6 Inhibition of JNK1 and ERK1/2 results in enlarged APPL1 endosomes
Formerly, we have determined evidence implicating that ERK1/2 inhibition
resulted in MTMR2 targeting to vesicular-like structures primarily as a result of Ser58
dephosphorylation and therefore, our next task was to address and identify these
subcellular compartments. Initially we began by examining localization with endogenous
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Figure 4. In vivo inhibition of ERK1/2 results in decrease of Ser58 MTMR2
phosphorylation
(A) HEK293 cells were transiently transfected with wt FLAG-MTMR2 for 42 h. Cells
were serum starved for 30 min then treated with 50 µM of U0126 (MEK1/2) for 1 h
(where indicated), followed by the addition of 5 ng/mL EGF for 5 and 30 min at 37°C.
Cells were then lysed and FLAG immunoprecipitated, then subsequently probed for
phosphorylation of MTMR2 at Ser58. FLAG-MTMR2 immunoblotting from FLAG-IP
was used to confirm equal transfection between samples. Total ERK, actin and Flag
levels from lysates served as loading controls and pERK indicates inhibition of the
activated kinase (ERK1/2:Thr202/Tyr204) with U0126 treatment. Decrease in the
phosphorylation of a downstream ERK1/2 substrate phospho-S6 (Ser235/236) served as
an additional control. (B) ERK1/2 and MTMR2 Ser58 phosphorylation levels were
quantified by densitometry using Image J, and normalized to total ERK1/2 or FLAG (IP)
levels (■ wt MTMR2;■ERK1/2) The values are shown as fold-change to control (n=3).
Error bars ± SD
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Rab5 utilizing the same MAPK inhibitors as previous and additionally combined
treatments with the ERK1/2 inhibitor considering that only this inhibitor had any effect
on MTMR2 localization. HeLa cells were transfected with wild-type MTMR2 and
examined by immunofluorescence (figure 5). Untreated, wild-type MTMR2 displayed
the characteristic cytoplasmic staining pattern with greater intensity in the perinuclear
region and lack of any Rab5 localization (figure 5. top row). Intriguingly however, when
cells were treated with the MEK1/2 inhibitor U0126, MTMR2 displayed a punctate
pattern with a subset of vesicles that were positive for both MTMR2 and Rab5 (figure 5.
second row and expanded view). These results are similar to that observed with S58A
and Rab5 where the colocalized staining seem to be directly adjacent or on opposite sides
of the same vesicle. Inhibition of MEK1/2 results in lack of ERK1/2 activation, and
considering that our wild-type MTMR2 was still active, this pattern could be a result of
endosomal PI(3)P levels. Alternatively, combined treatment of U0126 with the p38
inhibitor (+U+SB) resulted in the same punctate pattern however absence of any Rab5
colocalized vesicles (figure 5. third row). Combined inhibition of ERK1/2 and JNK1
(+U+SP) displayed a more pronounced punctate pattern and these vesicles did appear
enlarged yet lacking any Rab5 co-localization (figure 5. bottom row).
To investigate whether these inhibitor treatment were causing localization to a
distinct subpopulation of endosomes, HeLa cells were transfected with wild-type
MTMR2 and also immunostained for endogenous APPL1 (figure 6). As previously
observed, untreated wild-type MTMR2 was cytoplasmic and did not show any APPL1
co-localization (figure 6. top row).

Inhibition of ERK1/2 (+U) or ERK1/2 + p38

(+U+SB) resulted in a punctate staining pattern that was devoid of APPL1 co-staining
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Figure 5. ERK1/2 inhibition results in MTMR2 localization to Rab5 positive vesicles
HeLa cells were transiently transfected with FLAG-MTMR2 phosphovariants for 42 h
and analyzed by immunofluorescence microscopy. Cells were treated with various
inhibitors; U0126 (+U) at 50 µM for 1 h, or combined with SB203580 (+SB) at 20 µM
for 30 min, and SP600125 (+SP) at 40 µM for 1 h where indicated. Cells were probed
for endogenous Rab5 (green) and FLAG-MTMR2 (red). Merged images are shown to
indicate co-localization. White arrows indicate direct regions of co-localization and
purple arrows represent vesicles lacking co-localization. Regions of interest are
presented in expanded views. Images were collected using 63x objectives. The scale bar
represents 15 μm.
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(figure 6. second/third rows). In contrast, double inhibitor treatments of ERK1/2 and
JNK1 (+U+SP) resulted in a large number of vesicles that were positive for both
MTMR2 and APPL1 and were enlarged (figure 6. bottom row and expanded view). Size
measurement quantifications revealed colocalized vesicles to have an average area of
1.84µm2 (±0.4) and those only positive for APPL1 were determined to have an average
area of 0.57µm2 (±0.12) (Appendix 2. Table 1).
Most recently, Zoncu et.al identified that APPL1 vesicles defined an early
transient endosome subpopulation that reside downstream of clathrin-coated pits in RME
that are en route to PI(3)P positive early endosomes [1]. In this study it was also
determined that direct PI(3)P depletion at the early endosomes resulted in reversion of
PI(3)P/Rab5 endosomes, back to their preceding APPL1 endosomes with accompanying
vesicles enlargement [1]. As a comparative control to our inhibitor studies, we utilized
our MTMR2 phosphorylation-deficient mutant S58A in order to eliminate the use of
ERK1/2 inhibitor. To examine this, HeLa cells were transfected with MTMR2 S58A and
probed for endogenous APPL1 under saponin conditions in order to specifically identify
intact compartments (figure 7. top row). We observed a significant amount of intact
vesicles following saponin treatment that did not display any localization with APPL1.
However, when these cells were treated with the JNK1 inhibitor (+SP) the complete
opposite localization pattern was observed in which nearly all of the cells positive for
S58A (+SP) colocalized with APPL1 and also appeared to result in their enlargement
(figure 7. middle row). Quantification revealed that S58A colocalized vesicles were
nearly 3 times larger and had an average area of 4.08 µm2 (±0.12) and those only positive
for APPL1 were determined to have an average area of 1.32 µm2 (±0.16) (Appendix 2.
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Figure 6. Inhibition of ERK1/2 and JNK1 triggers MTMR2 localization to APPL1
endosomes
HeLa cells were transiently transfected with FLAG-MTMR2 phosphovariants for 42 h
and analyzed by immunofluorescence microscopy. Cells were treated with various
inhibitors; U0126 (+U) at 50 µM for 1 h, or combined with SB203580 (+SB) at 20 µM
for 30 min, and SP600125 (+SP) at 40 µM for 1 h where indicated. Cells were probed for
endogenous APPL1 (green) and FLAG-MTMR2 (red). Merged images are shown to
indicate co-localization. White arrows indicate direct co-localization and purple arrows
represent vesicles lacking co-localization. Regions of interest are presented in expanded
views. Images were collected using 63x objectives. The scale bar represents 15 μm.
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Figure 7. JNK1 and ERK1/2 inhibition results in enlarged APPL1 endosomes
HeLa cells were transiently transfected with FLAG-MTMR2 or S58A for 42 h and
analyzed by immunofluorescence microscopy. Cells were left untreated (top panel),
treated with SP600125 (+SP) at 40 µM for 1 h (middle panel) or combined with U0126
(+U) at 50 µM for 1 h (lower panel). Merged images are shown to indicate colocalization with white arrows indicating direct co-localization and purple arrows
represent vesicles devoid of co-localization. Regions of interest are presented in
expanded views. Images were collected using 40x objectives. The scale bar represents 15
μm.
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Table 1). The C-terminal region of MTMR2 contains Ser631 that resides within a similar
recognition sequence as Ser58 (S/T-P) and large scale phospho proteomic studies have
previously identified Ser631 as a phosphorylation site [47-49].

Thus, JNK1 may

phosphorylate MTMR2 at Ser631 and JNK1 inhibition in turn, targets MTMR2 to this
distinct sub-pool of endosomes.

Overall, these findings suggest that MTMR2

phosphorylation and targeting to specific pools of early endosomes is dynamically
regulated, with Ser58 phosphorylation mediated by ERK1/2 and Ser631 phosphorylation in
part regulated by JNK1.

PART II) Characterization of the MTMR2.Ser631 Phosphorylation Site
3.7 Dephosphorylation of N-terminal Ser58 and C-terminal Ser631 results in APPL1
endosomal targeting
In an effort to determine the relationship with respect to the N-terminal and Cterminal phosphorylation sites surrounding MTMR2 regulation we generated
combination variants by site-directed mutagenesis to mimic modifications at Ser58 and
Ser631 wherein mutations to an Ala (A) resembles dephosphorylation and mutations to a
Glu

(E)

mimic

phosphorylated.

We

then

examined

their

localization

by

immunofluorescence and initially examined co-localization with APPL1 to compliment
our MAPK inhibitor treatments.
HeLa cells were transfected with all the FLAG constructs and immunostained for
endogenous APPL1 (figure 8). It appears that mutations solely at the C-terminal Ser631
site do not have any effect on MTMR2 subcellular localization as detected by the
dispersed cytoplasmic staining in both of the single Ser631 mutants (figure 8. second and
bottom row). Also, the double phosphorylation mutant S58E/S631E displayed a similar
localization pattern that was present within the cytoplasm (figure 8. third row). Notably,
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Figure 8. Dephosphorylation of Ser58 and Ser631 results in MTMR2 subcellular
localization to APPL1 endosomes
HeLa cells were transiently transfected with FLAG-MTMR2 phosphovariants for 42 h
and analyzed by immunofluorescence microscopy. Cells were probed for endogenous
APPL1 (green) and FLAG-MTMR2 (red). Merged images are shown to indicate colocalization (yellow) of enlarge vesicles. White arrows indicate direct regions of colocalization and purple arrows represent smaller vesicles lacking co-localization.
Regions of interest are presented in expanded views. Images were collected using 63x
objectives. The scale bar represents 15 μm.
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occasionally we observed a subset of vesicles that appeared to have vacuolar-like
structures (appearance of hollow holes) present within the cytoplasm that were only
detected with the S58E/S631E mutant. Vacuolar-like structures have been shown to
contain higher levels of PI(3,5)P2, the other physiological substrate of MTMR2, most
prominently at the cell membrane. These results could be indicative that phosphorylation
at both sites could influence localization to regions that are predominantly rich in
PI(3,5)P2 and may provide a mechanism by which MTMR2 is specifically targeted to
these regions.

However, more in-depth analysis surrounding this localization and

observations needs to be addressed further. In all cases, no APPL1 co-localization was
detected most likely as a result of failure to target MTMR2 to endosomal vesicles by
modifications at Ser631.

Intriguingly, the double phosphorylation-deficient mutant

(S58A/S631A) displayed a distinct punctate staining pattern that appeared to be localized
just on the inside of the cell periphery (figure 8. first row). Moreover, these vesicles
displayed strong co-localization with APPL1 and also were enlarged compared to
adjacent vesicles lacking the MTMR2 S58A/S631A mutant (enlarged views).

Size

measurement quantifications revealed that co-localized vesicles were nearly 2.6 times
larger and had an average area of ~ 1.14µm2 (±0.11) whereas APPL vesicles were ~0.43
µm2 (±0.13) (Appendix 2.Table1). These results indicate that dephosphorylation at both
sites may mediate targeting to APPL1 endosomes, and in response to PI(3)P depletion at
Rab5 positive early endosomes, be prolonging receptor containment at these regions.
Furthermore this result confirms that Ser58 is the main phosphorylation site that regulates
general endosomal targeting and additionally implicates that this may occur as a
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preliminary step to Ser631 dephosphorylation because no change in localization is
observed when the Ser631 site is modified alone.
To further verify our hypothesis, we examined the co-localization of S58A/S631A
with Rab5 and compared the localization pattern to APPL1 (figure 9). It was determined
that there was a lack of any colocalized regions with Rab5 and most notably, it also
appeared that the MTMR2 vesicles were further towards the outer cells edge than those
containing Rab5 both with and without saponin treatment (figure 9. bottom panels).
What this potentially implicates is that the S58A/S631A mutant is most likely localized
to vesicles that precede the canonical early endosomes marked by Rab5. In order to
confirm this, we again immunostained for endogenous APPL1 and observed the similar
colocalized staining pattern as previously (figure 9. top panels). Most notably, following
saponin treatment we observed that nearly all vesicles were positive for S58A/S631A and
APPL1. Also, the colocalized vesicles displayed larger average area in comparison to
those only positive for APPL1 (enlarged views) similar to that observed previously
(Appendix 2. Table 1).
The observed vesicle enlargement could be a result of effects on the endosomal
PI(3)P levels considering that this mutant still contains catalytic activity. Therefore, as a
comparative control we also generated a catalytic inactive double phosphorylationdeficient mutant protein (S58A/C417S/S631A). It was determined that the enlargement
of APPL1 vesicles previously observed was dependent on the phosphatase activity as
displayed by the lack in vesicle enlargement within our inactive mutant and absence in
Rab5 localization (Supplemental figure 5). Collectively, these results coupled with the
MAPK inhibitor treatments suggests that dephosphorylation at Ser58 targets MTMR2 to
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Figure 9. Co-localization of S58A/S631A results in enlarged APPL1 endosomes
HeLa cells were transiently transfected with FLAG-MTMR2 S58A/S631A for 42 h and
analyzed by immunofluorescence microscopy. Cells were probed for endogenous APPL1
(green: top panels center), Rab5 (green: lower panels center) and FLAG-MTMR2 (red:
left panels). Merged images are shown to indicate co-localization with APPL1 (yellow)
and absence with Rab5 (green/red). White arrows indicate direct regions of colocalization and purple arrows represent smaller vesicles lacking co-localization.
Regions of interest are presented in expanded views. Images were collected using 63x
objectives. The scale bar represents 15 μm.
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Rab5 positive early endosomes which is mediated by ERK1/2.

The accompanying

dephosphorylation at Ser631 mediates targeting to APPL1 vesicles and that
phosphorylation of this C-terminal site could be regulated by JNK1 considering that
inhibition of both ERK1/2 and JNK1 results in a similar localization pattern as the double
phosphorylation-deficient mutant (S58A/S631A).
3.8 Effects on MTMR2 endocytic localization with Ser631 phosphorylation
We have previously determined that dephosphorylation at Ser58 results in
MTMR2 endosomal targeting, however, an additional prominent phosphorylation site
that resides in the C-terminal region near the coiled-coil and PDZ-binding motifs has yet
to be fully characterized. Additionally, considering the important of the N-terminal Ser58
site, this leads us to hypothesize that there may potentially be cross-talk occurring
between these two sites that governs localization to a particular PI(3)P subcellular
compartment. In order to examine the inherent possibility, we generated double mutants
containing Ser58 dephosphorylated and Ser631 phosphorylated (S58A/S631E) and vice
versa (S58E/S631A) by site directed mutagenesis as described under materials and
methods. These constructs were transfected in HeLa cells and immunofluorescence
analysis was performed probing for our FLAG overexpressed proteins and for
endogenous endosomal proteins APPL1 and Rab5 (figure 10). It was determined that the
S58A/S631E mutant displayed the characteristic punctate staining pattern similar to that
observed with single point mutations at Ser58 (S58A) however we did not observe any
regions of co-localization with APPL1 (figure 10. top panel first row). Additionally,
when cells were transfected with the S58E/S631A mutant, there was absence of any
punctate localization and also lack of APPL1 co-localization, fortifying that
dephosphorylation at Ser58 governs general endosomal targeting (figure 10. top panel
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Figure 10. Rab5 endosome targeting is regulated by dephosphorylation of Ser58 and
phosphorylation of Ser631
HeLa cells were transfected FLAG-MTMR2 phospho-variants; S58A/S631E and
S58E/S631A for 42 h and analyzed by immunofluorescence microscopy. After fixation,
with cells were incubated with anti-FLAG antibody and Alexa Fluor®568 (red). Cell
were also probed for endogenous APPL1 (green-top panels) and Rab5 (green-lower
panels). Boxes indicated regions of interest and are presented in expanded views.
Merged images show partial co-localization of S58A/S631E with Rab5 (top row-lower
panel) and are displayed in boxed regions with white arrows. Images were collected
using 40xoil and 63x objectives. The scale bar represents 15 µm.
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second row). Moreover, when HeLa cells were probed for endogenous Rab5 with the
S58A/S631E we observed a subset of vesicles that displayed positive colocalized
staining, similar to what had previously been observed with single mutations at Ser 58
(S58A) (figure 10.bottom panel first row). Furthermore, it was still observed that there
existed cytoplasmic localization following phosphorylation at Ser58 as displayed by the
S58E/S631A that shows dispersed cytoplasmic staining and lack of Rab5 co-localization
(figure 10.bottom panel second row).
Considering that Rab5 localization to early endosomes is dependent on the correct
cellular levels of PI(3)P, and that our own results show that overexpression of S58A in
HeLa cells results in altered Rab5 localization, we therefore addressed whether the
phosphatase activity was affecting co-localization with Rab5. We generated the double
mutant lacking any catalytic activity, represented as S58A/C417S/S631E as previously
described. This construct was then overexpressed in HeLa cells and immunofluorescence
analysis was performed. The endogenous localization of APPL1 was not affected and the
mutant displayed lack of any regions of co-localization (figure 11. top panels).
Furthermore, when cells transfected with S58A/C417S/S631E were probed for
endogenous Rab5, we observed a significant amount of vesicles displaying positive colocalization as highlighted in the expanded views (figure 11. bottom panels).
Accompanying control immunofluorescence images of single point mutations at the
Ser631 (S631A and S631E) phosphorylation site indicate that the punctate pattern and
Rab5 co-localization is dependent on the dephosphorylation at Ser58 (figure 12. first two
rows).

Likewise, the single catalytically inactive mutant (C417S) and double

dephosphorylation mutant (S58E/S631E) both displayed the characteristic cytoplasmic
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Figure 11. Dephosphorylation of catalytically inactive MTMR2 at Ser58 localizes to
Rab5-positive endosomes irrespective of Ser631 phosphorylation
HeLa cells were transfected with FLAG-MTMR2 catalytically inactive phospho-variant
(S58A/C417S/S631E) for 42 h and analyzed by immunofluorescence microscopy (red).
After fixation, cells were immunostained with anti-FLAG antibody. Cells were probed
for endogenous APPL1 (green: top panels center), Rab5 (green: lower panels center) and
FLAG-MTMR2 (red: left panels). Merged images are shown on the right panels with
yellow vesicles and white arrows indicative of vesicle co-localization. Top panels with
expanded views indicate lack of vesicle co-localization with APPL1. Boxes indicate
regions of interest and are presented in expanded views. Images were collected using
40xoil and 63x objectives. The scale bar represents 15 µm.
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Figure 12. MTMR2 mutations lacking dephosphorylation of Ser58 display dispersed
cytoplasmic localization
HeLa cells were transiently transfected with FLAG-MTMR2 phospho-variants for 42 h
and analyzed by immunofluorescence microscopy. Cells were probed for endogenous
Rab5 (green) and FLAG-MTMR2 (red). Images were collected using 63x objectives.
The scale bar represents 15 μm.
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staining as observed with wild-type and lacked any Rab5 co-localization (figure 12.
bottom two rows). Collectively, the strong co-localization of Rab5 and the inactive
S58A/C417S/S631E mutant combined with the previously reported data of inactive
S58A/C7417S is highly suggestive of the requirement of Ser58 dephosphorylation and
Ser631 phosphorylation for localization to Rab5 positive endosomes [17].
3.9 Endocytic PI(3)P depletion is dependent on Ser58 dephosphorylation and Ser631
phosphorylation
Because dephosphorylation of Ser58 results in PI(3)P depletion at Rab5-positive
vesicles (Chapter 2. figure 7), it was relevant to evaluate whether dephosphorylation at
the additional Ser631 site could also play a role in this process [17]. As mentioned
previously, the S58A/S631A mutant was found to localize to and enlarged APPL1
endosomes presumably as a result of effects on the early endosomal PI(3)P levels. In
order to address if this mutant had any large effect on cellular PI(3)P levels, we coexpressed the S58A/S631A and S58A/S631E mutants with EGFP-2xFYVE in HeLa cells
and performed immunofluorescence analysis (figure 13).
Co-expression of the S58A/S631A mutant with EGFP-2xFYVE revealed that
there was no effect on the localization of the PI(3)P marker as displayed by the punctate
staining pattern and lack of any co-localization (figure 13. top two rows). Interestingly,
when our dephosphorylation Ser58 mutant was phosphorylated at Ser631 (S58A/S631E),
we observed a complete loss of the characteristic punctate staining pattern for the PI(3)P
marker similar to what we had observed previously for S58A (figure 13. bottom two
panels). These results suggest that Ser58 dephosphorylation and Ser631 phosphorylation is
necessary for efficient PI(3)P depletion at Rab5 positive early endosomes.
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Figure 13. Dephosphorylation at Ser58 and phosphorylation at Ser631 induces PI(3)P
depletion at Rab5 early endosomes
HeLa cells were co-transfected with EGFP-2xFYVE (green) and FLAG-MTMR2
combination phospho-variants; S58A/S631A (top panels) and S58A/S631E (bottom
panels) for 42 h and analyzed by immunofluorescence microscopy. After fixation, cells
were incubated with anti-FLAG antibody and Alexa Fluor® 568 (red). The punctate
endosomal pattern of EGFP-2xFYVE remains with S58A/S631A displaying lack of
vesicle co-localization following saponin (0.01%) treatment. Images were collected
using 40x (top panels) and 63x (lower panels) objectives. The scale bar represents 15
µm.
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Figure 14. Inducible PI(3)P depletion at early endosomes is dependent on MTMR2
catalytic activity
HeLa cells were co-transfected with EGFP-2xFYVE (green) and FLAG-MTMR2
catalytically inactive phospho-variants (red); S58A/C417S/S631A (top panels) and
S58A/C417S/S631E (bottom panels) for 42 h and analyzed by immunofluorescence
microscopy. After fixation, cells were immunostained with anti-FLAG antibody. The
punctate endosomal pattern of EGFP-2xFYVE remains with S58A/C417S/S631A
displaying partial co-localization of vesicles following saponin (0.01%) treatment. Boxes
indicate regions of interest and are presented in expanded views. White arrows indicate
vesicles displaying co-localization and purple arrow distinguish individual vesicles
lacking co-localization. Images were collected using 40x oil objectives. The scale bar
represents 15 µm.
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Figure 15. Modifications at Ser631 does not induce PI(3)P depletion
HeLa cells were co-transfected with EGFP-2xFYVE (green) and FLAG-MTMR2 (red)
phospho-variants; S58E/S631A, S631A, S58E/S631E and S631E (left panels) for 42 h
and analyzed by immunofluorescence microscopy.
After fixation, cells were
immunostained with anti-FLAG antibody. The punctate endosomal pattern of EGFP2xFYVE remains with all constructs implicating lack of endosomal targeting and PI(3)P
depletion. Images were collected using 63x objectives. The scale bar represents 15 µm.
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Furthermore, similar to inactive S58A/C417S, the S58A/C417S/S631E mutant
displayed nearly complete co-localization with the PI(3)P marker EGFGP-2xFYVE both
without and following saponin treatment (figure 14. bottom panels).

Intriguingly,

S58A/C417S/S631A which was shown to localize to APPL1 endosomes displayed partial
regions of co-localization with the PI(3)P marker (figure 14. top panels). Initially, it was
hypothesized that there would not be any regions of co-localization considering that there
were no effects of the localization of EGFP-2xFYVE observed following co-transfection
with the active S58A/S631A mutant. However, APPL1 endosomes are shown to contain
relatively small amount of the PI(3)P lipid wherein staining for endogenous APPL1 with
cells transfected with EGFP-2xFYVE displayed a small subset of vesicles that showed
coalescent regions of co-localization compared to Rab5 (Supplemental figure 6).
Additionally, co-transfection of EGFP-2xFYVE with inactive MTMR2 (C417S) or single
and combined modifications at Ser631 with did not induce PI(3)P depletion (figure 15).
3.10 Effects of dephosphorylation at Ser58 and Ser631 on EGF signaling
Previously we have determined that endosomal targeting of MTMR2 is mediated
through dephosphorylation at Ser58 and subsequently results in earlier and pronounced
signaling events particularly with respect to ERK1/2.

Additionally, Zoncu et.al

demonstrated that prolonged residency of receptors within APPL1 endosomes, resulted in
extended receptor signaling as monitored by the activation of key signaling pathways
including ERK1/2 and Akt [1]. Considering that dephosphorylation at Ser58 and Ser631
appears to mediate targeting to APPL1 endosomes, we therefore sought to examine the
potential effects on downstream signaling events following EGF stimulation (figure 16).
To test this hypothesis, HEK293 cells were transfected with wild-type, S58A and
S58A/S631A and activation of signaling pathways were examined by immunoblotting.
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Figure 16. Dephosphorylation of Ser58 and Ser631 triggers sustained ERK1/2
activation
(A) HeLa cells were transfected with wt FLAG-MTMR2, S58A or S58A/S631A and
serum starved for 30 min then treated with 5 ng/ml EGF for the indicated times. Lysates
were immunoblotted (IB) for pERK1/2 and pAkt following EGF stimulation using the
Pathscan® Multiplex antibody. Total ERK1/2 levels served as loading control. Lysates
were immunostained with anti-FLAG to confirm equal expression. (B) ERK1/2
phosphorylation levels were quantified by densitometry using Image J, and normalized to
total ERK1/2 levels. The values indicate the mean ±S.D. (n =3).
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HEK293 cells were left untreated and additionally treated with EGF stimulation
following a 30 min serum starvation for various time periods and the downstream
phosphorylation of accompanied downstream EGFR targets was monitored. As observed
previously, a reproducible increase in the phosphorylation of ERK1/2 was observed with
cells expressing S58A as compared to wild-type which was predominantly enhanced at
the earlier time point of 5 min (figure 16.A top panel). Densitometry analysis revealed
approximately a 40% increase in the relative pERK1/2 expression levels with S58A
compared to wild-type at the 5 min time period and relative to total ERK1/2 control
levels (figure 16.B).

Although not as pronounced, we additionally observed a

reproducible and detectible increase in pAkt with S58A. In contrast, cells transfected
with S58A/S631A displayed a large increase in activation of both ERK1/2 and Akt at the
earlier time period of 5 min post EGF stimulation compared to S58A (figure 16.A).
Interestingly however, the increase in pERK1/2 was sustained following prolonged EGF
stimulation for the full length of the study (60 min) while pAkt levels appeared to
diminish around 30 min. Accompanying densitometry analysis revealed that there was
nearly a 50% and 80% difference at the 15-30 and 60 min time periods respectively for
cells expressing S58A/S631A compared to both wild-type and S58A (figure 16.B).
Altogether, these results are suggestive that the targeting of MTMR2 to APPL1
endosomes is mediated by dephosphorylation at Ser58 and Ser631, which then causes the
„block‟ of APPL1 endosome maturation and compartment expansion, generated by
PI(3)P depletion at the early endosomes and collectively leads to increase in EGFR
receptor signaling.
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DISCUSSION
PART I) MTMR2 Phosphorylation is mediated by MAPKs
3.11 ERK1/2 Regulates MTMR2 Phosphorylation at Ser58
An essential requirement for the efficient transmission of extracellular signals
through correctly modulating signal transduction systems is through the fast cellular
responses upon the receipt of a particular stimulus. The MAPKs are a primary route for
signal activation in response to extracellular signals and through the step-wise activation
of downstream targets, leads to biological responses affecting growth, proliferation,
apoptosis, differentiation and survival [18]. In particular, a number of MTMRs have
been linked to survival and pro-/apoptotic events in which a gene silencing (loss of
function) approaches were utilized [19,20-22]. The knockdown of MTMR2 lead to a
dramatic decrease in Schwann cell proliferation and resulted in the activation of caspasedependent pro-apoptotic events in Rat Schwann cell cultures [19]. However, the direct
mechanism(s) through which MTMRs promote cell survival have yet to be identified
although results implicate that they have important roles in addition to regulating cell
growth through specifically linked signaling transduction pathways.
In the current work we have examined the phosphorylation of MTMR2 at Ser58 in
vitro and through the use of activity assays show that ERK1/2 specifically phosphorylates
Ser58 (figure 1). MTMR2 dephosphorylation at Ser58 could lead to greater ERK1/2
activation as we have previously shown in our signaling experiments [17]. The effects of
increased and prolonged ERK1/2 activation, may lead to targeted Ser58 phosphorylation
through a type of negative feedback loop as a mechanism to regulate ERK1/2 signaling.
Our results indicate that ERK1/2 inhibition resulted in endosomal localization of wildtype MTMR2 as displayed by the punctate distribution similar to S58A (figure 3). Both
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ERK1 and ERK2 are nearly indistinguishable, that is they share 85% sequence identity
and most often utilize the same physiological substrates both in vitro and in vivo [23]. A
type of mechanism that kinases and in particular MAPKs utilize for precisely maintaining
signal specificity and efficiency is through the interaction with their substrates and
regulators through high-affinity docking sites. Primarily, both ERK1 and ERK2 have
been shown to phosphorylate substrates containing a consensus MAPK docking sequence
that consists of a cluster of about two or three basic residues (H/K/R), a short spacer (X),
and a hydrophobic-X-hydrophobic submotif (Φ) that is usually I/L such as (H/K/R2–3-X1–
6-Φ-X-Φ)

[24]. For example, ERK has been shown to phosphorylate PKCα through

association of the ERK consensus domain (S/T-P) and two docking sites KRGRIYL and
KRGIIYRDLKL [24]. However, there are no „exact‟ consensus docking sites located in
full length wild-type MTMR2. It is notable to mention there are two small regions near
the C-terminus that moderately resemble the minimal conserved docking site sequence
391

HIKLIL396 and

571

RHLEL575. These regions could potentially serve as additional

recognition motifs for the recruitment of ERK1/2, yet in order to fully address the
significance of these potential MAPK docking regions, further mutational analysis and
accompanying co-immunoprecipitation experiments are required. The effects of
increased and prolonged ERK1/2 activation, may lead to targeted Ser58 phosphorylation
through a type of negative feedback loop and as a mechanism to regulated ERK1/2
signaling.

However, experimental evidence within in vivo systems is an additional

necessity in order to fortify that the protein of interest is phosphorylated by the suspected
kinase. In addition to altered subcellular localization following MAPK inhibition, we
also examined changes in Ser58 phosphorylation following EGF treatments, a known
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MAPK stimulus.

We found that Ser58 phosphorylation was dramatically decreased

following serum starvation which was then restored to normal levels following ERK1/2
activation by EGF stimulation (figure 4). Moreover, following ERK1/2 inhibition and
subsequent EGF stimulation, there was no change and/or increase in Ser58
phosphorylation levels. Collectively, these results support our in vitro kinase assays
implicating ERK1/2 as regulating Ser58 phosphorylation.
Sustained and transient ERK1/2 activation are critical steps in Schwann cell
development and it is of importance to examine whether ERK1/2 mediated MTMR2
phosphorylation affects Schwann cell differentiation including myelination events [25].
The relationship of MTMR2 phosphorylation to ERK1/2 signaling and Schwann cell
myelination events could be suggested that altered Ser58 dephosphorylation would
prevent endosomal targeting. Ultimately this could lead to lowered ERK1/2 signaling
following extracellular stimulation that may lead to downstream effects in myelination
processes. Previous research has demonstrated that MTMR2 is highly expressed at the
onset of myelination, yet the levels of MTMR2.Ser58 phosphorylation at these stages is
not known [25,26]. To fully understand the relationship of MTMR2 phosphorylation and
myelination, DRG-Schwann cell co-culture experiments can be conducted to analyze the
levels of Ser58 phosphorylation at the differential stages of myelination. In this way, a
relationship of MTMR2 phosphorylation with disease relevancy to Schwann cell
myelination may be unveiled.
3.12 Inhibition of ERK1/2 and JNK1 Regulates APPL1 Endosomal Targeting
Extracellular stimuli at the plasma membrane transmit biological signals
throughout the cell via complex systems of highly organized protein-protein interactions
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and activation of signal cascades, ultimately travelling through cytoplasmic
compartments to the nucleus where gene transcription is modulated.

The idea that

receptors can signal in endocytic compartments has only been explored within the last
few years [1,27]. However, the particular extent to which endosomes participate in signal
transduction events is not well established [27]. There have been functional connections
discovered between the small GTPase Rab5 and endocytic flow. An example which
highlights this is the Rab5 activation cycle that can additionally be modified by
extracellular stimuli. Stimulation by EGF results in an increase in endocytosis through
activation of the GEF RIN1 which promotes the conversion of Rab5-GDP to its active
GTP bound state therein controlling the initial fusion events [28]. It has been determined
that activated Ras functions upstream of Rab5 by influencing RIN1 activity and
ultimately adding an additional regulatory mode for controlling Rab5 activation [28].
The small GTPase Ras is an important initial player in signal transduction leading to
activation of the Ras-Raf-MEK-ERK1/2 pathways resulting in downstream effects on
growth, differentiation and development [28]. Tall et.al identified that lack of RIN1
activity lead to a dramatic increase in ERK1/2 phosphorylation providing a link of Ras
and RIN1 activity to cell signaling events [28]. What these results indicated was that the
prevention of endocytosis through the inability of Rab5 to become activated by RIN1 was
resulting in halted progression of endocytosis. It also suggests that these events were
enhancing the length of receptor containment within endocytic vesicles allowing for
increased and prolonged receptor signaling.
Importantly to note is that activated Rab5 localization to early endosomes is
promoted not only by the activity of GEFs but is also regulated PI(3)P, which is present
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on these subcellular organelles. The inter-conversion of different PI species is controlled
and maintained by PI-kinases and PI-phosphatases. MTMR2 in particular, has been
shown to regulate the levels of PI(3)P and more recently, we have determined that it
preferentially controls the levels of PI(3)P at the early endosomes [17]. Therefore, events
which promote MTMR2 endosomal targeting such as Ser58 dephosphorylation may in
part play a role in regulating Rab5 localization and signaling events linked to the MAPK
and more specifically the ERK 1/2 cascade.
The well characterized MAPK pathways are tightly regulated and controlled in
such a manner as to modulate the appropriate steps in endocytosis which can in turn, alter
subcellular localization of proteins in addition to their activity if over stimulated or
inhibited.

Considering that our data implicates ERK1/2 as regulating Ser58

phosphorylation, it was therefore hypothesized that ERK1/2 inhibition may result in
MTMR2 localization similar to our observations with S58A. Intriguingly, MTMR2
preferentially localized to Rab5 positive endosomes following ERK1/2 inhibition (figure
5 second row) as opposed to the precursor APPL1 endosomes (figure 6 second row)
indicating that Ser58 dephosphorylation as represented by ERK1/2 inhibition, specifically
localizes MTMR2 to the early Rab5-endosomes.
The JNK pathway has been previously shown to augment recycling of the
Transferrin receptor via direct phosphorylation of the Rab-guanine nucleotide
dissociation inhibitor (GDI) that is complexed to Rab11a in which Rab11a is stabilized by
JNK phosphorylation of RabGDI [84]. Inhibition of JNK can alter receptor recycling as
a result of inactivity of RabGDI and altered subcellular localization in which the Rab11a
and RabGDI complex can no longer form. In addition, it has also been shown that p38-

147

mediated phosphorylation of RabGDI complexed to Rab5 modulates Rab5 activity
[29,30]. It has been previously determined that p38 regulates RabGDI activity in the
cytosolic cycle of Rab5 activation thereby stimulating the formation of the GDI:Rab5
complex [29,30]. Moreover, p38 activation modulates and increases endocytic rates in
vivo promoting more efficient receptor internalization [31]. Therefore, it was expected
that we observe some extent of Rab5 co-localization following dephosphorylation of
Ser58 with ERK1/2 inhibition however when MTMR2 was overexpressed in HeLa cells
and probed for Rab5 following combined inhibitor treatments for ERK1/2 and/or JNK1
we did not observed any regions of co-localization which presumably may be a result of
altered Rab5 localization (figure 5. bottom two rows). In order to fortify that JNK1 or
p38 inhibition was affecting the endogenous localization of Rab5, it would be of interest
to examine the normal localization patterns of both these MAPKs with Rab5 preceding
and following inhibition.
APPL1 is an adaptor protein that has been shown to interact through the PTB
domain with the catalytic subunit of PI3K, phosphoinositide-5-phosphatases and Akt
[19,32]. It has also been suggested that APPL1 functions as an adaptor that is linked to
distinct signaling pathways, and has been implicated as a Rab5 effector considering that it
only interacts with Rab5 in the GTP-bound state [32]. Recently, Chial et.al suggested
that APPL1 may function as a molecular scaffold contributing to the initial complete
organization of Rab5 dependent trafficking events and regulation of Rab5 subdomains in
the early stages of endocytosis [32]. Moreover, APPL1 contains a PH domain that
mediates interaction with PIs and can simultaneously allow for interaction with other
proteins through its PTB domain [19,32].
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The inter-conversion of APPL1 and the

canonical Rab5 early endosomes is highly dependent on the acquisition of PI(3)P. Zoncu
et.al (2009) have demonstrated that as the levels of PI(3)P increase, APPL1 is shed from
the endosomes and FYVE domain containing proteins such as EEA1 are then recruited
ultimately generating the characteristic Rab5-early endosomes [1]. In hindsight, the loss
of PI(3)P resulted in the „back-conversion‟ of EEA1 endosomes to generate enlarged
APPL1 vesicles and prevention of the formation of the early endosomes. The particular
reasons for vesicle enlargements are not fully understood although it has been
hypothesized that the loss of PI(3)P results in the „blockage‟ of endocytosis flow and
hence prolongs the residency of receptors in these compartments which then accumulate
[1,33,34]. The results presented here support a critical role of MTMR2 subcellular
regulation by both JNK1 and ERK1/2. We show that MTMR2 targeting to APPL1
vesicles is highly dependent on the inhibition of both ERK1/2 and JNK1 indicating that
MTMR2 localization is tightly controlled by reversible phosphorylation (figure 6).
Moreover, the finding that localization to APPL1 endosomes partially resulted in the
enlargement of colocalized vesicles, suggest that the levels of PI(3)P at the early
endosomes were affected as a result of MTMR2 targeted depletion, similar to previous
observed studies with MTM1 [1]. These studies also suggest an alternative role for
MTMR2 in the earliest stages of endocytosis, which in part may be regulated by
phosphorylation of an additional C-terminal site (Ser631) on MTMR2 that is controlled by
JNK1. Therefore, our results are highly suggestive that JNK1 may in part govern the
phosphorylation of Ser631 and regulation of this site may be dependent sequentially on
Ser58 phosphorylation by ERK1/2.
The shortcoming of utilizing inhibitors is that numerous other targeted systems
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can also be affected. Therefore, to eliminate the possibility that combined ERK1/2 and
JNK inhibition could be affecting APPL1 localization we explored single inhibitor
treatments using the phosphorylation-deficient mutant S58A. Under untreated conditions
S58A displayed the characteristic punctate localization with lack of APPL1 colocalization as expected. However JNK1 inhibition resulted in complete APPL1 colocalization and an increase in vesicle area nearly three times (figure 7. top two panels,
Appendix 2. Table 1). Moreover, combined inhibitor treatments of ERK1/2 and JNK1
resulted in a similar localization pattern and effect on the overall area of colocalized
vesicles at nearly the same amount (figure 7. bottom panel). It would be of great interest
to monitor the localization of both EGF and EGFR to determine if they also reside and/or
accumulate in these vesicles. Thus, the precise mechanism underlying the shuttling of
MTMR2 between Rab5 endosomes (ERK1/2 inhibition) and APPL1 vesicles (ERK1/2
and JNK1 inhibition) remains to be fully elucidated at this time.
PART II) Characterization of the MTMR2.Ser631 Phosphorylation Site
3.13 Reversible Phosphorylation at Ser631 Targets MTMR2 to Specific PI(3)P Pools
Because of the effects we observed on MTMR2 localization following ERK1/2
and JNK1 inhibitor treatments, it was relevant to generate a series of phospho-mutants to
test our hypotheses. Expression of single Ser631 MTMR2 mutants alone did not result in
altered MTMR2 subcellular localization nor localization to APPL1 or Rab5 positive
vesicles (figure 8).

Interestingly, expression of a double phosphorylation deficient

mutant S58A/S631A resulted in complete loss of cytoplasmic localization and to a
greater extent, co-localization with and to a partial degree enlargement of APPL1
endosomes (figure 8 top row). Moreover, the explicit localization to APPL1 as opposed
to Rab5 endosomes following the sequential dephosphorylation of Ser58 and Ser631
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implies that reversible phosphorylation governs multiple roles in MTMR2 regulation
(figure 9). Further investigations into the potential cross-talk between these two sites
revealed that targeting to Rab5 endosomes was highly dependent on Ser58
dephosphorylation (S58A) and Ser631 phosphorylation (S631E) events, which in turn
prevented targeting of MTMR2 to APPL1 vesicles (figure 10). This might provide an
additional level of regulation in order to control the extent of MAPK signaling by
regulating MTMR2 localization and trafficking between Rab5 and APPL1 endosomes,
thereby controlling the flow of endocytosis by modulating the levels of PI(3)P at distinct
stages. These results are highly suggestive that dephosphorylation of both Ser58 and
Ser631 is necessary to regulate MTMR2 targeting to APPL1 endosomes, and sufficiently
requires Ser58 dephosphorylation for initial vesicle targeting.
Accumulating evidence suggests that PI(3)P plays a critical role not only in the
initial fusion events at the early endosomes and the initial receptor sorting, but also
regulates the bulk transport from the early to late endosomes [1,35,36-38]. Moreover, the
lack of PI(3)P particularly at the early endosomes prevents the transport of downregulated receptors to the late endosomes for degradation and that these receptors then
remain trapped at the early endosomes [35]. The signaling events related to correct
PI(3)P levels primarily have been associated with the control of sorting rather than
receptor transport, meaning that the fate of receptors is in part governed by other factors
that regulate lipid levels at differential stages in endocytosis. We have evidence that
supports the notion in which a subset of APPL1 vesicles contain a modest levels of
PI(3)P in comparison to Rab5 positive endosomes (Supplemental figure 6). Although our
evidence and published data supports this notion, for the direct associated to Rab5-
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dependet trafficking, further experimental evidence utilizing live cell imaging would be
required.
The lack of APPL1 co-localization and positive Rab5 co-localization with the
S58A/S631E mutant (figure 11), leads us to postulate that the phosphorylation at Ser631
and lack thereof at Ser58 may target MTMR2 to PI(3)P rich Rab5 endosomes.
Additionally this could suggest that conformational changes may occur in the distant
regions of the protein that potentially allow for greater substrate accessibility and/or
interaction with accessory proteins that regulate trafficking to and from the early
endosomes. Moreover, the lack in Rab5 localization following single modifications
within the active site Cys residue of MTMR2 and the distant C-terminal Ser631 provides
further justification that dephosphorylation at Ser58 is the main event controlling
subcellular targeting (figure 12). This implies that MTMR2 structural rearrangements
occur following post-translational modification by reversible phosphorylation. Ongoing
in vitro HDX experiments in our laboratory with these mutants should clarify the
conformational dynamics in response to MTMR2 phosphorylation.
Physiological conditions which regulate phosphorylation cross-talk between these
two sites might be important. Interestingly, under high stress such as hypoosmotic shock
activate both ERK1/2 and JNK1 pathways. We hypothesize this would result in Ser58 and
Ser631 phosphorylation and prevent early endosomal targeting of MTMR2. Additionally,
hypoosmotic shock has been shown to boost the levels of PI(3,5)P2 wherein its presence
in living systems is general present at very low amounts. We speculate that MAPK
activation in response to hypoosmotic shock could lead to phosphorylation of MTMR2
and subsequently release from endocytic vesicles leading to increase in PI(3,5)P2 levels.
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The phosphatase activity of MTMR2 towards PI(3,5)P2 in vitro is highly comparable to PI(3)P however, there has yet to be identified in vivo, signals that trigger
localization to compartment(s) rich in this substrate. In this respect, if two pathways are
activated which govern MTMR2 phosphorylation those including ERK1/2 and JNK1
thereby resulting in Ser58 and Ser631 phosphorylation, this could be indicative of the
mechanism through which MTMR2 is targeted to regions rich in its other physiological
substrate PI(3,5)P2.

However, more detailed investigations into the particular

relationship(s) of dual MTMR2 phosphorylation at Ser58 and Ser631 which could
potentially be involved in the receptor and/or protein degradation pathway by regulating
the levels of PI(3,5)P2 in the cellular stress response system are required.
3.14 Early Endosomal PI(3)P Depletion is Mediated by Reversible Ser58 and Ser631
Phosphorylation
The dissociation of APPL1 from endosomes correlates with accumulation of
PI(3)P and in turn the recruitment of FYVE domain containing proteins including EEA1
and WDFY2 [1]. It has also been implicated that the generation of PI(3)P thereby
functions as the molecular switch that controls the maturation into the canonical early
endosomes. It is suggested that PI(3)P and APPL1 may compete for a limited number of
binding sites on Rab5 positive endosomes.

When PI(3)P was depleted, binding of

APPL1 to Rab5 positive endosomes was dramatically increased at the sites that had lost
PI(3)P. More specifically, the study by Zoncu et.al (2009) utilized wortmanin to inhibit
PI(3)P production and also targeted MTM1 to PI(3)P rich endosomes in order to
effectively deplete massive cellular levels of PI(3)P [1]. Moreover, it was determined
that attenuating APPL1 binding on endosomes by PI(3)P generation, allowed for the
proficient and stabilization of EEA1 binding to Rab5 endosomes. In this competition-
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type of scenario it can be suggested that both kinases and phosphatases that regulate
PI(3)P, ultimately could control the signaling and maturation properties of endocytosis
events following through these particular stages. In this respect, dephosphorylation of
MTMR2 at Ser58 and Ser631 which we have shown targets this lipid phosphatase
specifically to APPL1 endosomes, could in turn also regulate the inter-conversion and/or
intermediate processes en route to the early endosomes. Therefore, the catalytic activity
of MTMR2 would be required in order to successfully deplete PI(3)P. The localization of
the PI(3)P rich marker EGFP-2xFYVE is not affected when MTMR2 is
dephosphorylated at both these site however only when Ser631 is phosphorylated can
MTMR2 directly localize to Rab5 endosomes and effectively deplete PI(3)P (figure 13).
This implicates that the C-terminal Ser631 site functions as an additionally regulatory
mechanism that controls MTMR2 regulation and potentially serves as the prime switch
that governs targeting to APPL1 endosomes and in turn, trafficking into and between the
early endosomes. While this direct link cannot be completely vindicated from these
results and would require further validations including experiments such as live-cell
imaging, the significance of these findings cannot be underscored.
Only recently has it been determined how MTMR2 regulates and controls the
levels of PI(3)P and how this is associated with endocytic events, yet in eukaryotic
systems there can be suspected to be a more complex underlying regulation to avoid
repercussions [17]. Additionally, the question arises as to what consequence would be
derived following loss of this regulation particularly by loss of MTMR2 catalytic
function? The lipid phosphates activity of MTMR2 has been shown in numerous systems
to be critical, yet how this alters its function is not fully understood. Our observations
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indicate that when MTMR2 is dephosphorylated at Ser58 and Ser631 it results in targeting
to APPL1 endosomes, yet the loss of activity in this respect, only partially resulted in
localization to PI(3)P containing regions as opposed to those highly rich in its substrate
(figure 14). This partial localization and previously determined lack of effect on PI(3)P
marker distribution, implicates that the additional regulatory features surrounding
reversible Ser631 phosphorylation are more strictly regulated than initially anticipated. It
was surprising to observe co-localization between S58A/C417S/S631A and the PI(3)P
marker EGFP-2xFYVE because we did not observe any PI(3)P attenuation with
expression of active MTMR2 (S58A/S631A). The subset of vesicles observed that
displayed direct co-localization with the marker when MTMR2 was dephosphorylated at
both sites; suggest that MTMR2 could potentially have a function in the intermediate
stages of conversion between APPL1 and Rab5 endosomes and result in the accumulation
of PI(3)P in these compartments. Moreover, it was again determined that only once
Ser631 was phosphorylated (S58A/S631E) would MTMR2 then localize to compartments
that were highly rich in PI(3)P. Conversely, the Ser631 single mutant (S631E) or in the
case that Ser58 was phosphorylated (S58E, wt) did not affect localization and/or PI(3)P
levels (figure 15). This supports the observation that the endosomal targeting of MTMR2
is regulated by dephosphorylation at Ser58. Taken together, these results implicate that
the N-terminal Ser58 and C-terminal Ser631 function co-ordinately to mediate the
appropriate MTMR2 subcellular targeting and effectively, the specific dephosphorylation
of the lipid substrate.
3.15 Dephosphorylation of MTMR2 Ser58 and Ser631 results in sustained ERK1/2
activation
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The long held concept of endocytosis is primarily that it is used as a mechanism
to regulate receptor signaling by degrading these receptors following their internalization
thereby perpetuating the corresponding signals [45,46].

Moreover, it has been

accustomed that following receptor internalization, their bound ligands/stimuli become
dissociated and hence, these receptors are no longer capable of signaling. More recent
evidence however oppose this theory and suggest that once receptors become activated
and in turn internalized, they can continue to signal via distinct endosomal compartments
following their internalization [1,45]. In particular, the Akt and MAPK pathways have
been linked to the signaling capacity of EGFRs and the neuronal growth factor receptor
TrkA, particularly through interactions with the adaptor protein APPL1 [44]. The
signaling strength however, varies within different systems in addition to extent of the
stimulus. More specifically, there has been evidence determined that has linked the
formation of the APPL1 compartments and the residency time of these receptor within
these sub-organelles, directly to the signaling capacity of these newly defined endosome
subpopulations [1].
Activation of the Akt and MAPK signaling pathways are critical in a number of
biological processes and it has been shown that the loss of APPL1 on endosomes is
mediated primarily in a PI(3)P dependent fashion and is also associated with decreased
receptor signaling which in turn lowers the activation of corresponding cascades [1]. In
our system, we identified that dephosphorylation of both Ser58 and Ser631 resulted in
APPL1 endosomal targeting and sustained ERK1/2 activation and to a lesser extent
prolonged Akt activation (figure 16).

These data support the hypothesis that the

reversible phosphorylation of MTMR2 at these two critical sites, targets MTMR2 to
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APPL1 endosomes thereby prolonging the residency time of receptors within these
compartments and hence, extending receptor signaling. However, a question to ask is
what are the structural feature(s) of the C-terminal Ser631 that particularly governs
MTMR2 targeting to this unique and small endosome subpopulation? As an example,
PDZ-binding motifs have previously been shown to be important in anchoring proteins to
the actin cytoskeleton in addition to holding together key signaling complexes [41-43].
MTMR2 Ser631 resides near the C-terminal PDZ binding motif. Considering that our lab
has evidence indicating that dephosphorylation at Ser58 allows for greater solvent
accessibility (i.e. a greater open-complex), it can be hypothesized that dephosphorylation
at Ser631 may function in a similar manner. That is, allow for greater access of MTMR2
to other interacting proteins that assist in stabilizing these signaling complexes. On the
other hand, it may also provide additional docking sites for the recruitment of adaptor
proteins that are dependent on and/or sensitive to PI(3)P levels on APPL1 endosomes.
Similar HDX experiments in vitro would assist in identifying a structural relationship to
reinforce this hypothesis. Additionally, it would be of great interest to monitor EGFR
trafficking following EGF stimulation with these mutants in order to definitively identify
the localization of the active receptors with respect to particular stage of endocytosis.
Although the direct relationship of MTMR2 endosomal targeting to ERK1/2
signaling and activation cannot be definitively concluded from these studies, recent
evidence surrounding ERK1/2 regulation can assist in comprehending how MTMR2 may
play a functional role.

Under basal conditions, ERK1/2 activation triggers

phosphorylation of the MKP-1 protein phosphatase at two Ser residues in the extreme Cterminus thereby stabilizing MKP-1 which in turn, functions via a negative feedback
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mechanism to transiently dephosphorylate and inactivate ERK1/2 [18]. However, MKP1 can also be phosphorylated at other sites within its C-terminus which then results in
targeted ubiquitination and degradation [18]. Lin et.al (2003) have demonstrated that
overexpression of the upstream kinase MEK1/2 which governs ERK1/2 phosphorylation,
results in extended and increased strength of ERK1/2 activation [18]. The question arises
as to how ERK1/2 can maintain signaling if its activation triggers MKP-1 stabilization
and ultimately ERK1/2 inactivation?

It has been proposed that sustained ERK1/2

activation may result in phosphorylation of other sites on MKP-1 that trigger downregulation thereby allowing prolonged ERK1/2 activation [18].
dephosphorylation

mediates

earlier

ERK1/2

activation

and

MTMR2 Ser58
accompanying

dephosphorylation of Ser631 allows for sustained activation and signaling. Thus we are
interested in examining if dephosphorylated MTMR2 increases receptor residency that
results in increase in MEK1/2 activation, or if it results in activation of a signaling
cascade that targets MKP-1 stability.
Collectively, these results lead us to revise our initial proposed model of MTMR2
regulation by reversible phosphorylation (figure 17_Proposed Model 2). As previously
stated, it is hypothesized that phosphorylation at Ser58 sequesters MTMR2 in the
cytoplasm and that extracellular signal(s) are required to trigger dephosphorylation and in
turn, endosomal targeting. The efficient localization of MTMR2 to endocytic vesicles
results in targeted PI(3)P depletion with resultant effects on endosomal maturation and
signaling events. Our recent evidence leads us to suggest that dephosphorylation of
Ser631 is required for localization to APPL1 endosomes. In contrast, regulation of Ser631
phosphorylation may be regulated through the antagonistic action of JNK1 in order to
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modulate the extent of receptor signaling in a transient fashion. Conversely, APPL1
endosomal targeting of MTMR2 results in extended ERK1/2 activation that in part, is
controlled via a negative feedback mechanism in which sustained ERK1/2 signaling then
results in the phosphorylation of Ser58 and hence, perpetuates and regulates the extent of
receptor-endosome signaling events. Zoncu et.al (2009) determined that the conversion
of APPL1 endosomes that are en route to the classical Rab5-EEA1 early endosomes is
mediated by the accumulation in the levels of PI(3)P [1]. Therefore consistent with this
notion, the reversible phosphorylation of MTMR2 can be implicated to be a critical
regulatory event controlling not only its subcellular localization, but ultimately regulate
the flow of endocytosis and signaling events directly through controlling the levels of its
substrate.
In addition to ERK1/2 activation, it will also be necessary to monitor pERK1/2
localization following reversible MTMR2 phosphorylation. The data presented here
supports the hypothesis that MTMR2 dephosphorylation at both Ser58 and Ser631 triggers
sustained ERK1/2 activation however, more recent data may also suggest that MTMR2
could in fact additionally regulate pERK1/2 localization. According to recent evidence
by Liu et.al (2010) they have shown that repeated stimulation in cell culture using human
lung epithelial cells (BEAS-2B) with cytokines such as Interleukin 13 (IL-13) resulted in
sustained pERK1/2 activation leading to compartmentalization of pERK1/2 to Rab5
endosomes [39].

Additionally, pERK1/2 was also excluded from the characteristic

nuclear translocation wherein ERK1/2 is essentially sequestered into the cytosol and only
following a priming stimulation can it then be translocated to the nucleus [39]. This is
suggestive that prolonged and sustained pERK1/2 could prevent nuclear translocation and
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in turn have transcriptional consequences that prevents the induced expression of a
number of ERK1/2 target genes [39]. Furthermore, it can be postulated that other cellular
events modulating ERK1/2 activation and signaling could potentially govern not only its
localization, but also the transcription of down-stream regulatory genes.
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Figure 17. Endosomal Targeting of MTMR2 is mediated by MAPKs
Phosphorylation of Ser58 by ERK1/2 sequesters MTMR2 in the cytoplasm, thereby
preventing PI(3)P depletion and promoting endosome maturation events.
Dephosphorylation at Ser58 thus mediates endosomal targeting and PI(3)P depletion
wherein subsequent Ser631 dephosphorylation targets MTMR2 to APPL1 endosomes and
effectively determines the particular substrate lipid pool. Prolonged residency of
MTMR2 at APPL1 endosomes results in sustained ERK1/2 activation and endosomal
signaling. Phosphorylation at Ser631 by JNK1 prevents APPL1 targeting as a mechanism
to control receptor signaling.
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CHAPTER 4
Concluding Remarks and Future Directions
MTMR2 is a highly conserved lipid phosphatase ranging from yeast to complex
eukaryotes, yet the unique cellular functions that govern its regulation and how it is
specifically linked to its biological substrates remains scarce. Remarkably though, little
is understood into the vast biological consequences of substrate dephosphorylation
relatable to MTMR2 targeting and associated effects on signal transduction, in addition to
its main role in regulating cellular mechanisms. While MTMR2 seems to play a critical
role in endocytosis events primarily due to the location of its substrates, it remains
unclear as to the definitive role of MTMR2 in associative biological processes.
The current study has provided significant insights into the regulation of MTMR2
by reversible phosphorylation and how these events are linked to substrate targeting.
Considering that MTMR2 shares high sequence similarity and function with several
MTM family members particularly with respect to the phosphorylation sites examined in
this study, it is possible that other MTM members may also be regulated in a similar
manner.

Much emphasis can now be addressed into exploring the possibility that

reversible phosphorylation may be the link between MTM substrate targeting and
compartmental regulation. Furthermore, our results point to a mechanism by which
differential phosphorylation can not only govern MTMR2 subcellular localization, but
also control the extent to which substrate pools are targeted. This function likely entails
highly mediated cross-talk between the two phosphorylation sites under study, through
which their regulation may in turn, be controlled through uniform negative feedback
loops with the associated kinases.
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The aims of this study were to gain further understanding into the cellular
mechanisms that govern MTMR2 biology particularly with respect to regulation by
reversible phosphorylation.

More recently, Christopher Bonham from our lab has

identified in vitro by HDX-MS that dephosphorylation at Ser58 results in greater solvent
accessibility.

Presumably this suggests a mechanism by which dephosphorylation

triggers conformational changes that ultimately lead to an open three-dimensional protein
conformation thereby allowing greater access to the endosomal binding surface.
Collectively, there is still a great deal of information to be elucidated, ultimately in future
hopes of identifying the specific MTMR2 malfunctions that ultimately results in the
prevalent and devastating CMT4B1 disease.
Our next tasks will be to examine the in vivo alterations in Ser58 phosphorylation
stoichiometry with various kinase inhibitors using MS and the pSer58 antibody
accompanied by siRNA depletion of MAPKs in order to asses changes relatable to living
systems. Moreover, the importance of gaining further understanding into regulation by
phosphorylation and how these mechanism can be relatable to associated CMT4B1
features, it will be valuable to utilize Schwann cells in order to examine changes in the
stoichiometry of Ser58 phosphorylation during different myelination stages. Considering
that MTMR2 has been determined to be highly expressed at the onset of myelination
coupled to our results indicating that the definitive subcellular is controlled by differential
phosphorylation, it would be of great interest to monitor changes in MTMR2
phosphorylation at both Ser58 and Ser631 under various stimuli in addition to MTMR2
CMT4B1 associated mutations. It is likely that CMT4B1 mutations may inadvertently
affect MTMR2 phosphorylation through a number of yet to be identified mechanism, as
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research has previously shown that MTMR2 phosphorylation decreases with PH-GRAM
domain mutations [40].

Ultimately, the goal is to examine the levels of MTMR2

phosphorylation in patients affected with CMT in attempts to fully understand how
MTMR2 regulation in this respect may potentially be associated with disease
manifestations.
Abnormalities in PI synthesis and turnover could potentially affect both cell
survival factors and those mediating cell deaths. Therefore, it could be proposed that
decreased Schwann cell proliferation which is a characteristic feature of CMT4B1 could
substantially be connected to impaired endocytosis leading to prolonged or over
activation of receptors responsible for governing specific growth factor signaling
cascades. To better understand the mechanisms of action of MTMR2 and the relationship
between the various proposed biological roles in vesicular trafficking, it is important to
elucidate the structural features that are a consequence of dephosphorylation and how
these could in turn, affect protein function and particularly localization.

Future

experiments aimed at investigating structural changes that could occur, may yield
valuable

insights

into

the

compartmentalization

that

accompanies

Ser58

dephosphorylation and the recumbent effects associated with changes in PI(3)P.
Moreover, further investigations regarding the prolonged biological effects associated
with sustained ERK1/2 activation and how this in particular is associated with
myelination defects is of extreme importance and may provide the link between lack of
functional MTMR2 and disease characteristics.
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Supplemental Figure 1. Sample preparation for analysis by MALDI-TOF
HEK293 cells were transfected with wild-type MTMR2, immunoprecipitated and
separated by SDS-PAGE. The bands corresponding to the protein of interest were
excised, and control samples were additional taken (C1: Control, C2: Gel control, E1:
Experimental). The gel pieces excised were subjected to in gel-trypsin digestion and
analyzed by MADL-TOF.
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Supplemental Figure 2.
variants

Purification of Recombinant MTMR2 and Phospho-

IPTG induction was used to induced protein expression in BL21 cells transfected with
PET-His6 vectors containing wt-MTMR2, S58A or S58E. Cells were collected before
addition of IPTG (uninduced) and following 16 h IPTG induction (induced). Protein
purification was achieved by immobilization to HIS-select Ni2+-affinity resin followed by
elution and collection of the supernatant containing the purified protein of interest
(elution 1).
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Supplemental Figure 3. S58A co-localizes with Rab5 and not with wild-type or S58E
HeLa cells were transiently transfected with FLAG-wild-type-MTMR2 (A-C), FLAGS58A (D-F), and FLAG-S58E (G-I). Following 42 h transfection, cells transfected with
FLAG-S58A were pre-treated with 0.01 % saponin and all samples analyzed by
immunofluorescence.. Expanded views of marked areas demonstrate Rab5 localization
with S58A at distinct subcellular organelles. Colocalized regions are indicated by open
arrows and yellow in color merge. Images were collected using 63x (top/lower panel)
and 40x oil (middle panel) objectives. The scale bar represents 15 µm. (shown 10 µm in
expanded views)
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Supplemental Figure 4. MTMR2 dephosphorylation at Ser58 does not trigger late
endosome targeting
HeLa cells were transiently transfected with FLAG-wild-type-MTMR2 (A-C), FLAGS58A (D-F), or FLAG-S58E (G-I). Expanded views of positively transfected S58A HeLa
cells following a 0.01 % saponin treatment with marked areas demonstrating absence of
Rab7 localization and are indicated by closed arrows and in merge. Images were
collected using 63x (top and lower panel) and 40xoil (middle panel) objectives. The
scale bar represents 15 µm. (shown 10 µm in expanded views)
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Supplemental Figure 5. Vesicle enlargement is dependent on MTMR2 S58A/S631A
catalytic activity
HeLa cells were transiently transfected with FLAG-MTMR2 S58A/C417S/S631A for 42
h and analyzed by immunofluorescence microscopy. After fixation, cells were incubated
with anti-FLAG antibody and Alexa Fluor® 568 (red) and additionally stained
endogenous Rab5 or APPL1 (green). The lack of APPL1 vesicle enlargement is due to
the loss of MTMR2 catalytic activity. Images were collected using 63x objectives. The
scale bar represents 15 µm.
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Supplemental Figure 6. Subcellular localization of PI(3)P at endosomes
HeLa cells were transfected with EGFP-2xFYVE (green) for 24 h and analyzed by
immunofluorescence. Following fixation, cells were immunostained for endogenous
Rab5 or APPL1 (red). Merged images are displayed to show regions of co-localization
and are presented in expanded views. Yellow indicates co-localization of endogenous
markers to vesicles rich in PI(3)P. Images were collected using 63x objectives. Scale bar
represents 15 µm.
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Table 1. Summarization of Vesicle Size Measurements and Quantification
The quantitative analysis of size measurements from individual cells reveals colocalization with APPL1 results in increased vesicle area due to MTMR2 targeting and
PI(3)P depletion. Loss of activity with S58A/C417S/S631A indicate the requirement of
phosphatase activity for vesicle enlargement. The data is representative of the average
area (μm2) each of 10 independently measured vesicles spanning 3 independent
experiments. The standard deviations (μm) were determined for each measured vesicle
and is represented as the average from 3 separate trials. Vesicle area determination was
quantified using Image J with an analyze set scale to 15 μm based on image micrometer
bars.
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